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Abstract
The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human
drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org),
which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared
to information and links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at
http://onlinelibrary.wiley.com/doi/10.1111/bph.14749. Ion channels are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein-coupled re-
ceptors, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological
tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to
mid-2019, and supersedes data presented in the 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the International
Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classiﬁcation (NC-IUPHAR), therefore, providing ofﬁcial IUPHAR classiﬁcation and nomenclature for human
drug targets, where appropriate.
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Overview: Ion channels are pore-forming proteins that allow
the ﬂow of ions across membranes, either plasma membranes,
or the membranes of intracellular organelles [379]. Many ion
channels (such as most Na, K, Ca and some Cl channels) are
gated by voltage but others (such as certain K and Cl chan-
nels, TRP channels, ryanodine receptors and IP3 receptors) are
relatively voltage-insensitive and are gated by second messen-
gers and other intracellular and/or extracellular mediators. As
such, there is some blurring of the boundaries between "ion
channels" and "ligand-gated channels" which are compiled sep-
arately in the Guide. Resolution of ion channel structures, be-
ginning with K channels [239] then Cl channels [255] and most
recently Na channels [767] has greatly improved understanding
of the structural basis behind ion channel function. Many ion
channels (e.g., K, Na, Ca, HCN and TRP channels) share sev-
eral structural similarities. These channels are thought to have
evolved from a common ancestor and have been classﬁed to-
gether as the "voltage-gated-like (VGL) ion channel chanome"
(see [1122]). Other ion channels, however, such as Cl chan-
nels, aquaporins and connexins, have completely different struc-
tural properties to the VGL channels, having evolved quite
separately.
Currently, ion channels (including ligand-gated ion channels)
represent the second largest target for existing drugs after G
protein-coupled receptors [747]. However, the advent of novel,
faster screening techniques for compounds acting on ion chan-
nels [247] suggests that these proteins represent promising targets
for the development of additional, novel therapeutic agents for
the near future.
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Ligand-gated ion channels
Ion channels → Ligand-gated ion channels
Overview: Ligand-gated ion channels (LGICs) are integral mem-
brane proteins that contain a pore which allows the regulated ﬂow
of selected ions across the plasma membrane. Ion ﬂux is passive
and driven by the electrochemical gradient for the permeant ions.
These channels are open, or gated, by the binding of a neuro-
transmitter to an orthosteric site(s) that triggers a conformational
change that results in the conducting state. Modulation of gat-
ing can occur by the binding of endogenous, or exogenous, mod-
ulators to allosteric sites. LGICs mediate fast synaptic transmis-
sion, on a millisecond time scale, in the nervous system and at
the somatic neuromuscular junction. Such transmission involves
the release of a neurotransmitter from a pre-synaptic neurone and
the subsequent activation of post-synaptically located receptors
that mediate a rapid, phasic, electrical signal (the excitatory, or
inhibitory, post-synaptic potential). However, in addition to their
traditional role in phasic neurotransmission, it is now established
that some LGICs mediate a tonic form of neuronal regulation that
results from the activation of extra-synaptic receptors by ambient
levels of neurotransmitter. The expression of some LGICs by non-
excitable cells is suggestive of additional functions.
By convention, the LGICs comprise the excitatory, cation-
selective, nicotinic acetylcholine [144, 659], 5-HT3 [56, 1042],
ionotropic glutamate [588, 997] and P2X receptors [436, 946] and
the inhibitory, anion-selective, GABAA [76, 738] and glycine re-
ceptors [603, 1116]. The nicotinic acetylcholine, 5-HT3, GABAA
and glycine receptors (and an additional zinc-activated channel)
are pentameric structures and are frequently referred to as the Cys-
loop receptors due to the presence of a deﬁning loop of residues
formed by a disulphide bond in the extracellular domain of their
constituent subunits [662, 975]. However, the prokaryotic ances-
tors of these receptors contain no such loop and the term pen-
tameric ligand-gated ion channel (pLGIC) is gaining acceptance in
the literature [375]. The ionotropic glutamate and P2X receptors
are tetrameric and trimeric structures, respectively. Multiple genes
encode the subunits of LGICs and the majority of these receptors
are heteromultimers. Such combinational diversity results, within
each class of LGIC, in awide range of receptors with differing phar-
macological and biophysical properties and varying patterns of ex-
pression within the nervous system and other tissues. The LGICs
thus present attractive targets for new therapeutic agents with im-
proved discrimination between receptor isoforms and a reduced
propensity for off-target effects. The development of novel, faster
screening techniques for compounds acting on LGICs [247] will
greatly aid in the development of such agents.
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5-HT3 receptors
Ion channels → Ligand-gated ion channels → 5-HT3 receptors
Overview: The 5-HT3 receptor (nomenclature as agreed by
the NC-IUPHAR Subcommittee on 5-Hydroxytryptamine
(serotonin) receptors [402]) is a ligand-gated ion channel of
the Cys-loop family that includes the zinc-activated channels,
nicotinic acetylcholine, GABAA and strychnine-sensitive glycine
receptors. The receptor exists as a pentamer of 4TM subunits that
form an intrinsic cation selective channel [56]. Five human 5-
HT3 receptor subunits have been cloned and homo-oligomeric as-
semblies of 5-HT3A and hetero-oligomeric assemblies of 5-HT3A
and 5-HT3B subunits have been characterised in detail. The 5-
HT3C (HTR3C, Q8WXA8), 5-HT3D (HTR3D, Q70Z44) and 5-HT3E
(HTR3E, A5X5Y0) subunits [470, 705], like the 5-HT3B subunit,
do not form functional homomers, but are reported to assemble
with the 5-HT3A subunit to inﬂuence its functional expression
rather than pharmacological proﬁle [391, 707, 1041]. 5-HT3A, -C,
-D, and -E subunits also interact with the chaperone RIC-3 which
predominantly enhances the surface expression of homomeric 5-
HT3A receptor [1041]. The co-expression of 5-HT3A and 5-HT3C-E
subunits has been demonstrated in human colon [465]. A recom-
binant hetero-oligomeric 5-HT3AB receptor has been reported to
contain two copies of the 5-HT3A subunit and three copies of the
5-HT3B subunit in the order B-B-A-B-A [61], but this is inconsistent
with recent reports which show at least one A-A interface [587,
979]. The 5-HT3B subunit imparts distinctive biophysical proper-
ties upon hetero-oligomeric 5-HT3AB versus homo-oligomeric 5-
HT3A recombinant receptors [199, 244, 352, 438, 476, 786, 926],
inﬂuences the potency of channel blockers, but generally has only
a modest effect upon the apparent afﬁnity of agonists, or the afﬁn-
ity of antagonists ([106], but see [197, 210, 244]) which may be
explained by the orthosteric binding site residing at an interface
formed between 5-HT3A subunits [587, 979]. However, 5-HT3A
and 5-HT3AB receptors differ in their allosteric regulation by some
general anaesthetic agents, small alcohols and indoles [405, 853,
920]. The potential diversity of 5-HT3 receptors is increased by al-
ternative splicing of the genes HTR3A and E [116, 396, 704, 706,
707]. In addition, the use of tissue-speciﬁc promoters driving ex-
pression from different transcriptional start sites has been reported
for theHTR3A, HTR3B,HTR3D and HTR3E genes, which could re-
sult in 5-HT3 subunits harbouring different N-termini [438, 704,
1001]. To date, inclusion of the 5-HT3A subunit appears impera-
tive for 5-HT3 receptor function.
Nomenclature 5-HT3AB 5-HT3A
Subunits 5-HT3A, 5-HT3B 5-HT3A
Selective agonists – meta-chlorphenylbiguanide [75, 199, 536, 668, 669], 2-methyl-5-HT [75, 199, 536, 668],
SR57227A [258] – Rat, 1-phenylbiguanide [75]
Antagonists – vortioxetine (pKi 8.4) [51], metoclopramide (pKi 6–6.4) [106, 397]
Selective antagonists – palonosetron (pKi 10.5) [677], alosetron (pKi 9.5) [382], (S)-zacopride (pKi 9) [106],
granisetron (pKi ∼8.6–8.8) [397, 668], tropisetron (pKi 8.5–8.8) [536, 668], ondansetron
(pKi ∼7.8–8.3) [106, 397, 668]
Channel blockers picrotoxinin (pIC50 4.2) [974], bilobalide (pIC50 2.5) [974], ginkgolide B (pIC50 2.4) [974] picrotoxinin (pIC50 5) [973], TMB-8 (pIC50 4.9) [944], diltiazem (pIC50 4.7) [973],
bilobalide (pIC50 3.3) [973], ginkgolide B (pIC50 3.1) [973]
Labelled ligands – [3H]ramosetron (Antagonist) (pKd 9.8) [668], [
3H]GR65630 (Antagonist) (pKd 8.6–9.3)
[382, 536], [3H]granisetron (Antagonist) (pKd 8.9) [106, 397], [
3H](S)-zacopride
(Antagonist) (pKd 8.7) [757], [
3H]LY278584 (Antagonist) (pKd 8.5) [3]
Functional Characteristics γ = 0.4-0.8 pS [+ 5-HT3B, γ = 16 pS]; inwardly rectifying current [+ 5-HT3B, rectiﬁcation
reduced]; nH 2-3 [+ 5-HT3B 1-2]; relative permeability to divalent cations reduced by
co-expression of the 5-HT3B subunit
γ = 0.4-0.8 pS [+ 5-HT3B, γ = 16 pS]; inwardly rectifying current [+ 5-HT3B, rectiﬁcation
reduced]; nH 2-3 [+ 5-HT3B 1-2]; relative permeability to divalent cations reduced by
co-expression of the 5-HT3B subunit
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Subunits
Nomenclature 5-HT3A 5-HT3B 5-HT3C 5-HT3D 5-HT3E
HGNC, UniProt HTR3A, P46098 HTR3B, O95264 HTR3C, Q8WXA8 HTR3D, Q70Z44 HTR3E, A5X5Y0
Functional Characteristics γ = 0.4-0.8 pS [+ 5-HT3B, γ = 16 pS];
inwardly rectifying current [+ 5-HT3B,
rectiﬁcation reduced]; nH 2-3 [+
5-HT3B 1-2]; relative permeability to
divalent cations reduced by
co-expression of the 5-HT3B subunit
γ = 0.4-0.8 pS [+ 5-HT3B, γ = 16 pS];
inwardly rectifying current [+ 5-HT3B,
rectiﬁcation reduced]; nH 2-3 [+
5-HT3B 1-2]; relative permeability to
divalent cations reduced by
co-expression of the 5-HT3B subunit
– – –
Comments: Quantitative data in the table refer to homo-
oligomeric assemblies of the human 5-HT3A subunit, or the re-
ceptor native to human tissues. Signiﬁcant changes introduced
by co-expression of the 5-HT3B subunit are indicated in parenthe-
sis. Although not a selective antagonist, methadone displays mul-
timodal and subunit-dependent antagonism of 5-HT3 receptors
[210]. Similarly, TMB-8, diltiazem, picrotoxin, bilobalide and
ginkgolide B are not selective for 5-HT3 receptors (e.g.[974]). The
anti-malarial drugsmeﬂoquine and quinine exert amodestlymore
potent block of 5-HT3A versus 5-HT3AB receptor-mediated re-
sponses [976]. Known better as a partial agonist of nicotinic acetyl-
choline α4β2 receptors, varenicline is also an agonist of the 5-
HT3A receptor [601]. Human [75, 668], rat [419], mouse [628],
guinea-pig [536] ferret [670] and canine [441] orthologues of the 5-
HT3A receptor subunit have been cloned that exhibit intraspecies
variations in receptor pharmacology. Notably, most ligands dis-
play signiﬁcantly reduced afﬁnities at the guinea-pig 5-HT3 recep-
tor in comparison with other species. In addition to the agents
listed in the table, native and recombinant 5-HT3 receptors are
subject to allosteric modulation by extracellular divalent cations,
alcohols, several general anaesthetics and 5-hydroxy- and halide-
substituted indoles (see reviews [758, 977, 978, 1042]).
Further reading on 5-HT3 receptors
Andrews PL et al. (2014) Nausea and the quest for the perfect anti-emetic. Eur. J. Pharmacol. 722:
108-21 [PMID:24157981]
Fakhfouri G et al. (2015) From Chemotherapy-Induced Emesis to Neuroprotection: Therapeutic Op-
portunities for 5-HT3 Receptor Antagonists. Mol. Neurobiol. 52: 1670-1679 [PMID:25377794]
Gupta D et al. (2016) 5HT3 receptors: Target for new antidepressant drugs. Neurosci Biobehav Rev 64:
311-25 [PMID:26976353]
Hoyer D et al. (1994) International Union of Pharmacology classiﬁcation of receptors for 5-
hydroxytryptamine (Serotonin). Pharmacol. Rev. 46: 157-203 [PMID:7938165]
Lochner M et al. (2015) A review of ﬂuorescent ligands for studying 5-HT3 receptors. Neuropharma-
cology 98: 31-40 [PMID:25892507]
Rojas C et al. (2014) Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention
of emesis. Eur. J. Pharmacol. 722: 26-37 [PMID:24184669]
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Acid-sensing (proton-gated) ion channels (ASICs)
Ion channels → Ligand-gated ion channels → Acid-sensing (proton-gated) ion channels (ASICs)
Overview: Acid-sensing ion channels (ASICs,nomenclature as
agreed by NC-IUPHAR [475]) are members of a Na+ channel
superfamily that includes the epithelial Na+ channel (ENaC), the
FMRF-amide activated channel (FaNaC) of invertebrates, the de-
generins (DEG) of Caenorhabitis elegans, channels in Drosophila
melanogaster and ’orphan’ channels that include BLINaC [858]
and INaC [872] that have also been named BASICs, for bile acid-
activated ion channels [1070]. ASIC subunits contain two TM do-
mains and assemble as homo- or hetero-trimers [44, 321, 437]
to form proton-gated, voltage-insensitive, Na+ permeable, chan-
nels (reviewed in [339, 1067]). Splice variants of ASIC1 [termed
ASIC1a (ASIC, ASICα, BNaC2α) [1036], ASIC1b (ASICβ, BNaC2β)
[153] and ASIC1b2 (ASICβ2) [1004]; note that ASIC1a is also per-
meable to Ca2+] and ASIC2 [termed ASIC2a (MDEG1, BNaC1α,
BNC1α) [306, 808, 1037] and ASIC2b (MDEG2, BNaC1β) [575]]
have been cloned. Unlike ASIC2a (listed in table), heterologous
expression of ASIC2b alone does not support H+-gated currents.
A third member, ASIC3 (DRASIC, TNaC1) [1035], has been identi-
ﬁed. A fourth mammalian member of the family (ASIC4/SPASIC)
does not support a proton-gated channel in heterologous expres-
sion systems and is reported to downregulate the expression of
ASIC1a and ASIC3 [14, 235, 338, 572]. ASIC channels are primar-
ily expressed in central and peripheral neurons including noci-
ceptors where they participate in neuronal sensitivity to acido-
sis. They have also been detected in taste receptor cells (ASIC1-
3), photoreceptors and retinal cells (ASIC1-3), cochlear hair cells
(ASIC1b), testis (hASIC3), pituitary gland (ASIC4), lung epithelial
cells (ASIC1a and -3), urothelial cells, adipose cells (ASIC3), vascu-
lar smooth muscle cells (ASIC1-3), immune cells (ASIC1,-3 and -4)
and bone (ASIC1-3). A neurotransmitter-like function of protons
has been suggested, involving postsynaptically located ASICs of
the CNS in functions such as learning and fear perception [242,
516, 1150], responses to focal ischemia [1090] and to axonal de-
generation in autoimmune inﬂammation in a mouse model of
multiple sclerosis [298], as well as seizures [1151] and pain [98,
219, 220, 229]. Heterologously expressed heteromultimers form
ion channels with differences in kinetics, ion selectivity, pH- sen-
sitivity and sensitivity to blockers that resemble some of the native
proton activated currents recorded from neurones [42, 60, 269,
575].
Nomenclature ASIC1 ASIC2
HGNC, UniProt ASIC1, P78348 ASIC2, Q16515
Endogenous activators Extracellular H+ (ASIC1a) (pEC50 ∼6.2–6.8), Extracellular H+ (ASIC1b) (pEC50 ∼5.1–6.2) Extracellular H+ (pEC50 ∼4.1–5)
Channel blockers Pi-hexatoxin-Hi1a (ASIC1a) (pIC50 ∼9.3) [112], psalmotoxin 1 (ASIC1a) (pIC50 9), Pi-theraphotoxin-Hm3a (ASIC1a) (pIC50 ∼8.5) [264],
Zn2+ (ASIC1a) (pIC50 ∼8.2), mambalgin-1 (ASIC1a) (pIC50 ∼7.3) [229], mambalgin-1 (ASIC1b) (pIC50 ∼7) [57], diminazene (ASIC1a &
ASIC1b) (pIC50 ∼6.5) [544], Pb2+ (ASIC1b) (pIC50 ∼5.8), A-317567 (ASIC1a) (pIC50 ∼5.7) [245] – Rat, Pb2+ (ASIC1a) (pIC50 ∼5.4),
amiloride (ASIC1a) (pIC50 5), benzamil (ASIC1a) (pIC50 5), ethylisopropylamiloride (ASIC1a) (pIC50 5), nafamostat (ASIC1a) (pIC50 ∼4.9),
amiloride (ASIC1b) (pIC50 4.6–4.7), ﬂurbiprofen (ASIC1a) (pIC50 3.5) [1025] – Rat, ibuprofen (ASIC1a) (pIC50 ∼3.5), Ni2+ (ASIC1a) (pIC50
∼3.2)
diminazene (pIC50 ∼6.1) [544], amiloride
(pIC50 4.6), A-317567 (pIC50 ∼4.5),
nafamostat (pIC50 ∼4.2), Cd2+ (pIC50 ∼3)
Labelled ligands [125I]psalmotoxin 1 (ASIC1a) (pKd 9.7) –
Functional Characteristics ASIC1a: γ = 14pS
PNa/PK = 5-13, PNa/PCa =2.5
rapid activation rate (5.8-13.7 ms), rapid inactivation rate (1.2-4 s) @ pH 6.0, slow recovery (5.3-13s) @ pH 7.4
ASIC1b: γ = 19 pS
PNa/PK =14.0, PNa  PCa
rapid activation rate (9.9 ms), rapid inactivation rate (0.9-1.7 s) @ pH 6.0, slow recovery (4.4-7.7 s) @ pH 7.4
= γ10.4-13.4 pS
PNa/PK =10, PNa/PCa = 20
rapid activation rate, moderate
inactivation rate (3.3-5.5 s) @ pH 5
Comments ASIC1a and ASIC1b are activated by the heteromeric Texas coral snake toxin MitTx, with pEC50 values of 8 and 7.6 respectively [98]. ASIC2 is also blocked by diarylamidines
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Nomenclature ASIC3
HGNC, UniProt ASIC3, Q9UHC3
Endogenous activators Extracellular H+ (transient component) (pEC50 ∼6.2–6.7), Extracellular H+ (sustained component) (pEC50 ∼3.5–4.3)
Activators GMQ (largly non-desensitizing; at pH 7.4) (pEC50 ∼3), arcaine (at pH 7.4) (pEC50 ∼2.9), agmatine (at pH 7.4) (pEC50 ∼2)
Channel blockers APETx2 (transient component only) (pIC50 7.2), diminazene (pIC50 ∼6.5) [544], A-317567 (pIC50 6) [521], nafamostat (transient component) (pIC50 ∼5.6), amiloride (transient
component only - sustained component enhanced by 200μM amiloride at pH 4) (pIC50 4.2–4.8), Gd3+ (pIC50 4.4), Zn2+ (pIC50 4.2), aspirin (sustained component) (pIC50 4) [1025],
diclofenac (sustained component) (pIC50 4), salicylic acid (sustained component) (pIC50 3.6)
Functional Characteristics γ= 13-15 pS;
biphasic response consisting of rapidly inactivating transient and sustained components;
very rapid activation (<5 ms) and inactivation (0.4 s);
fast recovery (0.4-0.6 s) @ pH 7.4, transient component partially inactivated at pH 7.2
Comments ASIC3 is activated by Mit-Toxin (pEC50 6.1) [98].
Comments: Psalmotoxin 1 (PcTx1) inhibits ASIC1a by increas-
ing the afﬁnity toH+ and promoting channel desensitization [160,
269]. PcTx1 has little effect on ASIC2a, ASIC3 or ASIC1a expressed
as a heteromultimer with either ASIC2a, or ASIC3 but does in-
hibit ASIC1a expressed as a heteromultimer with ASIC2b [897].
PcTx1 and π-Hm3a potentiate ASIC1b currents [159, 264]. ASIC1-
containing homo- and heteromers are inhibited by Mambalgins,
toxins contained in the black mamba venom, which induce in
ASIC1a an acidic shift of the pH dependence of activation [229].
π-Hi1a is highly selective for ASIC1a with very little activity at
ASIC1b. It inhibits channel activation and is very slowly reversible
[146]. APETx2 most potently blocks homomeric ASIC3 channels,
but also ASIC2b+ASIC3, ASIC1b+ASIC3, and ASIC1a+ASIC3 het-
eromeric channels with IC50 values of 117 nM, 900 nM and 2 μM,
respectively. APETx2 has no effect on ASIC1a or ASIC2a+ASIC3,
however, it does potentiate ASIC1b and ASIC2a homomers in the
lowmicromolar range (1-10μM) [228, 230, 544]. APETx2 however
also inhibits voltage-gated Na+ channels [92, 776]. IC50 value for
A-317567 was determined using high throughput electrophysiol-
ogy on human ASIC3 expressed in HEK293 cells [521]. The pEC50
values for proton activation of ASIC channels are inﬂuenced by
numerous factors including extracellular di- and poly-valent ions,
Zn2+, protein kinase C and serine proteases (reviewed in [475,
1067]). Rapid acidiﬁcation is required for activation of ASIC1
and ASIC3 due to fast inactivation/desensitization. pEC50 values
for H+-activation of either transient, or sustained, currents me-
diated by ASIC3 vary in the literature and may reﬂect species
and/or methodological differences [43, 204, 1035]. The transient
ASIC current component is Na+-selective (PNa/PK of about 10)
[1035, 1109] whereas the sustained current component that is
observed with ASIC3 and some ASIC heteromers is non-selective
between Na+ and K+ [204]. The reducing agents dithiothreitol
(DTT) and glutathione (GSH) increase ASIC1a currents expressed
in CHO cells and ASIC-like currents in sensory ganglia and cen-
tral neurons [29, 169] whereas oxidation, through the forma-
tion of intersubunit disulphide bonds, reduces currents mediated
by ASIC1a [1134]. ASIC1a is also irreversibly modulated by ex-
tracellular serine proteases, such as trypsin, through proteolytic
cleavage [1030]. Non-steroidal anti-inﬂammatory drugs (NSAIDs)
are direct inhibitors of ASIC currents (reviewed in [58]). Extra-
cellular Zn2+ potentiates proton activation of homomeric and
heteromeric channels incorporating ASIC2a, but not homomeric
ASIC1a or ASIC3 channels [59]. However, removal of contami-
nating Zn2+ by chelation reveals a high afﬁnity block of homo-
meric ASIC1a and heteromeric ASIC1a+ASIC2 channels by Zn2+
indicating complex biphasic actions of the divalent [170]. Nitric
oxide potentiates submaximal currents activated by H+ mediated
by ASIC1a, ASIC1b, ASIC2a and ASIC3 [121]. Ammonium ions ac-
tivate ASIC channels (most likely ASIC1a) in midbrain dopamin-
ergic neurones: that may be relevant to neuronal disorders asso-
ciated with hyperammonemia [791]. The positive modulation of
homomeric, heteromeric and native ASIC channels by the peptide
FMRFamide and related substances, such as neuropeptides FF and
SF, is reviewed in detail in [1015]. Inﬂammatory conditions and
particular pro-inﬂammatory mediators such as arachidonic acid
induce overexpression of ASIC-encoding genes and enhance ASIC
currents [220, 624, 912]. The sustained current component me-
diated by ASIC3 is potentiated by hypertonic solutions in a man-
ner that is synergistic with the effect of arachidonic acid [220].
ASIC3 is partially activated by the lipids lysophosphatidylcholine
(LPC) and arachidonic acid [629]. Mit-Toxin, which is contained
in the venom of the Texas coral snake, activates several ASIC sub-
types [98]. Selective activation of ASIC3 by GMQ at a site separate
from the proton binding site is potentiated by mild acidosis and
reduced extracellular Ca2+ [1124].
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Epithelial sodium channel (ENaC)
Ion channels → Ligand-gated ion channels → Epithelial sodium channel (ENaC)
Overview: The epithelial sodium channels (ENaC) are located
on the apical membrane of epithelial cells in the distal kidney
tubules, lung, respiratory tract, male and female reproductive
tracts, sweat and salivary glands, placenta, colon and some other
organs [123, 246, 354]. In these epithelia, ENaC allows ﬂow of
Na+ ions from the extracellular ﬂuid in the lumen into the ep-
ithelial cell. Na+ ions are then pumped out of the cytoplasm into
the interstitial ﬂuid by the Na+/K+ ATPase located on the baso-
lateral membrane [1017]. As Na+ is one of the major electrolytes
in the extracellular ﬂuid (ECF), osmolarity change initiated by the
Na+ ﬂow is accompanied by a ﬂow of water accompanying Na+
ions [104]. Thus, ENaC has a central role in the regulation of ECF
volume and blood pressure, especially via its function in the kid-
ney [475, 845]. The expression of ENaC subunits, hence its activ-
ity, is regulated by the renin-angotensin-aldosterone system, and
other factors that are involved in electrolyte homeostasis [35, 749,
845]. In the respiratory tract and female reproductive tract large
segments of the tracts are covered by multi-ciliated cells. In these
cells ENaC has been shown to be located along the entire length of
the cilia [263]. Cilial location greatly increases ENaC density per
cell surface and allows ENaC to serve as a sensitive regulator of
osmolarity of the periciliary ﬂuid throughout the whole depth of
the ﬂuid bathing the cilia [263]. In contrast to ENaC, CFTR that is
defective in cystic ﬁbrosis is not located on non-cilial cell-surface
[263]. Thus, ENaC function is also essential for the clearance of
respiratory airways, transport of germ cells, fertilization, implan-
tation and cell migration [263, 846]. ENaC has been recently local-
ized in the germinal epithelium of the testis, Sertoli cells, sperma-
tozoa, along the epididymis ducts, and smooth muscle cells [890,
891]. Evidence has been provided that rare mutations in ENaC are
associated with female infertility [97].
Nomenclature ENaCαβγ
Subunits ENaC β, ENaC α, ENaC γ
Activators S3969 (pEC50 5.9) [598]
Channel blockers P552-02 (pIC50 8.1), benzamil (pIC50 ∼8), amiloride (pIC50 6.7–7), triamterene (pIC50 ∼5.3) [124, 474]
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Subunits
Nomenclature ENaC α ENaC β ENaC γ ENaC δ
HGNC, UniProt SCNN1A, P37088 SCNN1B, P51168 SCNN1G, P51170 SCNN1D, P51172
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GABAA receptors
Ion channels → Ligand-gated ion channels → GABAA receptors
Overview: The GABAA receptor is a ligand-gated ion channel of
the Cys-loop family that includes the nicotinic acetylcholine, 5-
HT3 and strychnine-sensitive glycine receptors. GABAA receptor-
mediated inhibition within the CNS occurs by fast synaptic trans-
mission, sustained tonic inhibition and temporally intermediate
events that have been termed ‘GABAA, slow’ [132]. GABAA re-
ceptors exist as pentamers of 4TM subunits that form an intrin-
sic anion selective channel. Sequences of six α, three β, three
γ, one δ, three ρ, one , one π and one   GABAA receptor sub-
units have been reported in mammals [737, 738, 900, 902]. The
π-subunit is restricted to reproductive tissue. Alternatively spliced
versions of many subunits exist (e.g. α4- and α6- (both not func-
tional) α5-, β2-, β3- and γ2), along with RNA editing of the α3 sub-
unit [196]. The three ρ-subunits, (ρ1-3) function as either homo-
or hetero-oligomeric assemblies [152, 1135]. Receptors formed
from ρ-subunits, because of their distinctive pharmacology that
includes insensitivity to bicuculline, benzodiazepines and barbitu-
rates, have sometimes been termed GABAC receptors [1135], but
they are classiﬁed as GABAA receptors by NC-IUPHAR on
the basis of structural and functional criteria [55, 737,
738].
Many GABAA receptor subtypes contain α-, β- and γ-subunits with
the likely stoichiometry 2α.2β.1γ [507, 738]. It is thought that
the majority of GABAA receptors harbour a single type of α- and
β -subunit variant. The α1β2γ2 hetero-oligomer constitutes the
largest population of GABAA receptors in the CNS, followed by
the α2β3γ2 and α3β3γ2 isoforms. Receptors that incorporate the
α4- α5-or α6-subunit, or the β1-, γ1-, γ3-, δ-, - and  -subunits, are
less numerous, but they may nonetheless serve important func-
tions. For example, extrasynaptically located receptors that con-
tain α6- and δ-subunits in cerebellar granule cells, or an α4- and
δ-subunit in dentate gyrus granule cells and thalamic neurones,
mediate a tonic current that is important for neuronal excitabil-
ity in response to ambient concentrations of GABA [76, 279, 671,
886, 917]. GABA binding occurs at the β+/α- subunit interface
and the homologous γ+/α- subunits interface creates the benzodi-
azepine site. A second site for benzodiazepine binding has recently
been postulated to occur at the α+/β- interface ([824]; reviewed by
[901]). The particular α-and γ-subunit isoforms exhibit marked
effects on recognition and/or efﬁcacy at the benzodiazepine site.
Thus, receptors incorporating either α4- or α6-subunits are not
recognised by ‘classical’ benzodiazepines, such as ﬂunitrazepam
(but see [1118]). The trafﬁcking, cell surface expression, internal-
isation and function of GABAA receptors and their subunits are
discussed in detail in several recent reviews [164, 427, 602, 1019]
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but one point worthy of note is that receptors incorporating the γ2
subunit (except when associated with α5) cluster at the postsynap-
tic membrane (but may distribute dynamically between synaptic
and extrasynaptic locations), whereas as those incorporating the
d subunit appear to be exclusively extrasynaptic.
NC-IUPHAR [55, 738] class the GABAA receptors according to
their subunit structure, pharmacology and receptor function. Cur-
rently, eleven native GABAA receptors are classed as conclusively
identiﬁed (i.e., α1β2γ2, α1βγ2, α3βγ2, α4βγ2, α4β2δ, α4β3δ, α5βγ2,
α6βγ2, α6β2δ, α6β3δ and ρ) with further receptor isoforms occur-
ring with high probability, or only tentatively [737, 738]. It is be-
yond the scope of this Guide to discuss the pharmacology of indi-
vidual GABAA receptor isoforms in detail; such information can be
gleaned in the reviews [55, 300, 448, 507, 518, 686, 737, 738, 900]
and [37, 38]. Agents that discriminate between α-subunit isoforms
are noted in the table and additional agents that demonstrate se-
lectivity between receptor isoforms, for example via β-subunit se-
lectivity, are indicated in the text below. The distinctive agonist
and antagonist pharmacology of ρ receptors is summarised in the
table and additional aspects are reviewed in [152, 449, 702, 1135].
Several high-resolution cryo-electron microscopy structures have
been described in which the full-length human α1β3γ2L GABAA
receptor in lipid nanodiscs is bound to the channel-blocker picro-
toxin, the competitive antagonist bicuculline, the agonist GABA
(γ-aminobutyric acid), and the classical benzodiazepines alprazo-
lam and diazepam [634].
Nomenclature GABAA receptor α1 subunit GABAA receptor α2 subunit
HGNC, UniProt GABRA1, P14867 GABRA2, P47869
Agonists gaboxadol [GABA site], isoguvacine [GABA site], isonipecotic acid [GABA site],
muscimol [GABA site], piperidine-4-sulphonic acid [GABA site]
gaboxadol [GABA site], isoguvacine [GABA site], isonipecotic acid [GABA site],
muscimol [GABA site], piperidine-4-sulphonic acid [GABA site]
Selective antagonists bicuculline [GABA site], gabazine [GABA site] bicuculline [GABA site], gabazine [GABA site]
Channel blockers TBPS, picrotoxin TBPS, picrotoxin
Endogenous allosteric modulators 5α-pregnan-3α-ol-20-one (Potentiation), Zn2+ (Inhibition),
tetrahydrodeoxycorticosterone (Potentiation)
5α-pregnan-3α-ol-20-one (Potentiation), Zn2+ (Inhibition),
tetrahydrodeoxycorticosterone (Potentiation)
Allosteric modulators ﬂumazenil [benzodiazepine site] (Antagonist) (pKi 9.1) [407], clonazepam (Positive)
(pKi 8.9) [809], ﬂunitrazepam [benzodiazepine site] (Positive) (pKi 8.3) [347],
diazepam [benzodiazepine site] (Positive) (pKi 7.8) [809], alprazolam [benzodiazepine
site] (Positive) (pEC50 7.4) [17], α3IA [benzodiazepine site] (Inverse agonist), α5IA
[benzodiazepine site] (Inverse agonist), DMCM [benzodiazepine site] (Inverse agonist)
ﬂumazenil [benzodiazepine site] (Antagonist) (pKi 9.1) [407], clonazepam (Positive)
(pKi 8.8) [809], ﬂunitrazepam [benzodiazepine site] (Positive) (pKi 8.3) [347],
alprazolam [benzodiazepine site] (Positive) (pEC50 7.9) [17], diazepam
[benzodiazepine site] (Positive) (pKi 7.8) [809], α3IA [benzodiazepine site] (Inverse
agonist), α5IA [benzodiazepine site] (Inverse agonist), DMCM [benzodiazepine site]
(Inverse agonist)
Selective allosteric modulators zolpidem (Positive) (pKi 7.4–7.7) [348, 878], L838417 [benzodiazepine site]
(Antagonist), ZK93426 [benzodiazepine site] (Antagonist), indiplon [benzodiazepine
site] (Full agonist), ocinaplon [benzodiazepine site] (Full agonist)
L838417 [benzodiazepine site] (Partial agonist), TPA023 [benzodiazepine site] (Partial
agonist)
Labelled ligands [11C]ﬂumazenil [benzodiazepine site] (Allosteric modulator, Antagonist),
[18F]ﬂuoroethylﬂumazenil [benzodiazepine site] (Allosteric modulator, Antagonist),
[35S]TBPS [anion channel] (Channel blocker), [3H]CGS8216 [benzodiazepine site]
(Allosteric modulator, Mixed), [3H]ﬂunitrazepam [benzodiazepine site] (Allosteric
modulator, Positive), [3H]gabazine [GABA site] (Antagonist), [3H]muscimol [GABA
site] (Agonist), [3H]zolpidem [benzodiazepine site] (Allosteric modulator, Positive)
[11C]ﬂumazenil [benzodiazepine site] (Allosteric modulator, Antagonist),
[18F]ﬂuoroethylﬂumazenil [benzodiazepine site] (Allosteric modulator, Antagonist),
[35S]TBPS [anion channel] (Channel blocker), [3H]CGS8216 [benzodiazepine site]
(Allosteric modulator, Mixed), [3H]ﬂunitrazepam [benzodiazepine site] (Allosteric
modulator, Full agonist), [3H]gabazine [GABA site] (Antagonist), [3H]muscimol [GABA
site] (Agonist)
Comments Zn2+ is an endogenous allosteric regulator and causes potent inhibition of receptors
formed from binary combinations of α and β subunits, incorporation of a δ or γ subunit
causes a modest, or pronounced, reduction in inhibitory potency, respectively [517]
Zn2+ is an endogenous allosteric regulator and causes potent inhibition of receptors
formed from binary combinations of α and β subunits, incorporation of a δ or γ subunit
causes a modest, or pronounced, reduction in inhibitory potency, respectively [517]
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Nomenclature GABAA receptor α3 subunit GABAA receptor α4 subunit
HGNC, UniProt GABRA3, P34903 GABRA4, P48169
Agonists gaboxadol [GABA site], isoguvacine [GABA site], isonipecotic acid [GABA site],
muscimol [GABA site], piperidine-4-sulphonic acid [GABA site]
gaboxadol [GABA site], isoguvacine [GABA site], muscimol [GABA site],
piperidine-4-sulphonic acid [GABA site] (low efﬁcacy)
Selective agonists – isonipecotic acid [GABA site] (relatively high efﬁcacy)
Selective antagonists bicuculline [GABA site], gabazine [GABA site] bicuculline [GABA site], gabazine [GABA site]
Channel blockers TBPS, picrotoxin TBPS, picrotoxin
Endogenous allosteric modulators 5α-pregnan-3α-ol-20-one (Potentiation), Zn2+ (Inhibition),
tetrahydrodeoxycorticosterone (Potentiation)
5α-pregnan-3α-ol-20-one (Potentiation), Zn2+ (Inhibition),
tetrahydrodeoxycorticosterone (Potentiation)
Allosteric modulators ﬂumazenil [benzodiazepine site] (Antagonist) (pKi 9) [407], clonazepam (Positive)
(pKi 8.7) [809], ﬂunitrazepam [benzodiazepine site] (Positive) (pKi 7.8) [347],
diazepam [benzodiazepine site] (Positive) (pKi 7.8) [809], alprazolam [benzodiazepine
site] (Positive) (pEC50 7.2) [17], α5IA [benzodiazepine site] (Inverse agonist), DMCM
[benzodiazepine site] (Inverse agonist)
–
Selective allosteric modulators α3IA [benzodiazepine site] (higher afﬁnity), L838417 [benzodiazepine site] (Partial
agonist), Ro19-4603 [benzodiazepine site] (Inverse agonist), TP003 [benzodiazepine
site] (Partial agonist), TPA023 [benzodiazepine site] (Partial agonist)
Ro15-4513 [benzodiazepine site] (Full agonist), bretazenil [benzodiazepine site] (Full
agonist)
Labelled ligands [11C]ﬂumazenil [benzodiazepine site] (Allosteric modulator, Antagonist),
[18F]ﬂuoroethylﬂumazenil [benzodiazepine site] (Allosteric modulator, Antagonist),
[35S]TBPS [anion channel] (Channel blocker), [3H]CGS8216 [benzodiazepine site]
(Allosteric modulator, Mixed), [3H]ﬂunitrazepam [benzodiazepine site] (Allosteric
modulator, Full agonist), [3H]gabazine [GABA site] (Antagonist), [3H]muscimol [GABA
site] (Agonist)
[11C]ﬂumazenil [benzodiazepine site] (Allosteric modulator, Partial agonist),
[18F]ﬂuoroethylﬂumazenil [benzodiazepine site] (Allosteric modulator, Antagonist),
[35S]TBPS [anion channel] (Channel blocker), [3H]CGS8216 [benzodiazepine site]
(Allosteric modulator, Mixed), [3H]Ro154513 [benzodiazepine site] (Allosteric
modulator, Full agonist), [3H]gabazine [GABA site] (Antagonist), [3H]muscimol [GABA
site] (Agonist)
Comments Zn2+ is an endogenous allosteric regulator and causes potent inhibition of receptors
formed from binary combinations of α and β subunits, incorporation of a δ or γ subunit
causes a modest, or pronounced, reduction in inhibitory potency, respectively [517]
Diazepam and ﬂunitrazepam are not active at this subunit. Zn2+ is an endogenous
allosteric regulator and causes potent inhibition of receptors formed from binary
combinations of α and β subunits, incorporation of a δ or γ subunit causes a modest,
or pronounced, reduction in inhibitory potency, respectively [517]. [3H]Ro154513
selectively labels α4-subunit-containing receptors in the presence of a saturating
concentration of a ’classical’ benzodiazepine (e.g. diazepam)
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Nomenclature GABAA receptor α5 subunit GABAA receptor α6 subunit
HGNC, UniProt GABRA5, P31644 GABRA6, Q16445
Agonists gaboxadol [GABA site], isoguvacine [GABA site], isonipecotic acid [GABA site], muscimol
[GABA site], piperidine-4-sulphonic acid [GABA site]
gaboxadol [GABA site], isoguvacine [GABA site], muscimol [GABA site],
piperidine-4-sulphonic acid [GABA site] (low efﬁcacy)
Selective agonists – isonipecotic acid [GABA site] (relatively high efﬁcacy)
Selective antagonists bicuculline [GABA site], gabazine [GABA site] bicuculline [GABA site], gabazine [GABA site]
Channel blockers TBPS, picrotoxin TBPS, picrotoxin
Endogenous allosteric
modulators
5α-pregnan-3α-ol-20-one (Potentiation), Zn2+ (Inhibition), tetrahydrodeoxycorticosterone
(Potentiation)
5α-pregnan-3α-ol-20-one (Potentiation), Zn2+ (Inhibition), tetrahydrodeoxycorticosterone
(Potentiation)
Allosteric modulators ﬂumazenil [benzodiazepine site] (Antagonist) (pKi 9.2) [407], ﬂunitrazepam
[benzodiazepine site] (Positive) (pKi 8.3) [347], alprazolam [benzodiazepine site] (Positive)
(pEC50 8) [17], α3IA [benzodiazepine site] (Inverse agonist), DMCM [benzodiazepine site]
(Inverse agonist)
ﬂumazenil [benzodiazepine site] (Partial agonist) (pKi 6.8) [407], bretazenil
[benzodiazepine site] (Full agonist)
Selective allosteric
modulators
α5IA [benzodiazepine site] (Inverse agonist), L655708 [benzodiazepine site] (Inverse
agonist), L838417 [benzodiazepine site] (Partial agonist), MRK016 [benzodiazepine site]
(Inverse agonist), RO4938581 [benzodiazepine site] (Inverse agonist), RY024
[benzodiazepine site] (Inverse agonist)
Ro15-4513 [benzodiazepine site] (Full agonist)
Labelled ligands [3H]RY80 [benzodiazepine site] (Selective Binding) (pKd 9.2) [907] – Rat, [
11C]ﬂumazenil
[benzodiazepine site] (Allosteric modulator, Antagonist), [18F]ﬂuoroethylﬂumazenil
[benzodiazepine site] (Allosteric modulator, Antagonist), [35S]TBPS [anion channel]
(Channel blocker), [3H]CGS8216 [benzodiazepine site] (Allosteric modulator, Mixed),
[3H]L655708 [benzodiazepine site] (Allosteric modulator, Inverse agonist),
[3H]ﬂunitrazepam [benzodiazepine site] (Allosteric modulator, Full agonist), [3H]gabazine
[GABA site] (Antagonist), [3H]muscimol [GABA site] (Agonist)
[11C]ﬂumazenil [benzodiazepine site] (Allosteric modulator, Partial agonist),
[18F]ﬂuoroethylﬂumazenil [benzodiazepine site] (Allosteric modulator, Antagonist),
[35S]TBPS [anion channel] (Channel blocker), [3H]CGS8216 [benzodiazepine site]
(Allosteric modulator, Mixed), [3H]Ro154513 [benzodiazepine site] (Allosteric modulator,
Full agonist), [3H]gabazine [GABA site] (Antagonist), [3H]muscimol [GABA site] (Agonist)
Comments Zn2+ is an endogenous allosteric regulator and causes potent inhibition of receptors
formed from binary combinations of α and β subunits, incorporation of a δ or γ subunit
causes a modest, or pronounced, reduction in inhibitory potency, respectively [517]
Diazepam and ﬂunitrazepam are not active at this subunit. Zn2+ is an endogenous
allosteric regulator and causes potent inhibition of receptors formed from binary
combinations of α and β subunits, incorporation of a δ or γ subunit causes a modest, or
pronounced, reduction in inhibitory potency, respectively [517]. [3H]Ro154513 selectively
labels α6-subunit-containing receptors in the presence of a saturating concentration of a
’classical’ benzodiazepine (e.g. diazepam)
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Nomenclature GABAA receptor β1 subunit GABAA receptor β2 subunit GABAA receptor β3 subunit
HGNC, UniProt GABRB1, P18505 GABRB2, P47870 GABRB3, P28472
Channel blockers TBPS, picrotoxin TBPS, picrotoxin TBPS, picrotoxin
Allosteric modulators – – etazolate (Binding) (pIC50 5.5) [1133]
Comments Zn2+ is an endogenous allosteric regulator and causes potent inhibition of receptors formed from binary combinations of α and β subunits,
incorporation of a δ or γ subunit causes a modest, or pronounced, reduction in inhibitory potency, respectively [517]
Nomenclature GABAA receptor γ1 subunit GABAA receptor γ2 subunit GABAA receptor γ3 subunit
HGNC, UniProt GABRG1, Q8N1C3 GABRG2, P18507 GABRG3, Q99928
Channel blockers TBPS, picrotoxin TBPS, picrotoxin TBPS, picrotoxin
Comments Zn2+ is an endogenous allosteric regulator and causes potent inhibition of receptors formed from binary combinations of α and β subunits,
incorporation of a δ or γ subunit causes a modest, or pronounced, reduction in inhibitory potency, respectively [517]
Nomenclature GABAA receptor δ subunit GABAA receptor  subunit GABAA receptor   subunit GABAA receptor π subunit
HGNC, UniProt GABRD, O14764 GABRE, P78334 GABRQ, Q9UN88 GABRP, O00591
Selective agonists gaboxadol [GABA site] – – –
Channel blockers TBPS, picrotoxin TBPS, picrotoxin TBPS, picrotoxin TBPS, picrotoxin
Comments Zn2+ is an endogenous allosteric regulator and causes potent inhibition of receptors formed from binary combinations of α and β subunits,
incorporation of a δ or γ subunit causes a modest, or pronounced, reduction in inhibitory potency, respectively
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Nomenclature GABAA receptor ρ1 subunit GABAA receptor ρ2 subunit GABAA receptor ρ3 subunit
HGNC, UniProt GABRR1, P24046 GABRR2, P28476 GABRR3, A8MPY1
Agonists isoguvacine [GABA site] (Partial agonist),
muscimol [GABA site] (Partial agonist)
isoguvacine [GABA site] (Partial agonist), muscimol [GABA site]
(Partial agonist)
isoguvacine [GABA site] (Partial agonist), muscimol [GABA site]
(Partial agonist)
Selective agonists (±)-cis-2-CAMP [GABA site], 5-Me-IAA
[GABA site]
(±)-cis-2-CAMP [GABA site], 5-Me-IAA [GABA site] (±)-cis-2-CAMP [GABA site], 5-Me-IAA [GABA site]
Antagonists gaboxadol [GABA site], isonipecotic acid
[GABA site], piperidine-4-sulphonic acid
[GABA site]
gaboxadol [GABA site], isonipecotic acid [GABA site],
piperidine-4-sulphonic acid [GABA site]
gaboxadol [GABA site], isonipecotic acid [GABA site],
piperidine-4-sulphonic acid [GABA site]
Selective antagonists cis-3-ACPBPA [GABA site], trans-3-ACPBPA
[GABA site], TPMPA [GABA site], aza-THIP
[GABA site]
cis-3-ACPBPA [GABA site], trans-3-ACPBPA [GABA site], TPMPA
[GABA site], aza-THIP [GABA site]
cis-3-ACPBPA [GABA site], trans-3-ACPBPA [GABA site], TPMPA
[GABA site], aza-THIP [GABA site]
Channel blockers TBPS, picrotoxin TBPS, picrotoxin TBPS, picrotoxin
Comments Bicuculline is not active at this subunit Bicuculline is not active at this subunit Bicuculline is not active at this subunit
Comments: The potency and efﬁcacy of many GABA agonists
vary between GABAA receptor isoforms [300, 469, 518]. For ex-
ample, gaboxadol is a partial agonist at receptors with the subunit
composition α4β3γ2, but elicits currents in excess of those evoked
by GABA at the α4β3δ receptor where GABA itself is a low efﬁcacy
agonist [86, 111]. The antagonists bicuculline and gabazine differ
in their ability to suppress spontaneous openings of the GABAA re-
ceptor, the former being more effective [982]. The presence of the
γ subunit within the heterotrimeric complex reduces the potency
and efﬁcacy of agonists [941]. The GABAA receptor contains dis-
tinct allosteric sites that bind barbiturates and endogenous (e.g.,
5α-pregnan-3α-ol-20-one) and synthetic (e.g., alphaxalone) neu-
roactive steroids in a diastereo- or enantio-selective manner [77,
370, 399, 1010]. Picrotoxinin and TBPS act at an allosteric site
within the chloride channel pore to negatively regulate channel
activity; negative allosteric regulation by γ-butyrolactone deriva-
tives also involves the picrotoxinin site, whereas positive allosteric
regulation by such compounds is proposed to occur at a distinct
locus. Many intravenous (e.g., etomidate, propofol) and inhala-
tional (e.g., halothane, isoﬂurane) anaesthetics and alcohols also
exert a regulatory inﬂuence upon GABAA receptor activity [101,
736]. Speciﬁc amino acid residues within GABAA receptor α- and
β-subunits that inﬂuence allosteric regulation by anaesthetic and
non-anaesthetic compounds have been identiﬁed [368, 399]. Pho-
toafﬁnity labelling of distinct amino acid residues within puriﬁed
GABAA receptors by the etomidate derivative, [3H]azietomidate,
has also been demonstrated [561] and this binding subject to pos-
itive allosteric regulation by anaesthetic steroids [560]. An ar-
ray of natural products including ﬂavonoid and terpenoid com-
pounds exert varied actions at GABAA receptors (reviewed in de-
tail in [448]).
In addition to the agents listed in the table, modulators of GABAA
receptor activity that exhibit subunit dependent activity include:
salicylidene salicylhydrazide [negative allosteric modulator selec-
tive for β1- versus β2-, or β3-subunit-containing receptors [983]];
fragrent dioxane derivatives [positive allosteric modulators selec-
tive for β1- versus β2-, or β3-subunit-containing receptors [888]];
loreclezole, etomidate, tracazolate, mefenamic acid, etifoxine,
stiripentol, valerenic acid amide [positive allosteric modulators
with selectivity for β2/β3- over β1-subunit-containing receptors
[291, 483, 507]]; tracazolate [intrinsic efﬁcacy, i.e., potentiation,
or inhibition, is dependent upon the identity of the γ1-3-, δ-, or
-subunit co-assembed with α1- and β1-subunits [981]]; amiloride
[selective blockade of receptors containing an α6-subunit [290]];
furosemide [selective blockade of receptors containing an α6-
subunit co-assembled with β2/β3-, but not β1-subunit [507]]; La3+
[potentiates responses mediated by α1β3γ2L receptors, weakly in-
hibits α6β3γ2L receptors, and strongly blocks α6β3δ and α4β3δ re-
ceptors [111, 871]]; ethanol [selectively potentiates responses me-
diated by α4β3δ and α6β3δ receptors versus receptors in which
β2 replaces β3, or γ replaces δ [1040], but see also [506]]; DS1
and DS2 [selectively potentiate responses mediated by δ-subunit-
containing receptors [1032]]. It should be noted that the appar-
ent selectivity of some positive allosteric modulators (e.g., neuros-
teroids such as 5α-pregnan-3α-ol-20-one for δ-subunit-containing
receptors (e.g., α1β3δ) may be a consequence of the unusually low
efﬁcacy of GABA at this receptor isoform [76, 86].
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Glycine receptors
Ion channels → Ligand-gated ion channels → Glycine receptors
Overview: The inhibitory glycine receptor (nomenclature as
agreed by the NC-IUPHAR Subcommittee on Glycine Re-
ceptors) is a member of the Cys-loop superfamily of transmitter-
gated ion channels that includes the zinc activated channels,
GABAA, nicotinic acetylcholine and 5-HT3 receptors [603]. The
receptor is expressed either as a homo-pentamer of α subunits, or
a complex now thought to harbour 2α and 3β subunits [82, 336],
that contain an intrinsic anion channel. Four differentially ex-
pressed isoforms of the α-subunit (α1-α4) and one variant of the
β-subunit (β1, GLRB, P48167) have been identiﬁed by genomic
and cDNA cloning. Further diversity originates from alternative
splicing of the primary gene transcripts for α1 (α1INS and α1del),
α2 (α2A and α2B), α3 (α3S and α3L) and β (β7) subunits and
by mRNA editing of the α2 and α3 subunit [260, 647, 731]. Both
α2 splicing and α3 mRNA editing can produce subunits (i.e., α2B
and α3P185L) with enhanced agonist sensitivity. Predominantly,
the mature form of the receptor contains α1 (or α3) and β sub-
units while the immature form ismostly composed of only α2 sub-
units. RNA transcripts encoding the α4-subunit have not been de-
tected in adult humans. The N-terminal domain of the α-subunit
contains both the agonist and strychnine binding sites that con-
sist of several discontinuous regions of amino acids. Inclusion of
the β-subunit in the pentameric glycine receptor contributes to
agonist binding, reduces single channel conductance and alters
pharmacology. The β-subunit also anchors the receptor, via an
amphipathic sequence within the large intracellular loop region,
to gephyrin. The latter is a cytoskeletal attachment protein that
binds to a number of subsynaptic proteins involved in cytoskeletal
structure and thus clusters and anchors hetero-oligomeric recep-
tors to the synapse [489, 497, 676]. G-protein βγ subunits enhance
the open state probability of native and recombinant glycine re-
ceptors by association with domains within the large intracellu-
lar loop [1114, 1115]. Intracellular chloride concentration mod-
ulates the kinetics of native and recombinant glycine receptors
[797]. Intracellular Ca2+ appears to increase native and recombi-
nant glycine receptor afﬁnity, prolonging channel open events,
by a mechanism that does not involve phosphorylation [301].
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Nomenclature glycine receptor α1 subunit glycine receptor α2 subunit glycine receptor α3 subunit glycine receptor α4 subunit
(pseudogene in humans)
HGNC, UniProt GLRA1, P23415 GLRA2, P23416 GLRA3, O75311 GLRA4, Q5JXX5
Selective agonists
(potency order)
glycine > β-alanine > taurine glycine > β-alanine > taurine glycine > β-alanine > taurine –
Selective antagonists ginkgolide X (pIC50 6.1), pregnenolone sulphate (pKi
5.7), nifedipine (pIC50 5.5), bilobalide (pIC50 4.7),
tropisetron (pKi 4.1), colchicine (pIC50 3.5), HU-308
(weak inhibition), PMBA, strychnine
HU-210 (pIC50 7), WIN55212-2 (pIC50 6.7),
HU-308 (pIC50 6), ginkgolide X (pIC50 5.6),
pregnenolone sulphate (pKi 5.3), bilobalide
(pIC50 5.1), tropisetron (pKi 4.9), colchicine
(pIC50 4.2), 5,7-dichlorokynurenic acid (pIC50
3.7), PMBA, strychnine
HU-210 (pIC50 7.3), HU-308 (pIC50 7),
WIN55212-2 (pIC50 7),
(12E,20Z,18S)-8-hydroxyvariabilin (pIC50 5.2),
nifedipine (pIC50 4.5), strychnine
–
Channel blockers ginkgolide B (pIC50 5.1–6.2), cyanotriphenylborate
(pIC50 5.9) [851], picrotin (pIC50 5.3), picrotoxinin
(pIC50 5.3), picrotoxin (pIC50 5.2)
picrotoxinin (pIC50 6.4), picrotoxin (pIC50 5.6),
ginkgolide B (pIC50 4.9–5.4), picrotin (pIC50
4.9), cyanotriphenylborate (pIC50 >4.7) [851]
picrotoxinin (pIC50 6.4), ginkgolide B (pIC50
5.7), picrotin (pIC50 5.2), picrotoxin (block is
weaker when β subunit is co-expressed)
–
Endogenous
allosteric modulators
Zn2+ (Potentiation) (pEC50 7.4), Cu2+ (Inhibition)
(pIC50 4.8–5.4), Zn2+ (Inhibition) (pIC50 4.8),
Extracellular H+ (Inhibition)
Zn2+ (Potentiation) (pEC50 6.3), Cu2+
(Inhibition) (pIC50 4.8), Zn2+ (Inhibition)
(pIC50 3.4)
Cu2+ (Inhibition) (pIC50 5), Zn2+ (Inhibition)
(pIC50 3.8)
–
Selective allosteric
modulators
anandamide (Potentiation) (pEC50 7.4), HU-210
(Potentiation) (pEC50 6.6), 9-tetrahydrocannabinol
(Potentiation) (pEC50 ∼5.5)
9-tetrahydrocannabinol (Potentiation) (pEC50
∼6)
9-tetrahydrocannabinol (Potentiation) (pEC50
∼5.3)
–
Labelled ligands [3H]strychnine (Antagonist) [3H]strychnine (Antagonist) [3H]strychnine (Antagonist) –
Functional
Characteristics
γ = 86 pS (main state); (+ β = 44 pS) γ = 111 pS (main state); (+ β = 54 pS) γ = 105 pS (main state); (+ β = 48) –
Nomenclature glycine receptor β subunit
HGNC, UniProt GLRB, P48167
Selective antagonists nifedipine (when co-expressed with the α1 subunit) (pIC50 5.9), pregnenolone sulphate (when co-expressed with the α1 subunit) (pKi 5.6), tropisetron (when co-expressed
with the α2 subunit) (pKi 5.3), pregnenolone sulphate (when co-expressed with the α2 subunit) (pKi 5), nifedipine (when co-expressed with the α3 subunit) (pIC50 4.9),
bilobalide (when co-expressed with the α2 subunit) (pIC50 4.3), bilobalide (when co-expressed with the α1 subunit) (pIC50 3.7), ginkgolide X (when co-expressed with the α1
subunit) (pIC50 >3.5), ginkgolide X (when co-expressed with the α2 subunit) (pIC50 >3.5)
Channel blockers ginkgolide B (when co-expressed with the α2 subunit) (pIC50 6.1–6.9), ginkgolide B (when co-expressed with the α1 subunit) (pIC50 5.6–6.7), ginkgolide B (when
co-expressed with the α3 subunit) (pIC50 6.3), cyanotriphenylborate (when co-expressed with the human α1 subunit) (pIC50 5.6) [851] – Rat, cyanotriphenylborate (when
co-expressed with the human α2 subunit) (pIC50 5.1) [851] – Rat, picrotoxinin (when co-expressed with the α3 subunit) (pIC50 5.1), picrotin (when co-expressed with the α1
subunit) (pIC50 4.6), picrotin (when co-expressed with the α3 subunit) (pIC50 4.6), picrotoxinin (when co-expressed with the α1 subunit) (pIC50 4.6), picrotoxin (when
co-expressed with the α2 subunit) (pIC50 4.5), picrotoxin (when co-expressed with the α1 subunit) (pIC50 3.7)
Endogenous allosteric modulators Zn2+ (Inhibition) (pIC50 4.9), Zn2+ (Inhibition) (pIC50 3.7)
Comments Ligand interaction data for hetero-oligomer receptors containing the β subunit are also listed under the α subunit
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Comments: Data in the table refer to homo-oligomeric assem-
blies of the α-subunit, signiﬁcant changes introduced by co-
expression of the β1 subunit are indicated in parenthesis. Not all
glycine receptor ligands are listed within the table, but some that
may be useful in distinguishing between glycine receptor isoforms
are indicated (see detailed view pages for each subunit: α1, α2,
α3, α4, β ). Pregnenolone sulphate, tropisetron and colchicine,
for example, although not selective antagonists of glycine recep-
tors, are included for this purpose. Strychnine is a potent and
selective competitive glycine receptor antagonist with afﬁnities in
the range 5–15 nM. RU5135 demonstrates comparable potency,
but additionally blocks GABAA receptors. There are conﬂicting re-
ports concerning the ability of cannabinoids to inhibit [594], or
potentiate and at high concentrations activate [12, 217, 366, 1089,
1111] glycine receptors. Nonetheless, cannabinoid analogues may
hold promise in distinguishing between glycine receptor subtypes
[1111]. In addition, potentiation of glycine receptor activity by
cannabinoids has been claimed to contribute to cannabis-induced
analgesia relying on Ser296/307 (α1/α3) in M3 [1089]. Several
analogues of muscimol and piperidine act as agonists and antag-
onists of both glycine and GABAA receptors. Picrotoxin acts as
an allosteric inhibitor that appears to bind within the pore, and
shows strong selectivity towards homomeric receptors. While its
components, picrotoxinin and picrotin, have equal potencies at
α1 receptors, their potencies at α2 and α3 receptors differ mod-
estly and may allow some distinction between different receptor
types [1112]. Binding of picrotoxin within the pore has been
demonstrated in the crystal structure of the related C. elegans
GluCl Cys-loop receptor [373]. In addition to the compounds
listed in the table, numerous agents act as allosteric regulators of
glycine receptors (comprehensively reviewed in [537, 604, 1062,
1116]). Zn2+ acts through distinct binding sites of high- and low-
afﬁnity to allosterically enhance channel function at low (<10
μM) concentrations and inhibits responses at higher concentra-
tions in a subunit selective manner [661]. The effect of Zn2+ is
somewhat mimicked by Ni2+. Endogenous Zn2+ is essential for
normal glycinergic neurotransmission mediated by α1 subunit-
containing receptors [383]. Elevation of intracellular Ca2+ pro-
duces fast potentiation of glycine receptor-mediated responses.
Dideoxyforskolin (4 μM) and tamoxifen (0.2–5 μM) both poten-
tiate responses to low glycine concentrations (15 μM), but act
as inhibitors at higher glycine concentrations (100 μM). Addi-
tional modulatory agents that enhance glycine receptor function
include inhalational, and several intravenous general anaesthet-
ics (e.g. minaxolone, propofol and pentobarbitone) and certain
neurosteroids. Ethanol and higher order n-alcohols also enhance
glycine receptor function although whether this occurs by a di-
rect allosteric action at the receptor [633], or through βγ subunits
[1113] is debated. Recent crystal structures of the bacterial ho-
mologue, GLIC, have identiﬁed transmembrane binding pockets
for both anaesthetics [724] and alcohols [401]. Solvents inhaled as
drugs of abuse (e.g. toluene, 1-1-1-trichloroethane) may act at sites
that overlap with those recognising alcohols and volatile anaes-
thetics to produce potentiation of glycine receptor function. The
function of glycine receptors formed as homomeric complexes
of α1 or α2 subunits, or hetero-oligomers of α1/β or α2/β sub-
units, is differentially affected by the 5-HT3 receptor antagonist
tropisetron (ICS 205-930) which may evoke potentiation (which
may occur within the femtomolar range at the homomeric glycine
α1 receptor), or inhibition, depending upon the subunit compo-
sition of the receptor and the concentrations of the modulator
and glycine employed. Potentiation and inhibition by tropeines
involves different binding modes [621]. Additional tropeines, in-
cluding atropine, modulate glycine receptor activity.
Further reading on Glycine receptors
Burgos CF et al. (2016) Structure and Pharmacologic Modulation of Inhibitory Glycine Receptors.
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Dutertre S et al. (2012) Inhibitory glycine receptors: an update. J. Biol. Chem. 287: 40216-23
[PMID:23038260]
Lynch JW. (2004) Molecular structure and function of the glycine receptor chloride channel. Physiol.
Rev. 84: 1051-95 [PMID:15383648]
Perkins DI et al. (2010) Molecular targets and mechanisms for ethanol action in glycine receptors.
Pharmacol. Ther. 127: 53-65 [PMID:20399807]
Yevenes GE et al. (2011) Allosteric modulation of glycine receptors. Br. J. Pharmacol. 164: 224-36
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Ionotropic glutamate receptors
Ion channels → Ligand-gated ion channels → Ionotropic glutamate receptors
Overview: The ionotropic glutamate receptors comprise mem-
bers of the NMDA (N-methyl-D-aspartate), AMPA (α-amino-
3-hydroxy-5-methyl-4-isoxazoleproprionic acid) and kainate re-
ceptor classes, named originally according to their preferred,
synthetic, agonist [226, 588, 997]. Receptor heterogeneity within
each class arises from the homo-oligomeric, or hetero-oligomeric,
assembly of distinct subunits into cation-selective tetramers. Each
subunit of the tetrameric complex comprises an extracellular
amino terminal domain (ATD), an extracellular ligand binding
domain (LBD), three transmembrane domains composed of three
membrane spans (M1, M3 and M4), a channel lining re-entrant
‘p-loop’ (M2) located between M1 and M3 and an intracellular
carboxy- terminal domain (CTD) [458, 523, 639, 691, 997]. The
X-ray structure of a homomeric ionotropic glutamate receptor
(GluA2 – see below) has recently been solved at 3.6Å resolu-
tion [919] and although providing the most complete struc-
tural information current available may not representative of the
subunit arrangement of, for example, the heteromeric NMDA
receptors [466]. It is beyond the scope of this supplement to dis-
cuss the pharmacology of individual ionotropic glutamate recep-
tor isoforms in detail; such information can be gleaned from [155,
190, 226, 266, 433, 434, 479, 750, 751, 752, 997, 1086]. Agents
that discriminate between subunit isoforms are, where appropri-
ate, noted in the tables and additional compounds that distin-
guish between receptor isoforms are indicated in the text below.
The classiﬁcation of glutamate receptor subunits has
been re-addressed by NC-IUPHAR [183]. The scheme devel-
oped recommends a nomenclature for ionotropic glutamate re-
ceptor subunits that is adopted here.
AMPA and Kainate receptors
AMPA receptors assemble as homomers, or heteromers, that may
be drawn from GluA1, GluA2, GluA3 and GluA4 subunits. Trans-
membrane AMPA receptor regulatory proteins (TARPs) of class I
(i.e. γ2, γ3, γ4 and γ8) act, with variable stoichiometry, as aux-
iliary subunits to AMPA receptors and inﬂuence their trafﬁck-
ing, single channel conductance gating and pharmacology (re-
viewed in [270, 426, 663, 991]). Functional kainate receptors can
be expressed as homomers of GluK1, GluK2 or GluK3 subunits.
GluK1-3 subunits are also capable of assembling into heterote-
tramers (e.g. GluK1/K2; [553, 783, 795]). Two additional kainate
receptor subunits, GluK4 and GluK5, when expressed individu-
ally, form high afﬁnity binding sites for kainate, but lack function,
but can form heteromers when expressed with GluK1-3 subunits
(e.g. GluK2/K5; reviewed in [433, 783, 795]). Kainate receptors
may also exhibit ‘metabotropic’ functions [553, 841]. As found
for AMPA receptors, kainate receptors are modulated by auxil-
iary subunits (Neto proteins, [554, 783]). An important function
difference between AMPA and kainate receptors is that the latter
require extracellular Na+ and Cl- for their activation [105, 803].
RNA encoding the GluA2 subunit undergoes extensive RNA edit-
ing in which the codon encoding a p-loop glutamine residue (Q)
is converted to one encoding arginine (R). This Q/R site strongly
inﬂuences the biophysical properties of the receptor. Recombi-
nant AMPA receptors lacking RNA edited GluA2 subunits are: (1)
permeable to Ca2+; (2) blocked by intracellular polyamines at de-
polarized potentials causing inward rectiﬁcation (the latter being
reduced by TARPs); (3) blocked by extracellular argiotoxin and
Joro spider toxins and (4) demonstrate higher channel conduc-
tances than receptors containing the edited form of GluA2 [417,
885]. GluK1 and GluK2, but not other kainate receptor subunits,
are similarly edited and broadly similar functional characteristics
apply to kainate receptors lacking either an RNA edited GluK1,
or GluK2, subunit [553, 783]. Native AMPA and kainate recep-
tors displaying differential channel conductances, Ca2+ perme-
abilites and sensitivity to block by intracellular polyamines have
been identiﬁed [189, 417, 583]. GluA1-4 can exist as two vari-
ants generated by alternative splicing (termed ‘ﬂip’ and ‘ﬂop’) that
differ in their desensitization kinetics and their desensitization in
the presence of cyclothiazide which stabilises the nondesensitized
state. TARPs also stabilise the non-desensitized conformation of
AMPA receptors and facilitate the action of cyclothiazide [663].
Splice variants of GluK1-3 also exist which affects their trafﬁcking
[553, 783].
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Nomenclature GluA1 GluA2 GluA3 GluA4
HGNC, UniProt GRIA1, P42261 GRIA2, P42262 GRIA3, P42263 GRIA4, P48058
Agonists (S)-5-ﬂuorowillardiine, AMPA (S)-5-ﬂuorowillardiine, AMPA (S)-5-ﬂuorowillardiine, AMPA (S)-5-ﬂuorowillardiine, AMPA
Selective antagonists ATPO, GYKI53655, GYKI53784 (active isomer,
non-competitive), NBQX, tezampanel
ATPO, GYKI53655, GYKI53784 (active isomer,
non-competitive), NBQX, tezampanel
ATPO, GYKI53655, GYKI53784 (active
isomer, non-competitive), NBQX,
tezampanel
ATPO, GYKI53655, GYKI53784 (active
isomer, non-competitive), NBQX,
tezampanel
Channel blockers extracellular argiotoxin, extracellular joro toxin
(selective for channels lacking GluA2)
extracellular argiotoxin extracellular argiotoxin, extracellular
joro toxin (selective for channels
lacking GluA2)
extracellular argiotoxin, extracellular
joro toxin (selective for channels
lacking GluA2)
Allosteric modulators LY392098 (Positive) (pEC50 5.8) [667], LY404187
(Positive) (pEC50 5.2) [667], cyclothiazide (Positive)
(pEC50 4.7) [667], CX516 (Positive), CX546
(Positive), IDRA-21 (Positive), LY503430 (Positive),
S18986 (Positive), aniracetam (Positive), piracetam
(Positive)
LY404187 (Positive) (pEC50 6.8) [667], LY392098
(Positive) (pEC50 6.7) [667], cyclothiazide (Positive)
(pEC50 5.7) [667], CX516 (Positive), CX546
(Positive), IDRA-21 (Positive), LY503430 (Positive),
S18986 (Positive), aniracetam (Positive), piracetam
(Positive)
LY404187 (Positive) (pEC50 5.8) [667],
LY392098 (Positive) (pEC50 5.7) [667],
cyclothiazide (Positive) (pEC50 4.9)
[667], CX516 (Positive), CX546
(Positive), IDRA-21 (Positive),
LY503430 (Positive), S18986 (Positive),
aniracetam (Positive), piracetam
(Positive)
LY392098 (Positive) (pEC50 6.7) [667],
LY404187 (Positive) (pEC50 6.7) [667],
cyclothiazide (Positive) (pEC50 5.4)
[667], CX516 (Positive), CX546
(Positive), IDRA-21 (Positive),
LY503430 (Positive), S18986 (Positive),
aniracetam (Positive), piracetam
(Positive)
Labelled ligands [3H]AMPA (Agonist), [3H]CNQX (Antagonist) [3H]AMPA (Agonist), [3H]CNQX (Antagonist) [3H]AMPA, [3H]CNQX [3H]AMPA (Agonist), [3H]CNQX
Comments Piracetam and aniracetam are examples of pyrrolidinones. Cyclothiazide, S18986, and IDRA-21 are examples of benzothiadiazides. CX516 and CX546 are examples of
benzylpiperidines. LY392098, LY404187 and LY503430 are examples of biarylpropylsulfonamides. Also blocked by intracellular polyamines.
Nomenclature GluD1 GluD2
HGNC, UniProt GRID1, Q9ULK0 GRID2, O43424
Comments: GluD1 and GluD2 comprise, on the basis of se-
quence homology, an ‘orphan’ class of ionotropic glutamate re-
ceptor subunit. They do not form a functional receptor when
expressed solely, or in combination with other ionotropic glu-
tamate receptor subunits, in transfected cells [1126]. However,
GluD2 subunits bind D-serine and glycine and GluD2 subunits
carrying the mutation A654T form a spontaneously open channel
that is closed by D-serine [694].
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Nomenclature GluK1 GluK2 GluK3 GluK4 GluK5
HGNC, UniProt GRIK1, P39086 GRIK2, Q13002 GRIK3, Q13003 GRIK4, Q16099 GRIK5, Q16478
Agonists dysiherbaine [859] – Rat,
SYM2081 [774], kainate [909],
(S)-4-AHCP, (S)-5-iodowillardiine,
8-deoxy-neodysiherbaine, ATPA,
domoic acid
dysiherbaine [859] – Rat,
domoic acid [128], SYM2081
[1144] – Rat, kainate [128, 909]
SYM2081 [857] – Rat, kainate
(low potency) [857] – Rat,
dysiherbaine
SYM2081, domoic acid,
dysiherbaine, kainate
SYM2081, domoic acid, dysiherbaine,
kainate
Selective agonists LY339434 [909] – – – –
Selective antagonists 2,4-epi-neodysiherbaine, ACET,
LY382884, LY466195, MSVIII-19,
NS3763 (non-competitive),
UBP302, UBP310
2,4-epi-neodysiherbaine – – –
Allosteric modulators concanavalin A (Positive) concanavalin A (Positive) – – –
Labelled ligands [3H]UBP310 (Antagonist) (pKd
7.7) [39], [3H]SYM2081
(Agonist), [3H]kainate (Agonist)
[3H]kainate (Agonist) [1144] –
Rat, [3H]SYM2081 (Agonist)
[3H]UBP310 (Antagonist) (pKd
6.3) [39], [3H]SYM2081
(Agonist), [3H]kainate (Agonist)
[3H]SYM2081 (Agonist),
[3H]kainate (Agonist)
[3H]SYM2081 (Agonist), [3H]kainate
(Agonist)
Comments – Intracellular polyamines are
subtype selective channel blockers
(GluK3  GluK2)
Domoic acid and concanavalin A
are inactive at the GluK3 subunit.
Intracellular polyamines are
subtype selective channel blockers
(GluK3  GluK2)
– –
Comments: All AMPA receptors are additionally activated by
kainate (and domoic acid) with relatively low potency, (EC50 100
μM). Inclusion of TARPs within the receptor complex increases
the potency and maximal effect of kainate [426, 663]. AMPA is
weak partial agonist at GluK1 and at heteromeric assemblies of
GluK1/GluK2, GluK1/GluK5 and GluK2/GluK5 [433]. Quinox-
alinediones such as CNQX and NBQX show limited selectiv-
ity between AMPA and kainate receptors. Tezampanel also has
kainate (GluK1) receptor activity as has GYKI53655 (GluK3 and
GluK2/GluK3) [433]. ATPO is a potent competitive antagonist of
AMPA receptors, has a weaker antagonist action at kainate recep-
tors comprising GluK1 subunits, but is devoid of activity at kainate
receptors formed from GluK2 or GluK2/GluK5 subunits. The
pharmacological activity of ATPO resides with the (S)-enantiomer.
ACET and UBP310 may block GluK3, in addition to GluK1 [39,
782]. (2S,4R)-4-methylglutamate (SYM2081) is equipotent in ac-
tivating (and desensitising) GluK1 and GluK2 receptor isoforms
and, via the induction of desensitisation at low concentrations,
has been used as a functional antagonist of kainate receptors. Both
(2S,4R)-4-methylglutamate and LY339434 have agonist activity at
NMDA receptors. (2S,4R)-4-methylglutamate is also an inhibitor
of the glutamate transporters EAAT1 and EAAT2.
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NMDA receptors
NMDA receptors assemble as obligate heteromers that may be
drawn from GluN1, GluN2A, GluN2B, GluN2C, GluN2D, GluN3A
and GluN3B subunits. Alternative splicing can generate eight iso-
forms of GluN1 with differing pharmacological properties. Vari-
ous splice variants of GluN2B, 2C, 2D and GluN3A have also been
reported. Activation of NMDA receptors containing GluN1 and
GluN2 subunits requires the binding of two agonists, glutamate
to the S1 and S2 regions of the GluN2 subunit and glycine to S1
and S2 regions of the GluN1 subunit [156, 265]. The minimal
requirement for efﬁcient functional expression of NMDA recep-
tors in vitro is a di-heteromeric assembly of GluN1 and at least
one GluN2 subunit variant, as a dimer of heterodimers arrange-
ment in the extracellular domain [303, 466, 639]. However, more
complex tri-heteromeric assemblies, incorporating multiple sub-
types of GluN2 subunit, or GluN3 subunits, can be generatedin
vitro and occurin vivo. The NMDA receptor channel commonly has
a high relative permeability to Ca2+ and is blocked, in a voltage-
dependent manner, by Mg2+ such that at resting potentials the
response is substantially inhibited.
Nomenclature GluN1 GluN2A GluN2B
HGNC, UniProt GRIN1, Q05586 GRIN2A, Q12879 GRIN2B, Q13224
Endogenous agonists D-aspartic acid [glutamate site], D-serine
[glycine site], L-aspartic acid [glutamate
site], glycine [glycine site]
D-aspartic acid [glutamate site] (GluN2D > GluN2C = GluN2B > GluN2A), D-serine [glycine site] (GluN2D > GluN2C > GluN2B > GluN2A),
L-aspartic acid [glutamate site] (GluN2D = GluN2B > GluN2C = GluN2A), glycine [glycine site] (GluN2D > GluN2C > GluN2B > GluN2A)
Agonists (+)-HA966 [glycine site] (Partial agonist),
(RS)-(tetrazol-5-yl)glycine [glutamate
site], NMDA [glutamate site],
homoquinolinic acid [glutamate site]
(Partial agonist)
(+)-HA966 [glycine site] (Partial agonist), (RS)-(tetrazol-5-yl)glycine [glutamate site] (GluN2D > GluN2C = GluN2B > GluN2A), NMDA [glutamate
site] (GluN2D > GluN2C > GluN2B > GluN2A), homoquinolinic acid [glutamate site] (GluN2B ≥ GluN2A ≥ GluN2D > GluN2C; partial agonist
at GluN2A and GluN2C)
Selective antagonists L701324 [glycine site] (pIC50 8.7) [522]
– Rat, GV196771A [glycine site] (pKi
8.1–8.4) [168] – Rat, L689560 [glycine
site] (pIC50 8.1) [548] – Rat,
5,7-dichlorokynurenic acid [glycine site]
5,7-dichlorokynurenic acid [glycine site], CGP37849 [glutamate site], GV196771A [glycine site], L689560 [glycine site], L701324 [glycine site],
LY233053 [glutamate site], NVP-AAM077 [glutamate site] (GluN2A > GluN2B (human), but weakly selective for rat GluN2A versus GluN2B) [40,
283, 299, 701], UBP141 [glutamate site] (GluN2D ≥ GluN2C > GluN2A ≥ GluN2B) [675], conantokin-G [glutamate site] (GluN2B > GluN2D =
GluN2C = GluN2A), d-AP5 [glutamate site], d-CCPene [glutamate site] (GluN2A = GluN2B > GluN2C = GluN2D), selfotel [glutamate site]
Channel blockers – Mg2+ (GluN2A = GluN2B > GluN2C = GluN2D), N1-dansyl-spermine (GluN2A = GluN2B  GluN2C = GluN2D), amantadine (GluN2C = GluN2D
≥ GluN2B ≥ GluN2A), dizocilpine, ketamine, phencyclidine
Labelled ligands [3H]MDL105519 [glycine site]
(Antagonist) (pKd ∼8.5) [151] – Rat,
[3H]CGP39653 [glutamate site]
(Selective Antagonist), [3H]CGP61594
[glycine site] (Antagonist),
[3H]CGS19755 [glutamate site]
(Antagonist), [3H]CPP [glutamate site]
(Selective Antagonist), [3H]L689560
[glycine site] (Antagonist),
[3H]dizocilpine [cation channel]
(Antagonist), [3H]glycine [glycine site]
(Agonist)
[3H]CGP39653 [glutamate site] (Antagonist), [3H]CGP61594 [glycine site] (Antagonist), [3H]CGS19755 [glutamate site] (Antagonist), [3H]CPP
[glutamate site] (Antagonist), [3H]L689560 [glycine site] (Antagonist), [3H]MDL105519 [glycine site] (Antagonist), [3H]dizocilpine [cation chan-
nel] (Channel blocker), [3H]glycine [glycine site] (Agonist)
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Nomenclature GluN2C GluN2D
HGNC, UniProt GRIN2C, Q14957 GRIN2D, O15399
Endogenous agonists D-aspartic acid [glutamate site] (GluN2D > GluN2C = GluN2B > GluN2A), D-serine [glycine site] (GluN2D > GluN2C > GluN2B > GluN2A),
L-aspartic acid [glutamate site] (GluN2D = GluN2B > GluN2C = GluN2A), glycine [glycine site] (GluN2D > GluN2C > GluN2B > GluN2A)
Agonists (RS)-(tetrazol-5-yl)glycine [glutamate site] (GluN2D > GluN2C = GluN2B > GluN2A), NMDA [glutamate site] (GluN2D > GluN2C > GluN2B >
GluN2A), homoquinolinic acid [glutamate site] (GluN2B ≥ GluN2A ≥ GluN2D > GluN2C; partial agonist at GluN2A and GluN2C)
Selective antagonists 5,7-dichlorokynurenic acid [glycine site], CGP37849 [glutamate site], GV196771A [glycine site], L689560 [glycine site], L701324 [glycine site],
LY233053 [glutamate site], UBP141 [glutamate site] (GluN2D ≥ GluN2C > GluN2A ≥ GluN2B) [675], conantokin-G [glutamate site] (GluN2B >
GluN2D = GluN2C = GluN2A), d-AP5 [glutamate site], d-CCPene [glutamate site] (GluN2A = GluN2B > GluN2C = GluN2D), selfotel [glutamate
site]
Channel blockers phencyclidine (pIC50 7.1) [240], ketamine (pIC50 6.2) [240], amantadine (GluN2C =
GluN2D ≥ GluN2B ≥ GluN2A) (pIC50 4.7) [240], Mg2+ (GluN2A = GluN2B > GluN2C =
GluN2D), N1-dansyl-spermine (GluN2A = GluN2B  GluN2C = GluN2D), dizocilpine
Mg2+ (GluN2A = GluN2B > GluN2C = GluN2D), N1-dansyl-spermine (GluN2A = GluN2B 
GluN2C = GluN2D), amantadine (GluN2C = GluN2D ≥ GluN2B ≥ GluN2A), dizocilpine,
ketamine, phencyclidine
Labelled ligands [3H]CGP39653 [glutamate site] (Antagonist), [3H]CGP61594 [glycine site] (Antagonist),
[3H]CGS19755 [glutamate site] (Antagonist), [3H]CPP [glutamate site] (Antagonist),
[3H]L689560 [glycine site] (Antagonist), [3H]MDL105519 [glycine site] (Antagonist),
[3H]dizocilpine [cation channel] (Channel blocker), [3H]glycine [glycine site] (Agonist)
[3H]CGP39653 [glutamate site] (Antagonist), [3H]CGP61594 [glycine site] (Antagonist),
[3H]CGS19755 [glutamate site] (Antagonist), [3H]CPP [glutamate site] (Antagonist),
[3H]L689560 [glycine site] (Selective Antagonist), [3H]MDL105519 [glycine site]
(Antagonist), [3H]dizocilpine [cation channel] (Channel blocker), [3H]glycine [glycine site]
(Agonist)
Nomenclature GluN3A GluN3B
HGNC, UniProt GRIN3A, Q8TCU5 GRIN3B, O60391
Comments See the main comments section below for information on the pharmacology of GluN3A and GluN3B subunits
Comments: Potency orders unreferenced in the table are from
[155, 240, 266, 524, 752, 997]. In addition to the glutamate
and glycine binding sites documented in the table, physiologi-
cally important inhibitory modulatory sites exist for Mg2+, Zn2+,
and protons [190, 226, 997]. Voltage-independent inhibition by
Zn2+ binding with high afﬁnity within the ATD is highly sub-
unit selective (GluN2A  GluN2B > GluN2C ≥ GluN2D; [752,
997]). The receptor is also allosterically modulated, in both posi-
tive and negative directions, by endogenous neuroactive steroids
in a subunit dependent manner [398, 622]. Tonic proton blockade
of NMDA receptor function is alleviated by polyamines and the in-
clusion of exon 5 within GluN1 subunit splice variants, whereas
the non-competitive antagonists ifenprodil and traxoprodil in-
crease the fraction of receptors blocked by protons at ambient
concentration. Inclusion of exon 5 also abolishes potentiation by
polyamines and inhibition by Zn2+ that occurs through binding
in the ATD [996]. Ifenprodil, traxoprodil, haloperidol, felbamate
and Ro 8-4304 discriminate between recombinant NMDA recep-
tors assembled from GluN1 and either GluN2A, or GluN2B, sub-
units by acting as selective, non-competitive, antagonists of het-
erooligomers incorporating GluN2B through a binding site at the
ATD GluN1/GluN2B subunit interface [466]. LY233536 is a com-
petitive antagonist that also displays selectivity for GluN2B over
GluN2A subunit-containing receptors. Similarly, CGP61594 is a
photoafﬁnity label that interacts selectively with receptors incor-
porating GluN2B versus GluN2A, GluN2D and, to a lesser extent,
GluN2C subunits. TCN 201 and TCN 213 have recently been
shown to block GluN2A NMDA receptors selectively by a mecha-
nism that involves allosteric inhibition of glycine binding to the
GluN1 site [81, 257, 353, 643]. In addition to inﬂuencing the
pharmacological proﬁle of the NMDA receptor, the identity of the
GluN2 subunit co-assembled with GluN1 is an important deter-
minant of biophysical properties that include sensitivity to block
by Mg2+, single-channel conductance and maximal open prob-
ablity and channel deactivation time [190, 265, 317]. Incorpora-
tion of the GluN3A subunit into tri-heteromers containing GluN1
and GluN2 subunits is associated with decreased single-channel
conductance, reduced permeability to Ca2+ and decreased suscep-
tibility to block by Mg2+ [140, 369]. Reduced permeability to
Ca2+ has also been observed following the inclusion of GluN3B
in tri-heteromers. The expression of GluN3A, or GluN3B, with
GluN1 alone forms, in Xenopus laevis oocytes, a cation channel
with unique properties that include activation by glycine (but not
NMDA), lack of permeation by Ca2+ and resistance to blockade by
Mg2+ and NMDA receptor antagonists [147]. The function of het-
eromers composed of GluN1 and GluN3A is enhanced by Zn2+,
or glycine site antagonists, binding to the GluN1 subunit [611].
Zn2+ also directly activates such complexes. The co-expression
of GluN1, GluN3A and GluN3B appears to be required to form
glycine-activated receptors in mammalian cell hosts [918].
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IP3 receptors
Ion channels → Ligand-gated ion channels → IP3 receptor
Overview: The inositol 1,4,5-trisphosphate receptors (IP3R) are
ligand-gated Ca2+-release channels on intracellular Ca2+ store
sites (such as the endoplasmic reticulum). They are responsible
for the mobilization of intracellular Ca2+ stores and play an im-
portant role in intracellular Ca2+ signalling in a wide variety of
cell types. Three different gene products (types I-III) have been
isolated, which assemble as large tetrameric structures. IP3Rs
are closely associated with certain proteins: calmodulin (CALM1
CALM2 CALM3, P62158) and FKBP (and calcineurin via FKBP).
They are phosphorylated by PKA, PKC, PKG and CaMKII.
Nomenclature IP3R1 IP3R2 IP3R3
HGNC, UniProt ITPR1, Q14643 ITPR2, Q14571 ITPR3, Q14573
Endogenous activators cytosolic ATP (< mM range), cytosolic Ca2+
Concentration range: <7.5×10−4M, IP3 (endogenous;
nM - μM range)
cytosolic Ca2+ (nM range), IP3 (endogenous; nM - μM
range)
cytosolic Ca2+ (nM range), IP3 (endogenous; nM - μM
range)
Activators adenophostin A (pharmacological; nM range),
inositol 2,4,5-trisphosphate (pharmacological; also
activated by other InsP3 analogues)
adenophostin A (pharmacological; nM range),
inositol 2,4,5-trisphosphate (pharmacological; also
activated by other InsP3 analogues)
–
Antagonists PIP2 (μM range), caffeine (mM range), decavanadate
(μM range), xestospongin C (μM range)
decavanadate (μM range) decavanadate (μM range)
Functional Characteristics Ca2+: (PBa/PK 6) single-channel conductance
70 pS (50 mM Ca2+)
Ca2+: single-channel conductance
70 pS (50 mM Ca2+)
390 pS (220 mM Cs+)
Ca2+: single-channel conductance
88 pS (55 mM Ba2+)
Comments IP3R1 is also antagonised by calmodulin at high
cytosolic Ca2+ concentrations
– –
Comments: The absence of a modulator of a particular isoform of receptor indicates that the action of that modulator has not been determined, not that it is without effect.
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Nicotinic acetylcholine receptors
Ion channels → Ligand-gated ion channels → Nicotinic acetylcholine receptors
Overview: Nicotinic acetylcholine receptors are members of the
Cys-loop family of transmitter-gated ion channels that includes
the GABAA, strychnine-sensitive glycine and 5-HT3 receptors [18,
659, 903, 963, 1083]. All nicotinic receptors are pentamers in
which each of the ﬁve subunits contains four α-helical transmem-
brane domains. Genes encoding a total of 17 subunits (α1-10,
β1-4, γ, δ and ) have been identiﬁed [459]. All subunits with
the exception of α8 (present in avian species) have been iden-
tiﬁed in mammals. All α subunits possess two tandem cysteine
residues near to the site involved in acetylcholine binding, and
subunits not named α lack these residues [659]. The orthos-
teric ligand binding site is formed by residues within at least
three peptide domains on the α subunit (principal component),
and three on the adjacent subunit (complementary component).
nAChRs contain several allosteric modulatory sites. One such
site, for positive allosteric modulators (PAMs) and allosteric ag-
onists, has been proposed to reside within an intrasubunit cav-
ity between the four transmembrane domains [318, 1119]; see
also [373]). The high resolution crystal structure of the mollus-
can acetylcholine binding protein, a structural homologue of the
extracellular binding domain of a nicotinic receptor pentamer,
in complex with several nicotinic receptor ligands (e.g.[142]) and
the crystal structure of the extracellular domain of the α1 subunit
bound to α-bungarotoxin at 1.94 Å resolution [212], has revealed
the orthosteric binding site in detail (reviewed in [145, 459, 850,
903]). Nicotinic receptors at the somatic neuromuscular junction
of adult animals have the stoichiometry (α1)2β1δ, whereas an ex-
trajunctional (α1)2β1γδ receptor predominates in embryonic and
denervated skeletal muscle and other pathological states. Other
nicotinic receptors are assembled as combinations of α(2-6) and
β(2-4) subunits. For α2, α3, α4 and β2 and β4 subunits, pair-
wise combinations of α and β (e.g. α3β4 and α4β2) are sufﬁcient
to form a functional receptor in vitro, but far more complex iso-
forms may exist in vivo (reviewed in [324, 325, 659]). There is
strong evidence that the pairwise assembly of some α and β sub-
units can occur with variable stoichiometry [e.g. (α4)2(β2)2 or
(α4)3(β2)2] which inﬂuences the biophysical and pharmacological
properties of the receptor [659]. α5 and β3 subunits lack function
when expressed alone, or pairwise, but participate in the forma-
tion of functional hetero-oligomeric receptors when expressed as
a third subunit with another α and β pair [e.g. α4α5αβ2, α4αβ2β3,
α5α6β2, see [659] for further examples]. The α6 subunit can form
a functional receptor when co-expressed with β4 in vitro, but more
efﬁcient expression ensues from incorporation of a third partner,
such as β3 [1108]. The α7, α8, and α9 subunits form functional
homo-oligomers, but can also combine with a second subunit to
constitute a hetero-oligomeric assembly (e.g. α7β2 and α9α10).
For functional expression of the α10 subunit, co-assembly with
α9 is necessary. The latter, along with the α10 subunit, appears to
be largely conﬁned to cochlear and vestibular hair cells. Compre-
hensive listings of nicotinic receptor subunit combinations identi-
ﬁed from recombinant expression systems, or in vivo, are given in
[659]. In addition, numerous proteins interact with nicotinic ACh
receptors modifying their assembly, trafﬁcking to and from the
cell surface, and activation by ACh (reviewed by [32, 451, 658]).
The nicotinic receptor Subcommittee of NC-IUPHAR has recom-
mended a nomenclature and classiﬁcation scheme for nicotinic
acetylcholine (nACh) receptors based on the subunit composition
of known, naturally- and/or heterologously-expressed nACh re-
ceptor subtypes [600]. Headings for this table reﬂect abbreviations
designating nACh receptor subtypes based on the predominant α
subunit contained in that receptor subtype. An asterisk following
the indicated α subunit denotes that other subunits are known to,
or may, assemble with the indicated α subunit to form the desig-
nated nACh receptor subtype(s). Where subunit stoichiometries
within a speciﬁc nACh receptor subtype are known, numbers of
a particular subunit larger than 1 are indicated by a subscript fol-
lowing the subunit (enclosed in parentheses – see also [183]).
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Nomenclature nicotinic acetylcholine receptor α1 subunit nicotinic acetylcholine receptor α2 subunit nicotinic acetylcholine receptor α3 subunit nicotinic acetylcholine receptor α4 subunit
HGNC, UniProt CHRNA1, P02708 CHRNA2, Q15822 CHRNA3, P32297 CHRNA4, P43681
Commonly used antagonists (α1)2β1γδ and (α1)2β1δ: α-bungarotoxin
> pancuronium > vecuronium >
rocuronium > tubocurarine (IC50 = 43 - 82
nM)
α2β2: DHβE (KB = 0.9 μM), tubocurarine
(KB = 1.4 μM); α2β4: DHβE (KB = 3.6 μM),
tubocurarine (KB = 4.2 μM)
α3β2: DHβE (KB = 1.6 μM, IC50 = 2.0
μM), tubocurarine (KB = 2.4 μM); α3β4:
DHβE (KB = 19 μM, IC50 = 26 μM),
tubocurarine (KB = 2.2 μM)
α4β2: DHβE (KB = 0.1 μM; IC50 = 0.08 -
0.9 μM), tubocurarine (KB = 3.2 μM, IC50
= 34 μM); α4β4: DHβE (KB = 0.01 μM,
IC50 = 0.19 – 1.2 μM), tubocurarine (KB =
0.2 μM, IC50 = 50 μM)
Selective agonists succinylcholine (selective for (α1)2β1γδ) – – varenicline [179], rivanicline [232],
TC-2559 (α4β2) [162]
Selective antagonists α-bungarotoxin, α-conotoxin GI,
α-conotoxin MI, pancuronium, waglerin-1
(selective for (α1)2β1δ)
– α-conotoxin AuIB (α3β4), α-conotoxin MII
(α3β2), α-conotoxin PnIA (α3β2),
α-conotoxin TxIA (α3β2), α-conotoxin-GIC
(α3β2)
–
Channel blockers gallamine ((α1)2β1γδ and (α1)2β1δ)
(pIC50 ∼6), mecamylamine ((α1)2β1δ)
(pIC50 ∼5.8)
hexamethonium, mecamylamine mecamylamine (α3β4) (pIC50 6.4),
mecamylamine (α3β2) (pIC50 5.1),
A-867744 (α3β4) [623], NS1738 (α3β4)
[985], hexamethonium (α3β2),
hexamethonium (α3β4)
mecamylamine (α4β4) (pIC50 5.3–6.5),
mecamylamine (α4β2) (pIC50 5.4–5.4),
hexamethonium (α4β2) (pIC50 4.5–5.2),
hexamethonium (α4β4) (pIC50 4),
A-867744 (α4β2) [623], NS1738 (α4β2)
[985]
Allosteric modulators – LY2087101 (Positive) [109] – LY2087101 (Positive) [109]
Selective allosteric modulators – – – NS9283 (Positive) [541]
Labelled ligands [125I]α-bungarotoxin (Selective
Antagonist), [3H]α-bungarotoxin (Selective
Antagonist)
[125I]epibatidine (Agonist), [3H]epibatidine
(Agonist), [3H]cytisine (Agonist)
[125I]epibatidine (Agonist), [3H]epibatidine
(Agonist), [125I]epibatidine (Agonist),
[3H]epibatidine (Agonist), [3H]cytisine
(Agonist)
[125I]epibatidine (Agonist),
[3H]epibatidine (Agonist), [3H]cytisine
(Agonist), [125I]epibatidine (Agonist),
[3H]epibatidine (Agonist), [3H]epibatidine
(Agonist) – Rat, [3H]cytisine (Agonist)
Functional Characteristics (α1)2βγδ: PCa/PNa = 0.16 - 0.2, Pf = 2.1 –
2.9%; (α1)2βδ: PCa/PNa = 0.65 – 1.38, Pf
= 4.1 – 7.2%
α2β2: PCa/PNa 1.5 α3β2: PCa/PNa = 1.5; α3β4: PCa/PNa =
0.78 - 1.1, Pf = 2.7 – 4.6%
α4β2: PCa/PNa = 1.65, Pf = 2.6 – 2.9%;
α4β4: Pf = 1.5 – 3.0 %
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Nomenclature nicotinic acetylcholine receptor α5 subunit nicotinic acetylcholine receptor α6 subunit nicotinic acetylcholine receptor α7 subunit
HGNC, UniProt CHRNA5, P30532 CHRNA6, Q15825 CHRNA7, P36544
Commonly used antagonists – α6/α3β2β3 chimera: DHβE (IC50 = 1.1 μM) (α7)5: DHβE (IC50 = 8 - 20 μM); (α7)5: tubocurarine (IC50 = 3.1 μM)
Selective agonists – – encenicline (Partial agonist) [640, 721], AQW051 ([125I]α- bungarotoxin
binding assay) [411], 4BP-TQS (allosteric) [318], A-582941 ((α7)5) [90],
PHA-543613 ((α7)5) [1074], PHA-709829 ((α7)5) [9], PNU-282987 ((α7)5)
[96], bradanicline ((α7)5) [362]
Selective antagonists α-conotoxin MII, α-conotoxin PnIA,
α-conotoxin TxIA, α-conotoxin-GIC
α-conotoxin MII (α6β2*),
α-conotoxin MII [H9A, L15A] (α6β2β3),
α-conotoxin PIA (α6/α3β2β3 chimera)
α-bungarotoxin ((α7)5), α-conotoxin ArIB ((α7)5), α-conotoxin ImI ((α7)5),
methyllycaconitine ((α7)5)
Channel blockers – mecamylamine (α6/α3β2β3 chimera) (pIC50 5),
hexamethonium (α6/α3β2β3 chimera) (pIC50 4)
mecamylamine ((α7)5) (pIC50 4.8)
Allosteric modulators – – A-867744 (Positive) [623], LY2087101 (Positive) [109], NS1738 (Positive)
[985]
Selective allosteric modulators – – JNJ1930942 (Positive) [227], PNU-120596 (Positive) [410]
Labelled ligands – [3H]epibatidine (Agonist) – Chicken,
[125I]α-conotoxin MII (Antagonist)
[3H]epibatidine (Agonist), [3H]A-585539 (Agonist) [24], [3H]AZ11637326
(Agonist) [323], [125I]α-bungarotoxin (Selective Antagonist) (pKd 8.3–9.1),
[3H]α-bungarotoxin (Selective Antagonist) (pKd 8.3–9.1),
[3H]methyllycaconitine (Antagonist) (pKd 8.7) – Rat
Functional Characteristics – – PCa/PNa = 6.6-20, Pf = 8.8 - 11.4%
Nomenclature nicotinic acetylcholine receptor α8 subunit (avian) nicotinic acetylcholine receptor α9 subunit nicotinic acetylcholine receptor α10 subunit
HGNC, UniProt – CHRNA9, Q9UGM1 CHRNA10, Q9GZZ6
Commonly used antagonists (α8)5: α-bungarotoxin > atropine ≥ tubocurarine ≥
strychnine
(α9)5: α-bungarotoxin > methyllycaconitine > strychnine
tropisetron > tubocurarine; α9α10: α-bungarotoxin >
tropisetron = strychnine > tubocurarine
α9α10: α-bungarotoxin > tropisetron = strychnine >
tubocurarine
Selective antagonists – α-bungarotoxin ((α9)5), α-bungarotoxin (α9α10),
α-conotoxin RgIA (α9α10), muscarine ((α9)5), muscarine
(α9α10), nicotine ((α9)5), nicotine (α9α10), strychnine
((α9)5), strychnine (α9α10)
α-bungarotoxin (α9α10), α-conotoxin RgIA (α9α10),
muscarine (α9α10), nicotine (α9α10), strychnine (α9α10)
Labelled ligands [3H]epibatidine ((α8)5) (pKd 9.7), [
125I]α-bungarotoxin
(native α8*) (pKd 8.3), [
3H]α-bungarotoxin (native α8*)
(pKd 8.3)
[3H]methyllycaconitine (Antagonist) (pKd 8.1),
[125I]α-bungarotoxin (Antagonist), [3H]α-bungarotoxin
(Antagonist)
[3H]methyllycaconitine (Antagonist) (pKd 8.1)
Functional Characteristics – (α9)5: PCa/PNa = 9; α9α10: PCa/PNa = 9, Pf = 22% α9α10: PCa/PNa = 9, Pf = 22%
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Nomenclature nicotinic acetylcholine
receptor β1 subunit
nicotinic acetylcholine
receptor β2 subunit
nicotinic acetylcholine
receptor β3 subunit
nicotinic acetylcholine
receptor β4 subunit
nicotinic acetylcholine
receptor γ subunit
nicotinic acetylcholine
receptor δ subunit
nicotinic acetylcholine
receptor  subunit
HGNC, UniProt CHRNB1, P11230 CHRNB2, P17787 CHRNB3, Q05901 CHRNB4, P30926 CHRNG, P07510 CHRND, Q07001 CHRNE, Q04844
Antagonists – – – – – PhTX-11 (pIC50 6.2–6.3)
[938]
–
Comments Ligand interaction data for hetero-oligomeric receptors containing the β1 subunit are listed under the α1 subunits
Comments: Commonly used agonists of nACh receptors that
display limited discrimination in functional assays between re-
ceptor subtypes include A-85380, cytisine, DMPP, epibatidine,
nicotine and the natural transmitter, acetylcholine (ACh). A sum-
mary of their proﬁle across differing receptors is provided in [325]
and quantitative data across numerous assay systems are summa-
rized in [439]. Quantitative data presented in the table for com-
monly used antagonists and channel blockers for human recep-
tors studied under voltage-clamp are from [119, 150, 754, 755,
765, 1082]. Type I PAMs increase peak agonist-evoked responses
but have little, or no, effect on the rate of desensitization of α7
nicotinic ACh receptors whereas type II PAMs also cause a large
reduction in desensitization (reviewed in [1071]).
Further reading on Nicotinic acetylcholine receptors
Auerbach A. (2015) Agonist activation of a nicotinic acetylcholine receptor. Neuropharmacology 96:
150-6 [PMID:25446670]
Bertrand D et al. (2015) Therapeutic Potential of α7 Nicotinic Acetylcholine Receptors. Pharmacol.
Rev. 67: 1025-73 [PMID:26419447]
Bouzat C et al. (2018) Nicotinic acetylcholine receptors at the single-channel level. Br. J. Pharmacol.
175: 1789-1804 [PMID:28261794]
Chatzidaki A et al. (2015) Allosteric modulation of nicotinic acetylcholine receptors. Biochem. Phar-
macol. 97: 408-417 [PMID:26231943]
Corradi J et al. (2016) Understanding the Bases of Function and Modulation of α7 Nicotinic Recep-
tors: Implications for Drug Discovery. Mol. Pharmacol. 90: 288-99 [PMID:27190210]
Crespi A et al. (2018) Proteins and chemical chaperones involved in neuronal nicotinic receptor
expression and function: an update. Br. J. Pharmacol. 175: 1869-1879 [PMID:28294298]
Dineley KT et al. (2015) Nicotinic ACh receptors as therapeutic targets in CNS disorders. Trends
Pharmacol. Sci. 36: 96-108 [PMID:25639674]
Lukas RJ et al. (1999) International Union of Pharmacology. XX. Current status of the nomen-
clature for nicotinic acetylcholine receptors and their subunits. Pharmacol. Rev. 51: 397-401
[PMID:10353988]
Stokes C et al. (2015) Looking below the surface of nicotinic acetylcholine receptors. Trends Pharma-
col. Sci. 36: 514-23 [PMID:26067101]
Wang J et al. (2018) Orthosteric and allosteric potentiation of heteromeric neuronal nicotinic acetyl-
choline receptors. Br. J. Pharmacol. 175: 1805-1821 [PMID:28199738]
Wu J et al. (2016) Heteromeric α7β2 Nicotinic Acetylcholine Receptors in the Brain. Trends Pharmacol.
Sci. 37: 562-574 [PMID:27179601]
P2X receptors
Ion channels → Ligand-gated ion channels → P2X receptors
Overview: P2X receptors (nomenclature as agreed by the
NC-IUPHAR Subcommittee on P2X Receptors [183, 481])
have a trimeric topology [443, 473, 703] with two putative TM do-
mains, gating primarily Na+, K+ and Ca2+, exceptionally Cl-. The
Nomenclature Subcommittee has recommended that for P2X re-
ceptors, structural criteria should be the initial criteria for nomen-
clature where possible. X-ray crystallography indicates that func-
tional P2X receptors are trimeric and three agonist molecules are
required to bind to a single receptor in order to activate it [321,
361, 473, 626]. Native receptors may occur as either homotrimers
(e.g. P2X1 in smooth muscle) or heterotrimers (e.g. P2X2:P2X3 in
the nodose ganglion [1031], P2X1:P2X5 in mouse cortical astro-
cytes [529], and P2X2:P2X5 in mouse dorsal root ganglion, spinal
cord and mid pons [184, 869]. P2X2, P2X4 and P2X7 receptors
have been shown to form functional homopolymers which, in
turn, activate pores permeable to low molecular weight solutes
[946]. The hemi-channel pannexin-1 has been implicated in the
pore formation induced by P2X7 [777], but not P2X2 [149], recep-
tor activation.
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Nomenclature P2X1 P2X2 P2X3 P2X4 P2X5 P2X6 P2X7
HGNC, UniProt P2RX1, P51575 P2RX2, Q9UBL9 P2RX3, P56373 P2RX4, Q99571 P2RX5, Q93086 P2RX6, O15547 P2RX7, Q99572
Endogenous
agonists
– ATP [429] – Rat ATP [430] ATP [430] ATP [430] – Rat ATP [430] – Rat ATP [430]
Agonists αβ-meATP, BzATP,
L-βγ-meATP
– αβ-meATP, BzATP – – – –
Antagonists TNP-ATP (pIC50
∼8.9) [1018], Ip5I
(pIC50 ∼8.5),
NF023 (pIC50
∼6.7), NF449
(pIC50 ∼6.3) [471]
NF770 (pIC50 7–8)
[722], NF778
(pIC50 7–8) [722],
PSB-10211 (pIC50
∼7) [722]
TNP-ATP (pIC50
∼8.9) [1018],
AF-906 (pIC50 8.9)
[432], AF-219
(pIC50 8.5) [432],
A317491 (pIC50
∼7.5) [435]
5-BDBD (pIC50
5–6) [432, 722],
BX-430 (pIC50 5–6)
[432, 722],
PSB-12062 (pIC50
5–6) [432, 722],
paroxetine (pIC50
5–6) [432, 722]
– – AZ10606120 (pKd 8.9) [650], A804598 (pIC50 ∼8),
brilliant blue G (pIC50 ∼8) [444], A839977 (pIC50 ∼7.7)
[236, 238, 394], A740003 (pIC50 7.4) [395], decavanadate
(pA2 = 7.4) (pA2 7.4) [655], A438079 (pIC50 ∼6.9) [236],
AZ11657312 (salt free) (pA2 6.1) [36]
Selective
antagonists
– – – – – – JNJ-47965567 (pKi 7.9) [84]
Allosteric
modulators
– – – – – – AZ10606120 (Negative) [650], GW791343 (Negative)
[650, 652], GW791343 (Positive) [650, 652] – Rat, LL-37
(CAMP, P49913) (Positive) [988], clemastine (Positive)
[725], polymyxin B (Positive) [285]
Selective
allosteric
modulators
MRS 2219
(Positive) [431]
– – ivermectin
(Positive) (pEC50
∼6.6) [482] – Rat
– – chelerythrine (Negative) (pIC50 5.2) [893], AZ11645373
(Negative) [653, 932], KN62 (Negative) [309, 893],
ivermectin (Positive) [726]
Comments – – – – – – Effects of the allosteric regulators at P2X7 receptors are
species-dependent.
Comments: A317491 and RO3 also block the P2X2:P2X3 het-
eromultimer [295, 435]. NF449, A317491 and RO3 are more than
10-fold selective for P2X1 and P2X3 receptors, respectively.
Agonists listed show selectivity within recombinant P2X receptors
of ca. one order of magnitude. A804598, A839977, A740003 and
A438079 are at least 10-fold selective for P2X7 receptors and show
similar afﬁnity across human and rodent receptors [236, 238, 394].
Several P2X receptors (particularly P2X1 and P2X3) may be in-
hibited by desensitisation using stable agonists (e.g. αβ-meATP);
suramin and PPADS are non-selective antagonists at rat and hu-
man P2X1-3,5 and hP2X4, but not rP2X4,6,7 [118], and can also
inhibit ATPase activity [186]. Ip5I is inactive at rP2X2, an an-
tagonist at rP2X3 (pIC50 5.6) and enhances agonist responses
at rP2X4 [486]. Antagonist potency of NF023 at recombinant
P2X2, P2X3 and P2X5 is two orders of magnitude lower than
that at P2X1 receptors [922]. The P2X7 receptor may be in-
hibited in a non-competitive manner by the protein kinase in-
hibitors KN62 and chelerythrine [893], while the p38 MAP ki-
nase inhibitor GTPγS and the cyclic imide AZ11645373 show a
species-dependent non-competitive action [237, 653, 654, 932].
The pH-sensitive dye used in culture media, phenol red, is also
reported to inhibit P2X1 and P2X3 containing channels [487].
Some recombinant P2X receptors expressed to high density bind
[35S]ATPγS and [3H]αβ-meATP, although the latter can also bind
to 5′-nucleotidase [651]. [3H]A317491 and [3H]A804598 have
been used as high afﬁnity antagonist radioligands for P2X3 (and
P2X2/3) and P2X7 receptors, respectively [238]. Several high afﬁn-
ity radioligands for the P2X7 receptor have been recently synthe-
sized [278, 592, 969]. AF-219 has shown clinical efﬁcacy in reduc-
ing refractory chronic cough [2].
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Further reading on P2X receptors
Di Virgilio F et al. (2017) The P2X7 Receptor in Infection and Inﬂammation. Immunity 47: 15-31
[PMID:28723547]
Di Virgilio F et al. (2018) The Elusive P2X7Macropore. Trends Cell Biol. 28: 392-404 [PMID:29439897]
Habermacher C et al. (2016) Molecular structure and function of P2X receptors. Neuropharmacology
104: 18-30 [PMID:26231831]
Jacobson KA et al. (2016) Medicinal chemistry of adenosine, P2Y and P2X receptors. Neuropharma-
cology 104: 31-49 [PMID:26686393]
Khakh BS et al. (2001) International union of pharmacology. XXIV. Current status of the nomen-
clature and properties of P2X receptors and their subunits. Pharmacol. Rev. 53: 107-18
[PMID:11171941]
North RA. (2016) P2X receptors. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 371: [PMID:27377721]
Stokes L et al. (2017) P2X4 Receptor Function in the Nervous System and Current Breakthroughs in
Pharmacology. Front Pharmacol 8: 291 [PMID:28588493]
ZAC
Ion channels → Ligand-gated ion channels → ZAC
Overview: The zinc-activated channel (ZAC, nomenclature as
agreed by the NC-IUPHAR Subcommittee for the Zinc Ac-
tivated Channel) is a member of the Cys-loop family that in-
cludes the nicotinic ACh, 5-HT3, GABAA and strychnine-sensitive
glycine receptors [200, 400, 995]. The channel is likely to exist as
a homopentamer of 4TM subunits that form an intrinsic cation
selective channel equipermeable to Na+, K+ and Cs+, but imper-
meable to Ca2+ andMg2+ [995]. ZAC displays constitutive activity
that can be blocked by tubocurarine and high concentrations of
Ca2+ [995]. Although denoted ZAC, the channel is more potently
activated by protons and copper, with greater and lesser efﬁcacy
than zinc, respectively [995]. ZAC is present in the human, chim-
panzee, dog, cow and opossum genomes, but is functionally ab-
sent from mouse, or rat, genomes [200, 400].
Nomenclature ZAC
HGNC, UniProt ZACN, Q401N2
Endogenous agonists H+ [995], Cu2+ [995], Zn2+ [200, 995]
Antagonists tubocurarine (pIC50 5.2) [200], Ca2+ (pIC50 2) [995]
Functional Characteristics Outwardly rectifying current (both constitutive and evoked by Zn2+)
Comments: The ZAC subunit does not appear to exist in the mouse or rat genomes [200]. Although tabulated as an antagonist, it is possible that tubocurarine acts as a channel blocker. Antagonism
by Ca2+ is voltage-independent. ZAC is not activated (at 1 mM) by transition metals including Fe2+, Co2+, Ni2+, Cd2+, or Al3+ [995]. The concentration response relationship to Cu2+ is biphasic, with
concentrations exceeding 30 μM being associated with reduced activation [995].
Further reading on ZAC
Collingridge GL et al. (2009) A nomenclature for ligand-gated ion channels. Neuropharmacology 56:
2-5 [PMID:18655795]
Peralta FA et al. (2016) Zinc as Allosteric Ion Channel Modulator: Ionotropic Receptors as Metallo-
proteins. Int J Mol Sci 17: [PMID:27384555]
Trattnig SM et al. (2016) Copper and protons directly activate the zinc-activated channel. Biochem.
Pharmacol. 103: 109-17 [PMID:26872532]
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Voltage-gated ion channels
Ion channels → Voltage-gated ion channels
Overview: The voltage-gated ion channels and their structural
relatives comprise a superfamily encoded by at least 143 genes in
the human genome and are therefore one of the largest super-
families of signal transduction proteins, following the G protein-
coupled receptors and the protein kinases in number [137]. In
addition to their prominence in signal transduction, these ion
channels are also among the most common drug targets. As for
other large protein superfamilies, understanding the molecular re-
lationships among family members, developing a uniﬁed, ratio-
nal nomenclature for the ion channel families and subfamilies,
and assigning physiological functions and pharmacological signif-
icance to each family member has been an important challenge.
Further reading on Voltage-gated ion channels
Catterall WA et al. (2005) Introduction to the IUPHAR Compendium of Voltage-Gated Ion Channels
2005 Pharmacological Reviews 57: 385
CatSper and Two-Pore channels
Ion channels → Voltage-gated ion channels → CatSper and Two-Pore channels
Overview: CatSper channels (CatSper1-4, nomenclature as
agreed by NC-IUPHAR [177]) are putative 6TM, voltage-gated,
alkalinization-activated calcium permeant channels that are pre-
sumed to assemble as a tetramer of α-like subunits and medi-
ate the current ICatSper [488]. In mammals, CatSper subunits are
structurally most closely related to individual domains of voltage-
activated calcium channels (Cav) [830]. CatSper1 [830], CatSper2
[820] and CatSpers 3 and 4 [445, 586, 815], in common with a
putative 2TM auxiliary CatSperβ protein [581] and two putative
1TM associated CatSperγ and CatSperδ proteins [172, 1044], are
restricted to the testis and localised to the principle piece of sperm
tail. The novel cross-species CatSper channel inhibitor, RU1968,
has been proposed as a useful tool to aid characterisation of native
CatSper channels [831].
Two-pore channels (TPCs) are structurally related to CatSpers,
CaVs and NaVs. TPCs have a 2x6TM structure with twice the num-
ber of TMs of CatSpers and half that of CaVs. There are three an-
imal TPCs (TPC1-TPC3). Humans have TPC1 and TPC2, but not
TPC3. TPC1 and TPC2 are localized in endosomes and lysosomes
[122]. TPC3 is also found on the plasma membrane and forms
a voltage-activated, non-inactivating Na+ channel [125]. All the
three TPCs are Na+-selective under whole-cell or whole-organelle
patch clamp recording [126, 127, 1087]. The channels may also
conduct Ca2+ [674].
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Nomenclature CatSper1 CatSper2 CatSper3 CatSper4
HGNC, UniProt CATSPER1, Q8NEC5 CATSPER2, Q96P56 CATSPER3, Q86XQ3 CATSPER4, Q7RTX7
Activators CatSper1 is constitutively active, weakly facilitated
by membrane depolarisation, strongly augmented
by intracellular alkalinisation. In human, but not
mouse, progesterone (EC50 8 nM) also potentiates
the CatSper current (ICatSper). [577, 940]
– – –
Channel blockers ruthenium red (Inhibition) (pIC50 5) [488] –
Mouse, HC-056456 (pIC50 4.7) [134], Cd2+
(Inhibition) (pIC50 3.7) [488] – Mouse, Ni2+
(Inhibition) (pIC50 3.5) [488] – Mouse
– – –
Selective channel blockers NNC55-0396 (Inhibition) (pIC50 5.7) [-80mV –
80mV] [577, 940], mibefradil (Inhibition) (pIC50
4.4–4.5) [940]
– – –
Functional Characteristics Calcium selective ion channel
(Ba2+>Ca2+Mg2+Na+);
quasilinear monovalent cation current in the
absence of extracellular divalent cations;
alkalinization shifts the voltage-dependence of
activation towards negative potentials [V
 
@ pH
6.0 = +87 mV (mouse); V
 
@ pH 7.5 = +11mV
(mouse) or pH 7.4 = +85 mV (human)]; required
for ICatSper and male fertility (mouse and human)
Required for ICatSper and male fertility
(mouse and human)
Required for ICatSper and male fertility
(mouse)
Required for ICatSper and male fertility
(mouse)
Nomenclature TPC1 TPC2
HGNC, UniProt TPCN1, Q9ULQ1 TPCN2, Q8NHX9
Activators phosphatidyl (3,5) inositol bisphosphate (pEC50 6.5) [126] phosphatidyl (3,5) inositol bisphosphate (pEC50 6.4) [1051]
Channel blockers verapamil (Inhibition) (pIC50 4.6) [126], Cd2+ (Inhibition) (pIC50 3.7) [126] verapamil (Inhibition) (pIC50 5) [1051]
Functional Characteristics Organelle voltage-gated Na+-selective channel (Na+K+Ca2+); Required for the
generation of action potential-like long depolarization in lysosomes. Voltage-dependence
of activation is sensitive to luminal pH (determined from lysosomal recordings). ψ1/2 @
pH4.6 = +91 mV; ψ1/2 @ pH6.5 = +2.6 mV. Maximum activity requires PI(3,5)P2 and
reduced [ATP], or depletion of extracellular amino acids.
Organelle voltage-independent Na+-selective channel (Na+K+Ca2+). Sensitive to the
levels of PI(3,5)P2. Activated by decreases in [ATP] or depletion of extracellular amino acids
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Comments: CatSper channel subunits expressed singly, or in
combination, fail to functionally express in heterologous expres-
sion systems [820, 830]. The properties of CatSper1 tabulated
above are derived from whole cell voltage-clamp recordings com-
paring currents endogenous to spermatozoa isolated from the cor-
pus epididymis of wild-type andCatsper1(-/-) mice [488] and alsoma-
ture human sperm [577, 940]. ICatSper is also undetectable in the
spermatozoa of Catsper2(-/-) ,Catsper3(-/-), Catsper4(-/-), or CatSperδ
(-/-) mice, and CatSper 1 associates with CatSper 2, 3, 4, β, γ, and
δ [172, 581, 815]. Moreover, targeted disruption of Catsper1, 2, 3,
4, or δ genes results in an identical phenotype in which spermato-
zoa fail to exhibit the hyperactive movement (whip-like ﬂagellar
beats) necessary for penetration of the egg cumulus and zona pellu-
cida and subsequent fertilization. Such disruptions are associated
with a deﬁcit in alkalinization and depolarization-evoked Ca2+ en-
try into spermatozoa [135, 172, 815]. Thus, it is likely that the
CatSper pore is formed by a heterotetramer of CatSpers1-4 [815]
in association with the auxiliary subunits (β, γ, δ) that are also es-
sential for function [172]. CatSper channels are required for the
increase in intracellular Ca2+ concentration in sperm evoked by
egg zona pellucida glycoproteins [1087]. Mouse and human sperm
swim against the ﬂuid ﬂow and Ca2+ signaling through CatSper
is required for the rheotaxis [657]. In vivo, CatSper1-null sper-
matozoa cannot ascend the female reproductive tracts efﬁciently
[173, 385]. It has been shown that CatSper channels form four
linear Ca2+ signaling domains along the ﬂagella, which orches-
trate capacitation-associated tyrosine phosphorylation [173].The
driving force for Ca2+ entry is principally determined by a mildly
outwardly rectifying K+ channel (KSper) that, like CatSpers, is ac-
tivated by intracellular alkalinization [695]. Mouse KSper is en-
coded by mSlo3, a protein detected only in testis [632, 695, 1132].
In human sperm, such alkalinization may result from the acti-
vation of Hv1, a proton channel [578]. Mutations in CatSpers
are associated with syndromic and non-syndromic male infertility
[374]. In human ejaculated spermatozoa, progesterone (<50 nM)
potentiates the CatSper current by a non-genomic mechanism
and acts synergistically with intracellular alkalinisation [577, 940].
Sperm cells from infertile patients with a deletion inCatSper2 gene
lack ICatSper and the progesterone response [913]. In addition,
certain prostaglandins (e.g. PGF1α, PGE1) also potentiate CatSper
mediated currents [577, 940].
In human sperm, CatSper channels are also activated by various
small molecules including endocrine disrupting chemicals (EDC)
and proposed as a polymodal sensor [107, 107].
TPCs are the major Na+ conductance in lysosomes; knocking out
TPC1 and TPC2 eliminates the Na+ conductance and renders the
organelle’s membrane potential insensitive to changes in [Na+]
(31). The channels are regulated by luminal pH [126], PI(3,5)P2
[1051], intracellular ATP and extracellular amino acids [127]. TPCs
are also involved in the NAADP-activated Ca2+ release from lyso-
somal Ca2+ stores [122, 674]. Mice lacking TPCs are viable but
have phenotypes including compromised lysosomal pH stabil-
ity, reduced physical endurance [127], resistance to Ebola viral
infection [860] and fatty liver [331]. No major human disease-
associated TPC mutation has been reported.
Further reading on CatSper and Two-Pore channels
Clapham DE et al. (2005) International Union of Pharmacology. L. Nomenclature and structure-
function relationships of CatSper and two-pore channels. Pharmacol. Rev. 57: 451-4
[PMID:16382101]
Grimm C et al. (2017) Two-Pore Channels: Catalyzers of Endolysosomal Transport and Function.
Front Pharmacol 8: 45 [PMID:28223936]
Kintzer AF et al. (2018) On the structure and mechanism of two-pore channels. FEBS J. 285: 233-243
[PMID:28656706]
Cyclic nucleotide-regulated channels
Ion channels → Voltage-gated ion channels → Cyclic nucleotide-regulated channels
Overview: Cyclic nucleotide-gated (CNG) channels are re-
sponsible for signalling in the primary sensory cells of the verte-
brate visual and olfactory systems.
CNG channels are voltage-independent cation channels formed as
tetramers. Each subunit has 6TM, with the pore-forming domain
between TM5 and TM6. CNG channels were ﬁrst found in rod
photoreceptors [287, 472], where light signals through rhodopsin
and transducin to stimulate phosphodiesterase and reduce intra-
cellular cyclic GMP level. This results in a closure of CNG channels
and a reduced ‘dark current’. Similar channels were found in the
cilia of olfactory neurons [692] and the pineal gland [241]. The
cyclic nucleotides bind to a domain in the C terminus of the sub-
unit protein: other channels directly binding cyclic nucleotides
include HCN, eag and certain plant potassium channels.
A standardised nomenclature for CNG and HCN channels
has been proposed by the NC-IUPHAR subcommittee on
voltage-gated ion channels [388].
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Nomenclature CNGA1 CNGA2 CNGA3 CNGB3
HGNC, UniProt CNGA1, P29973 CNGA2, Q16280 CNGA3, Q16281 CNGB3, Q9NQW8
Activators cyclic GMP (EC50 30 μM)  cyclic AMP cyclic GMP > cyclic AMP (EC50 1 μM) cyclic GMP (EC50 30 μM)  cyclic AMP –
Inhibitors – – L-(cis)-diltiazem (high afﬁnity binding
requires presence of CNGB subunits)
–
Channel blockers dequalinium (Antagonist) (pIC50 6.7)
[0mV] [844], L-(cis)-diltiazem
(Antagonist) (pKi 4) [-80mV – 80mV]
[158]
dequalinium (Antagonist) (pIC50 5.6)
[0mV] [843]
– L-(cis)-diltiazem (Antagonist) (pIC50 5.5)
[0mV] [313] – Mouse
Functional Characteristics γ = 25-30 pS
PCa/PNa = 3.1
γ = 35 pS
PCa/PNa = 6.8
γ = 40 pS
PCa/PNa = 10.9
–
Comments: CNGA1, CNGA2 and CNGA3 express functional
channels as homomers. Three additional subunits CNGA4
(Q8IV77), CNGB1 (Q14028) and CNGB3 (Q9NQW8) do not, and
are referred to as auxiliary subunits. The subunit composi-
tion of the native channels is believed to be as follows. Rod:
CNGA13/CNGB1a; Cone: CNGA32/CNGB32; Olfactory neurons:
CNGA22/CNGA4/CNGB1b [779, 1066, 1139, 1140, 1142].
Hyperpolarisation-activated, cyclic nucleotide-gated
(HCN)
The hyperpolarisation-activated, cyclic nucleotide-gated (HCN)
channels are cation channels that are activated by hyperpolar-
isation at voltages negative to ˜-50 mV. The cyclic nucleotides
cyclic AMP and cyclic GMP directly activate the channels and
shift the activation curves of HCN channels to more positive volt-
ages, thereby enhancing channel activity. HCN channels underlie
pacemaker currents found in many excitable cells including car-
diac cells and neurons [225, 753]. In native cells, these currents
have a variety of names, such as Ih, Iq andIf. The four known HCN
channels have six transmembrane domains and form tetramers.
It is believed that the channels can form heteromers with each
other, as has been shown for HCN1 and HCN4 [22]. High reso-
lution structural studies of CNG and HCN channels has provided
insight into the the gating processes of these channels [540, 563].
Nomenclature HCN1 HCN2 HCN3 HCN4
HGNC, UniProt HCN1, O60741 HCN2, Q9UL51 HCN3, Q9P1Z3 HCN4, Q9Y3Q4
Activators cyclic AMP > cyclic GMP (both weak) cyclic AMP > cyclic GMP – cyclic AMP > cyclic GMP
Channel blockers ivabradine (Antagonist) (pIC50 5.7) [929],
ZD7288 (Antagonist) (pIC50 4.7) [928], Cs+
(Antagonist) (pIC50 3.7) [-40mV] [928]
ivabradine (Antagonist) (pIC50 5.6) [929] –
Mouse, ZD7288 (Antagonist) (pIC50 4.4)
[928], Cs+ (Antagonist) (pIC50 3.7) [-40mV]
[928]
ivabradine (Antagonist) (pIC50 5.7) [929],
ZD7288 (Antagonist) (pIC50 4.5) [928], Cs+
(Antagonist) (pIC50 3.8) [-40mV] [928]
ivabradine (Antagonist) (pIC50 5.7) [929],
ZD7288 (Antagonist) (pIC50 4.7) [928], Cs+
(Antagonist) (pIC50 3.8) [-40mV] [928]
Comments: HCN channels are permeable to both Na+ and K+
ions, with a Na+/K+ permeability ratio of about 0.2. Functionally,
they differ from each other in terms of time constant of activation
with HCN1 the fastest, HCN4 the slowest and HCN2 and HCN3
intermediate. The compounds ZD7288 [102] and ivabradine [117]
have proven useful in identifying and studying functional HCN
channels in native cells. Zatebradine and cilobradine are also use-
ful blocking agents.
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Further reading on Cyclic nucleotide-regulated channels
James ZM et al. (2018) Structural insights into the mechanisms of CNBD channel function. J. Gen.
Physiol. 150: 225-244 [PMID:29233886]
Michalakis S et al. (2018) Retinal Cyclic Nucleotide-Gated Channels: From Pathophysiology to Ther-
apy. Int J Mol Sci 19: [PMID:29518895]
Podda MV et al. (2014) New perspectives in cyclic nucleotide-mediated functions in the CNS:
the emerging role of cyclic nucleotide-gated (CNG) channels. Pﬂugers Arch. 466: 1241-57
[PMID:24142069]
Sartiani L et al. (2017) The Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels: from
Biophysics to Pharmacology of a Unique Family of Ion Channels. Pharmacol. Rev. 69: 354-395
[PMID:28878030]
Wahl-Schott C et al. (2014) HCN channels: new roles in sinoatrial node function. Curr Opin Pharma-
col 15: 83-90 [PMID:24441197]
Potassium channels
Ion channels → Voltage-gated ion channels → Potassium channels
Overview: Activation of potassium channels regulates excitabil-
ity and can control the shape of the action potential waveform.
They are present in all cells within the body and can inﬂuence pro-
cesses as diverse as cognition, muscle contraction and hormone se-
cretion. Potassium channels are subdivided into families, based on
their structural and functional properties. The largest family con-
sists of potassium channels that activated by membrane depolar-
ization, with other families consisting of channels that are either
activated by a rise of intracellular calcium ions or are constitutively
active. A standardised nomenclature for potassium channels has
been proposed by the NC-IUPHAR subcommittees on potas-
sium channels [320, 346, 520, 1064], which has placed cloned
channels into groups based on gene family and structure of chan-
nels that exhibit 6, 4 or 2 transmembrane domains (TM).
Calcium- and sodium-activated potassium channels
Ion channels → Voltage-gated ion channels → Potassium channels → Calcium- and sodium-activated potassium channels
Overview: Calcium- and sodium- activated potassium channels
are members of the 6TM family of K channels which comprises
the voltage-gated KV subfamilies, including the KCNQ subfam-
ily, the EAG subfamily (which includes herg channels), the Ca2+-
activated Slo subfamily (actually with 6 or 7TM) and the Ca2+-
and Na+-activated SK subfamily (nomenclature as agreed by
the NC-IUPHAR Subcommittee on Calcium- and sodium-
activated potassium channels [457]). As for the 2TM fam-
ily, the pore-forming a subunits form tetramers and heteromeric
channels may be formed within subfamilies (e.g. KV1.1 with
KV1.2; KCNQ2 with KCNQ3).
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Nomenclature KCa1.1
HGNC, UniProt KCNMA1, Q12791
Activators NS004, NS1619
Inhibitors paxilline (pKi 8.7) [0mV] [865] – Mouse
Channel blockers charybdotoxin, iberiotoxin, tetraethylammonium
Functional Characteristics Maxi KCa
Nomenclature KCa2.1 KCa2.2 KCa2.3
HGNC, UniProt KCNN1, Q92952 KCNN2, Q9H2S1 KCNN3, Q9UGI6
Activators EBIO (Agonist) Concentration range: 2×10−3M [-80mV]
[771, 1061], NS309 (Agonist) Concentration range:
3×10−8M-1×10−7M [-90mV] [937, 1061]
NS309 (Agonist) (pEC50 6.2) Concentration range:
3×10−8M-1×10−7M [770, 937, 1061], EBIO (Agonist)
(pEC50 3.3) [770, 1061], EBIO (Agonist) (pEC50 3)
Concentration range: 2×10−3M [130, 771] – Rat
EBIO (Agonist) (pEC50 3.8) [1061, 1076], NS309 (Agonist)
Concentration range: 3×10−8M [937, 1061]
Inhibitors UCL1684 (pIC50 9.1) [936, 1061], apamin (pIC50 7.9–8.5)
[889, 931, 936]
UCL1684 (pIC50 9.6) [277, 1061], apamin (pKd 9.4) [456] apamin (pIC50 7.9–9.1) [970, 1076], UCL1684 (pIC50 8–9)
[277, 1061]
Channel blockers tetraethylammonium (pIC50 2.7) [1061] tetraethylammonium (pIC50 2.7) [1061] tetraethylammonium (pIC50 2.7) [1061]
Functional Characteristics SKCa SKCa SKCa
Comments The rat isoform does not form functional channels when
expressed alone in cell lines. N- or C-terminal chimeric
constructs permit functional channels that are insensitive to
apamin [1061]. Heteromeric channels are formed between
KCa2.1 and 2.2 subunits that show intermediate sensitivity
to apamin [176].
– –
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Nomenclature KCa3.1 KNa1.1 KNa1.2 KCa5.1
HGNC, UniProt KCNN4, O15554 KCNT1, Q5JUK3 KCNT2, Q6UVM3 KCNU1, A8MYU2
Activators NS309 (Agonist) (pEC50 8) [-90mV]
[937, 1061], SKA-121 (Agonist) (pEC50
7) [181], EBIO (Agonist) (pEC50 4.1–4.5)
[-100mV – -50mV] [771, 953, 1061]
bithionol (Agonist) (pEC50 5–6) [1105] –
Rat, niclosamide (Agonist) (pEC50 5.5)
[91], loxapine (Agonist) (pEC50 5.4) [91]
niﬂumic acid (Agonist) (pEC50 8.7)
[194, 308]
–
Inhibitors – – – –
Gating inhibitors – bepridil (pIC50 5–6) [1105] – Rat – –
Channel blockers charybdotoxin (pIC50 7.6–8.7) [440,
450]
quinidine (pIC50 4) [83, 1105] – Rat Ba2+ (Inhibition) (pIC50 3) [83],
quinidine (Inhibition) Concentration
range: 1×10−3M [83] – Rat
quinidine Concentration range:
2×10−5M [966, 1080] – Mouse
Selective channel blockers TRAM-34 (Inhibition) (pKd 7.6–8) [527,
1085], senicapoc (Inhibition) (pIC50 8)
[930]
– – –
Functional Characteristics IKCa KNa KNa Sperm pH-regulated K+ current, KSPER
Further reading on Calcium- and sodium-activated potassium channels
Dopico AM et al. (2018) Calcium- and voltage-gated BK channels in vascular smooth muscle. Pﬂugers
Arch. 470: 1271-1289 [PMID:29748711]
Kaczmarek LK et al. (2017) International Union of Basic and Clinical Pharmacology. C. Nomencla-
ture and Properties of Calcium-Activated and Sodium-Activated Potassium Channels. Pharmacol.
Rev. 69: 1-11 [PMID:28267675]
Kshatri AS et al. (2018) Physiological Roles and Therapeutic Potential of Ca2+ Activated Potassium
Channels in the Nervous System. Front Mol Neurosci 11: 258 [PMID:30104956]
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Inwardly rectifying potassium channels
Ion channels → Voltage-gated ion channels → Potassium channels → Inwardly rectifying potassium channels
Overview: The 2TM domain family of K channels are also known
as the inward-rectiﬁer K channel family. This family includes the
strong inward-rectiﬁer K channels (Kir2.x) that are constitutively
active, the G-protein-activated inward-rectiﬁer K channels (Kir3.x)
and the ATP-sensitive K channels (Kir6.x, which combine with
sulphonylurea receptors (SUR1-3)). The pore-forming α subunits
form tetramers, and heteromeric channels may be formed within
subfamilies (e.g. Kir3.2 with Kir3.3).
Nomenclature Kir1.1
HGNC, UniProt KCNJ1, P48048
Ion Selectivity and Conductance NH4+ [62pS] > K+ [38. pS] > Tl+ [21pS] > Rb+ [15pS] (Rat) [167, 384]
Channel blockers tertiapin-Q (Inhibition) (pIC50 8.9) [447], Ba2+ (Antagonist) (pIC50 2.3–4.2) Concentration range: 1×10−4M [voltage dependent 0mV – -100mV] [384, 1143] – Rat,
Cs+ (Antagonist) (pIC50 2.9) [voltage dependent -120mV] [1143] – Rat
Functional Characteristics Kir1.1 is weakly inwardly rectifying, as compared to classical (strong) inward rectiﬁers.
Comments –
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Nomenclature Kir2.1 Kir2.2 Kir2.3 Kir2.4
HGNC, UniProt KCNJ2, P63252 KCNJ12, Q14500 KCNJ4, P48050 KCNJ14, Q9UNX9
Endogenous activators PIP2 (Agonist) Concentration range:
1×10−5M-5×10−5M [-30mV] [406, 829,
921] – Mouse
– – Intracellular Mg2+
Endogenous inhibitors – Intracellular Mg2+ (pIC50 5) [40mV]
[1103]
– –
Gating inhibitors – Ba2+ (Antagonist) Concentration range:
5×10−5M [-150mV – -50mV] [957] –
Mouse, Cs+ (Antagonist) Concentration
range: 5×10−6M-5×10−5M [-150mV –
-50mV] [957] – Mouse
– –
Endogenous channel blockers spermine (Antagonist) (pKd 9.1)
[voltage dependent 40mV] [423, 1107] –
Mouse, spermidine (Antagonist) (pKd
8.1) [voltage dependent 40mV] [1107] –
Mouse, putrescine (Antagonist) (pKd
5.1) [voltage dependent 40mV] [423,
1107] – Mouse, Intracellular Mg2+
(Antagonist) (pKd 4.8) [voltage
dependent 40mV] [1107] – Mouse
– Intracellular Mg2+ (Antagonist) (pKd 5)
[voltage dependent 50mV] [590],
putrescine (Antagonist) Concentration
range: 5×10−5M-1×10−3M [-80mV –
80mV] [590], spermidine (Antagonist)
Concentration range:
2.5×10−5M-1×10−3M [-80mV – 80mV]
[590], spermine (Antagonist)
Concentration range:
5×10−5M-1×10−3M [-80mV – 80mV]
[590]
–
Channel blockers Ba2+ (Antagonist) (pKd 3.9–5.6)
Concentration range:
1×10−6M-1×10−4M [voltage dependent
0mV – -80mV] [16] – Mouse, Cs+
(Antagonist) (pKd 1.3–4) Concentration
range: 3×10−5M-3×10−4M [voltage
dependent 0mV – -102mV] [6] – Mouse
– Ba2+ (Antagonist) (pIC50 5)
Concentration range:
3×10−6M-5×10−4M [-60mV] [620, 806,
967], Cs+ (Antagonist) (pKi 1.3–4.5)
Concentration range:
3×10−6M-3×10−4M [0mV – -130mV]
[620]
Cs+ (Antagonist) (pKd 3–4.1) [voltage
dependent -60mV – -100mV] [408], Ba2+
(Antagonist) (pKd 3.3) [voltage
dependent 0mV] [408]
Functional Characteristics IK1 in heart, ‘strong’ inward-rectiﬁer
current
IK1 in heart, ‘strong’ inward-rectiﬁer
current
IK1 in heart, ‘strong’ inward-rectiﬁer
current
IK1 in heart, ‘strong’ inward-rectiﬁer
current
Comments Kir2.1 is also inhibited by intracellular
polyamines
Kir2.2 is also inhibited by intracellular
polyamines
Kir2.3 is also inhibited by intracellular
polyamines
Kir2.4 is also inhibited by intracellular
polyamines
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Nomenclature Kir3.1 Kir3.2 Kir3.3 Kir3.4
HGNC, UniProt KCNJ3, P48549 KCNJ6, P48051 KCNJ9, Q92806 KCNJ5, P48544
Endogenous activators PIP2 (Agonist) (pKd 6.3) Concentration
range: 5×10−5M [physiological voltage]
[406]
PIP2 (Agonist) (pKd 6.3) Concentration
range: 5×10−5M [physiological voltage]
[406]
PIP2 [376] PIP2 [63, 376]
Gating inhibitors – pimozide (Antagonist) (pEC50 5.5)
[-70mV] [500] – Mouse
– –
Endogenous channel blockers – –
Channel blockers tertiapin-Q (Antagonist) (pIC50 7.9)
[446], Ba2+ (Antagonist) (pIC50 4.7)
[198] – Rat
desipramine (Antagonist) (pIC50 4.4)
[-70mV] [501] – Mouse
– tertiapin-Q (Antagonist) (pIC50 7.9)
[446]
Functional Characteristics G protein-activated inward-rectiﬁer
current
G protein-activated inward-rectiﬁer
current
G protein-activated inward-rectiﬁer
current
G protein-activated inward-rectiﬁer
current
Comments Kir3.1 is also activated by Gβγ. Kir3.1 is
not functional alone. The functional
expression of Kir3.1 in Xenopus oocytes
requires coassembly with the
endogenous Xenopus Kir3.5 subunit.
The major functional assembly in the
heart is the Kir3.1/3.4 heteromultimer,
while in the brain it is Kir3.1/3.2,
Kir3.1/3.3 and Kir3.2/3.3.
Kir3.2 is also activated by Gβγ. Kir3.2
forms functional heteromers with
Kir3.1/3.3.
Kir3.3 is also activated by Gβγ Kir3.4 is also activated by Gβγ
Nomenclature Kir4.1 Kir4.2 Kir5.1
HGNC, UniProt KCNJ10, P78508 KCNJ15, Q99712 KCNJ16, Q9NPI9
Channel blockers Ba2+ (Antagonist) Concentration range:
3×10−6M-1×10−3M [-160mV – 60mV] [505, 960, 965]
– Rat, Cs+ (Antagonist) Concentration range:
3×10−5M-3×10−4M [-160mV – 50mV] [960] – Rat
Ba2+ (Antagonist) Concentration range:
1×10−5M-1×10−4M [-120mV – 100mV] [769] – Mouse,
Cs+ (Antagonist) Concentration range:
1×10−5M-1×10−4M [-120mV – 100mV] [769] – Mouse
Ba2+ (Antagonist) Concentration range: 3×10−3M
[-120mV – 20mV] [964] – Rat
Functional Characteristics Inward-rectiﬁer current Inward-rectiﬁer current Weakly inwardly rectifying
Comments Kir3.3 is also activated by Gβγ Kir3.4 is also activated by Gβγ –
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Nomenclature Kir6.1 Kir6.2 Kir7.1
HGNC, UniProt KCNJ8, Q15842 KCNJ11, Q14654 KCNJ13, O60928
Associated subunits SUR1, SUR2A, SUR2B SUR1, SUR2A, SUR2B –
Activators cromakalim, diazoxide (Agonist) Concentration
range: 2×10−4M [-60mV] [1100] – Mouse,
minoxidil, nicorandil (Agonist) Concentration
range: 3×10−4M [-60mV – 60mV] [1100] – Mouse
diazoxide (Agonist) (pEC50 4.2) [physiological
voltage] [413] – Mouse, cromakalim (Agonist)
Concentration range: 3×10−5M [-60mV] [414] –
Mouse, minoxidil, nicorandil
–
Inhibitors glibenclamide, tolbutamide glibenclamide, tolbutamide –
Channel blockers – – Ba2+ (Antagonist) (pKi 3.2) [voltage dependent
-100mV] [256, 513, 526, 760], Cs+ (Antagonist)
(pKi 1.6) [voltage dependent -100mV] [256, 513,
760]
Functional Characteristics ATP-sensitive, inward-rectiﬁer current ATP-sensitive, inward-rectiﬁer current Inward-rectiﬁer current
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Two P domain potassium channels
Ion channels → Voltage-gated ion channels → Potassium channels → Two P domain potassium channels
Overview: The 4TM family of K channels mediate many of the
background potassium currents observed in native cells. They are
open across the physiological voltage-range and are regulated by a
wide array of neurotransmitters and biochemical mediators. The
pore-forming α-subunit contains two pore loop (P) domains and
two subunits assemble to form one ion conduction pathway lined
by four P domains. It is important to note that single channels do
not have two pores but that each subunit has two P domains in its
primary sequence; hence the name two P domain, or K2P chan-
nels (and not two-pore channels). Some of the K2P subunits can
form heterodimers across subfamilies (e.g. K2P3.1 with K2P9.1).
The nomenclature of 4TM K channels in the literature is still a
mixture of IUPHAR and common names. The suggested division
into subfamilies, described in the More detailed introduction, is
based on similarities in both structural and functional properties
within subfamilies and this explains the “common abbreviation”
nomenclature in the tables below.
Nomenclature K2P1.1 K2P2.1 K2P3.1 K2P4.1
Common abbreviation TWIK1 TREK1 TASK1 TRAAK
HGNC, UniProt KCNK1, O00180 KCNK2, O95069 KCNK3, O14649 KCNK4, Q9NYG8
Endogenous activators – arachidonic acid (studied at 1-10 μM)
(pEC50 5) [764]
– arachidonic acid (studied at 1-10 μM)
[288]
Activators – GI-530159 (pEC50 6.1) [593], BL-1249
(pEC50 5.3) [804], chloroform (studied at
1-5 mM) Concentration range: 8×10−3M
[763], halothane (studied at 1-5 mM)
[763], isoﬂurane (studied at 1-5 mM) [763]
halothane (studied at 1-10 mM) [538] riluzole (studied at 1-100 μM) [248]
Inhibitors – norﬂuoxetine (pIC50 5.1) [477] – –
Channel blockers – – R-(+)-methanandamide (pIC50 ∼6.2) [616],
anandamide (pIC50 ∼6.2) [616]
–
Functional Characteristics Background current Background current Background current Background current
Comments K2P1.1 is inhibited by acid pHo external
acidiﬁcation with a pKa 6.7 [799]. K2P1
forms heterodimers with K2P3 and K2P9
[800].
K2P2.1 is also activated by membrane
stretch, heat and acid pHi [615, 617]. K2P2
can heterodimerize with K2P4 [93] and
K2P10 [558].
Knock-out of the kcnk3 gene leads to a
prolonged QT interval in mice [207] and
disrupted development of the adrenal cortex
[365]. K2P3.1 is inhibited by acid pHo with a
pKa of 6.4 [591]. K2P3 forms heterodimers
with K2P1 [800] and K2P9 [193].
K2P4 is activated by membrane stretch
[614], and increased temperature (12 to
20-fold between 17 and 40°C [462]) and
can heterodimerize with K2P2 [93].
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Nomenclature K2P5.1 K2P6.1 K2P7.1 K2P9.1 K2P10.1
Common abbreviation TASK2 TWIK2 – TASK3 TREK2
HGNC, UniProt KCNK5, O95279 KCNK6, Q9Y257 KCNK7, Q9Y2U2 KCNK9, Q9NPC2 KCNK10, P57789
Endogenous activators – – – – arachidonic acid (studied at 1-10
μM) [555]
Activators – – – halothane (studied at 1-5 mM)
[962]
GI-530159 [593], halothane
(studied at 1-5 mM) [555]
Inhibitors – – – R-(+)-methanandamide (studied at
1-10 μM) [822], anandamide
(studied at 1-10 μM) [822]
–
Functional Characteristics Background current Unknown Unknown Background current Background current
Comments K2P5.1 is activated by alkaline pHo
[833]. Knockout of the kcnk5 gene
in mice is associated with
metabolic acidosis, hyponatremia
and hypotension due to impaired
bicarbonate handling in the kidney
[1057], as well as deafness [141].
The T108P mutation is associated
with Balkan Endemic Nephropathy
in humans [992].
– – K2P9.1 is also inhibited by acid
pHo with a pKa of 6 [822].
Imprinting of the KCNK9 gene is
associated with Birk Barel
syndrome [54]. K2P9 can form
heterodimers with K2P1 [800] or
K2P3 [193].
K2P10.1 is also activated by
membrane stretch [555] and can
heterodimerize with K2P2 [558].
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Nomenclature K2P12.1 K2P13.1 K2P15.1 K2P16.1 K2P17.1 K2P18.1
Common abbreviation THIK2 THIK1 TASK5 TALK1 TALK2 TRESK
HGNC, UniProt KCNK12, Q9HB15 KCNK13, Q9HB14 KCNK15, Q9H427 KCNK16, Q96T55 KCNK17, Q96T54 KCNK18, Q7Z418
Endogenous inhibitors – – – – – arachidonic acid (studied at
10-50 μM) [866]
Inhibitors – halothane (studied at 5
mM) [94]
– – – –
Functional Characteristics Does not function as a
homodimer [821] but can
form a functional
heterodimer with K2P13
[94].
Background current Unknown Background current Background current Background current
Comments – Forms a heterodimer with
K2P12 [94].
– K2P16.1 current is increased
by alkaline pHo with a pKa
of 7.8 [463].
K2P17.1 current is increased
by alkaline pHo with a pKa
of 8.8 [463].
A frame-shift mutation
(F139WfsX24) in the
KCNK18 gene, is associated
with migraine with aura in
humans [528].
Comments: The K2P6, K2P7.1, K2P15.1 and K2P12.1 subtypes, when expressed in isolation, are nonfunctional. All 4TM channels are insensitive to the classical potassium channel blockers tetraethylammonium
and fampridine, but are blocked to varying degrees by Ba2+ ions.
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Voltage-gated potassium channels
Ion channels → Voltage-gated ion channels → Potassium channels → Voltage-gated potassium channels
Overview: The 6TM family of K channels comprises the voltage-
gated KV subfamilies, the EAG subfamily (which includes hERG
channels), the Ca2+-activated Slo subfamily (actually with 7TM,
termed BK) and the Ca2+-activated SK subfamily. These channels
possess a pore-forming α subunit that comprise tetramers of iden-
tical subunits (homomeric) or of different subunits (heteromeric).
Heteromeric channels can only be formed within subfamilies (e.g.
Kv1.1 with Kv1.2; Kv7.2 with Kv7.3). The pharmacology largely
reﬂects the subunit composition of the functional channel.
Nomenclature Kv1.1 Kv1.2 Kv1.3 Kv1.4 Kv1.5 Kv1.6 Kv1.7
HGNC, UniProt KCNA1, Q09470 KCNA2, P16389 KCNA3, P22001 KCNA4, P22459 KCNA5, P22460 KCNA6, P17658 KCNA7, Q96RP8
Associated subunits Kv1.2, Kv1.4, Kvβ1 and
Kvβ2 [182]
Kv1.1, Kv1.4, Kv β1 and
Kv β2 [182]
Kv1.1, Kv1.2, Kv1.4,
Kv1.6 , Kv β1 and Kv β2
[182]
Kv1.1, Kv1.2, Kvβ1 and
Kvβ2 [182]
Kv β1 and Kv β2 Kv β1 and Kv β2 Kv β1 and Kv β2
Channel blockers α-dendrotoxin (pEC50
7.7–9) [335, 409] – Rat,
margatoxin (Inhibition)
(pIC50 8.4) [62],
tetraethylammonium
(Inhibition) (pKd 3.5)
[335] – Mouse
margatoxin (Inhibition)
(pIC50 11.2) [62],
α-dendrotoxin (pIC50
7.8–9.4) [335, 409] –
Rat, noxiustoxin (pKd
8.7) [335] – Rat
margatoxin (pIC50
10–10.3) [305, 315],
noxiustoxin (pKd 9)
[335] – Mouse,
maurotoxin (pIC50 6.8)
[838],
tetraethylammonium
(pKd 2) [335] – Mouse
fampridine (pIC50 1.9)
[942] – Rat
fampridine (pIC50 4.3)
[281]
α-dendrotoxin (pIC50
7.7) [337],
tetraethylammonium
(pIC50 2.2) [337]
noxiustoxin (pIC50 7.7)
[461] – Mouse,
fampridine (pIC50 3.6)
[461] – Mouse
Selective channel
blockers
– – correolide (pIC50 7.1)
[282]
– – – –
Functional
Characteristics
KV KV KV KA Kv KV KV
Comments – – Resistant to
dendrotoxins
Resistant to
dendrotoxins
Resistant to external TEA – –
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Nomenclature Kv1.8 Kv2.1 Kv2.2 Kv3.1 Kv3.2 Kv3.3 Kv3.4
HGNC, UniProt KCNA10, Q16322 KCNB1, Q14721 KCNB2, Q92953 KCNC1, P48547 KCNC2, Q96PR1 KCNC3, Q14003 KCNC4, Q03721
Associated subunits Kv β1 and Kv β2 Kv5.1, Kv6.1-6.4,
Kv8.1-8.2 and Kv9.1-9.3
Kv5.1, Kv6.1-6.4,
Kv8.1-8.2 and Kv9.1-9.3
– – – MiRP2 is an associated
subunit for Kv3.4
Channel blockers fampridine (pIC50 2.8)
[534]
tetraethylammonium
(Pore blocker) (pIC50 2)
[364] – Rat
fampridine (pIC50 2.8)
[876],
tetraethylammonium
(pIC50 2.6) [876]
fampridine (pIC50 4.5)
[335] – Mouse,
tetraethylammonium
(pIC50 3.7) [335] –
Mouse
fampridine (pIC50 4.6)
[568] – Rat,
tetraethylammonium
(pIC50 4.2) [568] – Rat
tetraethylammonium
(pIC50 3.9) [1008] – Rat
tetraethylammonium
(pIC50 3.5) [832, 881] –
Rat
Selective channel
blockers
– – – – – – sea anemone toxin BDS-I
(pIC50 7.3) [231] – Rat
Functional
Characteristics
KV KV – KV KV KA KA
Nomenclature Kv4.1 Kv4.2 Kv4.3
HGNC, UniProt KCND1, Q9NSA2 KCND2, Q9NZV8 KCND3, Q9UK17
Associated subunits KChIP 1-4, DP66, DPP10 KChIP 1-4, DPP6, DPP10, Kvβ1, NCS-1, Navβ1 KChIP 1-4, DPP6 and DPP10, MinK, MiRPs
Channel blockers fampridine (pIC50 2) [418] – –
Functional Characteristics KA KA KA
Nomenclature Kv5.1 Kv6.1 Kv6.2 Kv6.3 Kv6.4
HGNC, UniProt KCNF1, Q9H3M0 KCNG1, Q9UIX4 KCNG2, Q9UJ96 KCNG3, Q8TAE7 KCNG4, Q8TDN1
Searchable database: http://www.guidetopharmacology.org/index.jsp Voltage-gated potassium channels S186
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.14749/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Ion channels. British Journal of Pharmacology (2019) 176, S142–S228
Nomenclature Kv7.1 Kv7.2 Kv7.3 Kv7.4 Kv7.5
HGNC, UniProt KCNQ1, P51787 KCNQ2, O43526 KCNQ3, O43525 KCNQ4, P56696 KCNQ5, Q9NR82
Activators – retigabine (pEC50 5.6) [968] gabapentin (pEC50 8.3) [627],
retigabine (pEC50 6.2) [968]
retigabine (pEC50 5.2) [968] retigabine (pEC50 5) [249]
Selective activators – – – – gabapentin (pEC50 8.7) [627]
Inhibitors XE991 (pKd 6.1) [1047],
linopirdine (pIC50 4.4) [732] –
Mouse
XE991 (pIC50 6.2) [1048],
linopirdine (pIC50 5.3) [1048]
linopirdine (pIC50 5.4) [1048] –
Rat
XE991 (pIC50 5.3) [956],
linopirdine (pIC50 4.9) [956]
linopirdine (pKd 4.8) [552]
Sub/family-selective inhibitors – – – – XE991 (pIC50 4.2) [880]
Channel blockers – tetraethylammonium (pIC50
3.5–3.9) [349, 1069]
– tetraethylammonium (pIC50 1.3)
[48]
–
Functional Characteristics cardiac IK5 M current as a heteromer
between KV7.2 and KV7.3
M current as heteromeric
KV7.2/KV7.3 or KV7.3/KV7.5
– M current as heteromeric
KV7.3/KV7.5
Nomenclature Kv8.1 Kv8.2 Kv9.1 Kv9.2 Kv9.3 Kv10.1 Kv10.2
HGNC, UniProt KCNV1, Q6PIU1 KCNV2, Q8TDN2 KCNS1, Q96KK3 KCNS2, Q9ULS6 KCNS3, Q9BQ31 KCNH1, O95259 KCNH5, Q8NCM2
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Nomenclature Kv11.1 Kv11.2 Kv11.3 Kv12.1 Kv12.2 Kv12.3
HGNC, UniProt KCNH2, Q12809 KCNH6, Q9H252 KCNH7, Q9NS40 KCNH8, Q96L42 KCNH3, Q9ULD8 KCNH4, Q9UQ05
Associated subunits minK (KCNE1) and MiRP1
(KCNE2)
minK (KCNE1) minK (KCNE1) minK (KCNE1) minK (KCNE1) and MiRP2
(KCNE3)
–
Channel blockers astemizole (pIC50 9) [1147],
terfenadine (pIC50 7.3)
[825], disopyramide
(Inhibition) (pIC50 4) [478]
– – – – –
Sub/family-selective channel
blockers
E4031 (pIC50 8.1) [1146] – – – – –
Selective channel blockers dofetilide (Inhibition) (pKi
8.2) [904], ibutilide (pIC50
7.6–8) [478, 785]
– – – – –
Functional Characteristics cardiac IKR – – – – –
Comments RPR260243 is an activator of
Kv11.1 [464].
– – – – –
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Ryanodine receptors
Ion channels → Voltage-gated ion channels → Ryanodine receptors
Overview: The ryanodine receptors (RyRs) are found on in-
tracellular Ca2+ storage/release organelles. The family of RyR
genes encodes three highly related Ca2+ release channels: RyR1,
RyR2 and RyR3, which assemble as large tetrameric structures.
These RyR channels are ubiquitously expressed in many types
of cells and participate in a variety of important Ca2+ signaling
phenomena (neurotransmission, secretion, etc.). In addition to
the three mammalian isoforms described below, various non-
mammalian isoforms of the ryanodine receptor have been iden-
tiﬁed [947]. The function of the ryanodine receptor channels
may also be inﬂuenced by closely associated proteins such as
the tacrolimus (FK506)-binding protein, calmodulin [1101], tri-
adin, calsequestrin, junctin and sorcin, and by protein kinases and
phosphatases. Recent studies solving the structure of the ryan-
odine receptor have shed light on the structural basis of ryan-
odine receptor function [see, for example, Samso (2017) [864] and
Meissner (2017) [648]].
Nomenclature RyR1 RyR2 RyR3
HGNC, UniProt RYR1, P21817 RYR2, Q92736 RYR3, Q15413
Endogenous activators cytosolic ATP (endogenous; mM range), cytosolic Ca2+
(endogenous; μM range), luminal Ca2+ (endogenous)
cytosolic ATP (endogenous; mM range), cytosolic Ca2+
(endogenous; μM range), luminal Ca2+ (endogenous)
cytosolic ATP (endogenous; mM range), cytosolic Ca2+
(endogenous; μM range)
Activators caffeine (pharmacological; mM range), ryanodine
(pharmacological; nM - μM range), suramin
(pharmacological; μM range)
caffeine (pharmacological; mM range), ryanodine
(pharmacological; nM - μM range), suramin
(pharmacological; μM range)
caffeine (pharmacological; mM range), ryanodine
(pharmacological; nM - μM range)
Endogenous antagonists cytosolic Ca2+ Concentration range: >1×10−4M, cytosolic
Mg2+ (mM range)
cytosolic Ca2+ Concentration range: >1×10−3M, cytosolic
Mg2+ (mM range)
cytosolic Ca2+ Concentration range: >1×10−3M, cytosolic
Mg2+ (mM range)
Antagonists dantrolene – dantrolene
Channel blockers procaine, ruthenium red, ryanodine Concentration range:
>1×10−4M
procaine, ruthenium red, ryanodine Concentration range:
>1×10−4M
ruthenium red
Functional Characteristics Ca2+: (P Ca/P K6) single-channel conductance: 90 pS
(50mM Ca2+), 770 pS (200 mM K+)
Ca2+: (P Ca/P K6) single-channel conductance: 90 pS
(50mM Ca2+), 720 pS (210 mM K+)
Ca2+: (P Ca/PK6) single-channel conductance: 140 pS
(50mM Ca2+), 777 pS (250 mM K+)
Comments RyR1 is also activated by depolarisation via DHP receptor,
calmodulin at low cytosolic Ca2+ concentrations, CaM
kinase and PKA; antagonised by calmodulin at high
cytosolic Ca2+ concentrations
RyR2 is also activated by CaM kinase and PKA; antagonised
by calmodulin at high cytosolic Ca2+ concentrations
RyR3 is also activated by calmodulin at low cytosolic Ca2+
concentrations; antagonised by calmodulin at high
cytosolic Ca2+ concentrations
Comments: The modulators of channel function included in
this table are those most commonly used to identify ryanodine-
sensitive Ca2+ release pathways. Numerous other modulators of
ryanodine receptor/channel function can be found in the reviews
listed below. The absence of a modulator of a particular isoform
of receptor indicates that the action of that modulator has not
been determined, not that it is without effect. The potential role
of cyclic ADP ribose as an endogenous regulator of ryanodine
receptor channels is controversial. A region of RyR likely to be
involved in ion translocation and selection has been identiﬁed
[304, 1138].
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Further reading on Ryanodine receptors
Dulhunty AF et al. (2017) Physiology and Pharmacology of Ryanodine Receptor Calcium Release
Channels. Adv. Pharmacol. 79: 287-324 [PMID:28528672]
Meissner G. (2017) The structural basis of ryanodine receptor ion channel function. J. Gen. Physiol.
149: 1065-1089 [PMID:29122978]
O’Brien F et al. (2015) The ryanodine receptor provides high throughput Ca2+-release but is precisely
regulated by networks of associated proteins: a focus on proteins relevant to phosphorylation.
Biochem. Soc. Trans. 43: 426-33 [PMID:26009186]
Samsó M. (2017) A guide to the 3D structure of the ryanodine receptor type 1 by cryoEM. Protein Sci.
26: 52-68 [PMID:27671094]
Van Petegem F. (2015) Ryanodine receptors: allosteric ion channel giants. J. Mol. Biol. 427: 31-53
[PMID:25134758]
Zalk R et al. (2017) Ca2+ Release Channels Join the ’Resolution Revolution’. Trends Biochem. Sci. 42:
543-555 [PMID:28499500]
Transient Receptor Potential channels
Ion channels → Voltage-gated ion channels → Transient Receptor Potential channels
Overview: The TRP superfamily of channels (nomenclature
as agreed by NC-IUPHAR [178, 1084]), whose founder mem-
ber is the Drosophila Trp channel, exists in mammals as six fami-
lies; TRPC, TRPM, TRPV, TRPA, TRPP and TRPML based on amino
acid homologies. TRP subunits contain six putative transmem-
brane domains and assemble as homo- or hetero-tetramers to form
cation selective channels with diversemodes of activation and var-
ied permeation properties (reviewed by [748]). Established, or po-
tential, physiological functions of the individual members of the
TRP families are discussed in detail in the recommended reviews
and in a number of books [262, 424, 711, 1148]. The established,
or potential, involvement of TRP channels in disease is reviewed in
[492, 709] and [713], together with a special edition of Biochemica
et Biophysica Acta on the subject [709]. Additional disease related
reviews, for pain [673], stroke [1136], sensation and inﬂamma-
tion [1009], itch [136], and airway disease [326, 1068], are avail-
able. The pharmacology of most TRP channels has been advanced
in recent years. Broad spectrum agents are listed in the tables
along with more selective, or recently recognised, ligands that are
ﬂagged by the inclusion of a primary reference. See Rubaiy (2019)
for a review of pharmacological tools for TRPC1/C4/C5 chan-
nels [847]. Most TRP channels are regulated by phosphoinostides
such as PtIns(4,5)P2 although the effects reported are often com-
plex, occasionally contradictory, and likely to be dependent upon
experimental conditions, such as intracellular ATP levels (re-
viewed by [714, 842, 1021]). Such regulation is generally not
included in the tables.When thermosensitivity is mentioned, it
refers speciﬁcally to a high Q10 of gating, often in the range of 10-
30, but does not necessarily imply that the channel’s function is to
act as a ’hot’ or ’cold’ sensor. In general, the search for TRP activa-
tors has led to many claims for temperature sensing, mechanosen-
sation, and lipid sensing. All proteins are of course sensitive to
energies of binding, mechanical force, and temperature, but the
issue is whether the proposed input is within a physiologically
relevant range resulting in a response.
TRPA (ankyrin) family
TRPA1 is the sole mammalian member of this group (reviewed by
[307]). TRPA1 activation of sensory neurons contribute to no-
ciception [452, 644, 933]. Pungent chemicals such as mustard
oil (AITC), allicin, and cinnamaldehyde activate TRPA1 by mod-
iﬁcation of free thiol groups of cysteine side chains, especially
those located in its amino terminus [65, 381, 608, 610]. Alkenals
with α, β-unsaturated bonds, such as propenal (acrolein), bute-
nal (crotylaldehyde), and 2-pentenal can react with free thiols
via Michael addition and can activate TRPA1. However, potency
appears to weaken as carbon chain length increases [30, 65].
Covalent modiﬁcation leads to sustained activation of TRPA1.
Chemicals including carvacrol, menthol, and local anesthetics re-
versibly activate TRPA1 by non-covalent binding [467, 549, 1092,
1093]. TRPA1 is not mechanosensitive under physiological con-
ditions, but can be activated by cold temperatures [211, 468].
The electron cryo-EM structure of TRPA1 [766] indicates that it
is a 6-TM homotetramer. Each subunit of the channel contains
two short ‘pore helices’ pointing into the ion selectivity ﬁlter,
which is big enough to allow permeation of partially hydrated
Ca2+ ions.
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Nomenclature TRPA1
HGNC, UniProt TRPA1, O75762
Chemical activators Isothiocyanates (covalent) and 1,4-dihydropyridines (non-covalent)
Oxidative stress compounds 4-oxo-nonenal: pEC50 5.7, H2O2 : pEC50 3.6 (Mouse) [27, 870]
Physical activators Cooling (<17°C) (disputed) [452, 689, 1007]
Activators polygodial (pEC50 6.4) [268], acrolein (Agonist) (pEC50 5.3) [physiological voltage] [65], allicin (Agonist) (pEC50 5.1) [physiological voltage] [66],
9-tetrahydrocannabinol (Agonist) (pEC50 4.9) [-60mV] [452], nicotine (non-covalent) (pEC50 4.8) [-75mV] [961], thymol (non-covalent) (pEC50 4.7)
Concentration range: 6.2×10−6M-2.5×10−5M [546], URB597 (Agonist) (pEC50 4.6) [708], (-)-menthol (Partial agonist) (pEC50 4–4.5) [467, 1088],
cinnamaldehyde (Agonist) (pEC50 4.2) [physiological voltage] [49] – Mouse, icilin (Agonist) Concentration range: 1×10−4M [physiological voltage] [933] – Mouse
Selective activators JT010 (pEC50 9.2) [958], chlorobenzylidene malononitrile (covalent) (pEC50 6.7) [115], ASP7663 (pEC50 6.3) [503], formalin (covalent. This level of activity is
also observed for rat TRPA1) (pEC50 3.4) [610, 644] – Mouse
Channel blockers AP18 (Inhibition) (pIC50 5.5) [788], ruthenium red (Inhibition) (pIC50 5.5) [-80mV] [689] – Mouse, HC030031 (Inhibition) (pIC50 5.2) [644]
Selective channel blockers AM-0902 (Antagonist) (pIC50 7.7) [874]
Functional Characteristics γ = 87–100 pS; conducts mono- and di-valent cations non-selectively (PCa/PNa = 0.84); outward rectiﬁcation; activated by elevated intracellular Ca2+
Comments miRNA-711 is a selective activator of TRPA1 (pEC50 5.0) [351].
Comments: Agents activating TRPA1 in a covalent manner
are thiol reactive electrophiles that bind to cysteine and lysine
residues within the cytoplasmic domain of the channel [381, 607].
TRPA1 is activated by a wide range of endogenous and exoge-
nous compounds and only a few representative examples aremen-
tioned in the table: an exhaustive listing can be found in [52]. In
addition, TRPA1 is potently activated by intracellular zinc (EC50 =
8 nM) [26, 403]. A gain-of-function mutation in TRPA1 was found
to cause familial episodic pain syndrome [515].
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TRPC (canonical) family
Members of the TRPC subfamily (reviewed by [5, 23, 72, 89, 297,
490, 761, 813]) fall into the subgroups outlined below. TRPC2 is
a pseudogene in humans. It is generally accepted that all TRPC
channels are activated downstream of Gq/11-coupled receptors,
or receptor tyrosine kinases (reviewed by [801, 998, 1084]). A
comprehensive listing of G-protein coupled receptors that acti-
vate TRPC channels is given in [5]. Hetero-oligomeric complexes
of TRPC channels and their association with proteins to form sig-
nalling complexes are detailed in [23] and [491]. TRPC channels
have frequently been proposed to act as store-operated chan-
nels (SOCs) (or compenents of mulimeric complexes that form
SOCs), activated by depletion of intracellular calcium stores (re-
viewed by [23, 68, 165, 166, 741, 773, 805, 862, 1125]). How-
ever, the weight of the evidence is that they are not directly gated
by conventional store-operated mechanisms, as established for
Stim-gated Orai channels. TRPC channels are not mechanically
gated in physiologically relevant ranges of force. All members of
the TRPC family are blocked by 2-APB and SKF96365 [357, 358].
Activation of TRPC channels by lipids is discussed by [72]. Im-
portant progress has been recently made in TRPC pharmacology
[100, 480, 664, 847]. TRPC channels regulate a variety of phys-
iological functions and are implicated in many human diseases
[73, 311, 927, 1053].
TRPC1/C4/C5 subgroup
TRPC1 alone may not form a functional ion channel [223].
TRPC4/C5 may be distinguished from other TRP channels by their
potentiation by micromolar concentrations of La3+. TRPC2 is a
pseudogene in humans, but in other mammals appears to be an
ion channel localized to microvilli of the vomeronasal organ. It
is required for normal sexual behavior in response to pheromones
in mice. It may also function in the main olfactory epithelia in
mice [571, 739, 740, 1117, 1120, 1123, 1155].
TRPC3/C6/C7 subgroup
All members are activated by diacylglycerol independent of pro-
tein kinase C stimulation [358].
Nomenclature TRPC1 TRPC2 TRPC3 TRPC4
HGNC, UniProt TRPC1, P48995 TRPC2, – TRPC3, Q13507 TRPC4, Q9UBN4
Chemical activators NO-mediated cysteine S-nitrosylation Diacylglycerol (SAG, OAG, DOG): strongly
inhibited by Ca2+/CaM once activated by
DAG [923]
diacylglycerols NO-mediated cysteine S-nitrosylation,
potentiation by extracellular protons
Physical activators – DAG kinase; regulates DAG concentration in
vomeronasal sensory neurons
– –
Endogenous activators membrane stretch (likely direct) Intracellular Ca2+ – –
Activators DOG (Agonist) Concentration range:
1×10−4M [-80mV] [599] – Mouse, SAG
(Agonist) Concentration range: 1×10−4M
[-80mV] [599] – Mouse
pyrazolopyrimidine 4n (pEC50 7.7) [818],
GSK1702934A (Agonist) (pEC50 7.1) [1099]
(-)-englerin A (Agonist) (pEC50 7.9) [13],
tonantzitlolone (pEC50 6.9) [849], La3+ (μM
range)
Channel blockers 2-APB (Antagonist) [-70mV] [939], Gd3+
(Antagonist) Concentration range:
2×10−5M [-70mV] [1154], La3+
(Antagonist) Concentration range:
1×10−4M [-70mV] [939]
2-APB (Antagonist) Concentration range:
5×10−5M [-70mV – 80mV] [599] – Mouse,
U73122 (Antagonist) Concentration range:
1×10−5M – Mouse
GSK2833503A (pIC50 7.7) [80mV] [887],
GSK417651A (Antagonist) (pIC50 7.1)
[1058], Gd3+ (Antagonist) (pEC50 7)
[-60mV] [350], SAR7334 (pIC50 6.6) [613],
BTP2 (Antagonist) (pIC50 6.5) [-80mV]
[363], Pyr3 (pIC50 6.2) [494], Pyr10
(Antagonist) (pIC50 6.1) [875],
norgestimate (pKi 5.5) [656], La
3+
(Antagonist) (pIC50 5.4) [-60mV] [350],
clemizole (pIC50 5) [834], 2-APB
(Antagonist) (pIC50 5) [physiological
voltage] [569], Ni2+, SKF96365
HC-070 (Antagonist) (pIC50 7.3) [454],
ML204 (pIC50 5.5) [660], M084 (Inhibition)
(pIC50 5.3) [1149], clemizole (pIC50 5.2)
[834], La3+ (mM range), SKF96365,
niﬂumic acid (Antagonist) Concentration
range: 3×10−5M [-60mV] [1039] – Mouse
Functional Characteristics It is not yet clear that TRPC1 forms a
homomer. It does form heteromers with
TRPC4 and TRPC5
γ = 42 pS linear single channel conductance
in 150 mM symmetrical Na+ in vomeronasal
sensory neurons. PCa/PNa = 2.7; permeant
to Na+, Cs+, Ca2+, but not NMDG [739,
1120]
γ = 66 pS; conducts mono and di-valent
cations non-selectively (PCa/PNa = 1.6);
monovalent cation current suppressed by
extracellular Ca2+; dual (inward and
outward) rectiﬁcation
γ = 30 –41 pS, conducts mono and di-valent
cations non-selectively (PCa/PNa = 1.1 –
7.7); dual (inward and outward)
rectiﬁcation
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Nomenclature TRPC5 TRPC6 TRPC7
HGNC, UniProt TRPC5, Q9UL62 TRPC6, Q9Y210 TRPC7, Q9HCX4
Chemical activators NO-mediated cysteine S-nitrosylation (disputed),
potentiation by extracellular protons
Diacylglycerols diacylglycerols
Physical activators Membrane stretch Membrane stretch –
Endogenous activators intracellular Ca2+ (at negative potentials) (pEC50 6.2),
lysophosphatidylcholine
20-HETE, arachidonic acid, lysophosphatidylcholine –
Activators (-)-englerin A (Agonist) (pEC50 8.1) [13], tonantzitlolone
(pEC50 7.1) [849], BTD (pEC50 5.8) [71], riluzole (pEC50 5)
[835], methylprednisolone (pEC50 4.9) [71], rosiglitazone
(pEC50 4.5) [619], Gd3+ Concentration range: 1×10−4M,
La3+ (μM range), Pb2+ Concentration range: 5×10−6M,
genistein (independent of tyrosine kinase inhibition) [1078]
GSK1702934A (Agonist) (pIC50 6.4) [1099],
pyrazolopyrimidine 4n (pEC50 5.9) [818], ﬂufenamate,
hyp 9 [556], hyperforin [557]
pyrazolopyrimidine 4n (pIC50 6.1) [818]
Channel blockers Pico145 (Inhibition) (pIC50 8.9) [848], HC-070
(Antagonist) (pIC50 8) [454], AM12 (Inhibition) (pIC50 6.6)
[696], galangin (pKi 6.3) [696], clemizole (pIC50 6) [834],
KB-R7943 (Inhibition) (pIC50 5.9) [509], M084 (Inhibition)
(pIC50 5.1) [1149], ML204 (pIC50 ∼5) [660], 2-APB
(Antagonist) (pIC50 4.7) [-80mV] [1097], La3+ (Antagonist)
Concentration range: 5×10−3M [-60mV] [453] – Mouse
GSK2833503A (pIC50 8.5) [80mV] [887], SAR7334 (pIC50
8) [613], larixyl acetate (Inhibition) (pIC50 7) [1006],
GSK417651A (Antagonist) (pIC50 6.4) [1058], clemizole
(pIC50 5.9) [834], Gd3+ (Antagonist) (pIC50 5.7) [-60mV]
[415] – Mouse, SKF96365 (Antagonist) (pIC50 5.4) [-60mV]
[415] – Mouse, norgestimate (pIC50 5.3) [656], La3+ (pIC50
∼5.2), amiloride (Antagonist) (pIC50 3.9) [-60mV] [415] –
Mouse, Cd2+ (Antagonist) (pIC50 3.6) [-60mV] [415] –
Mouse, 2-APB, ACAA, GsMTx-4, Extracellular H+,
KB-R7943, ML9
SAR7334 (pIC50 6.7) [613], 2-APB, La3+ (Antagonist)
Concentration range: 1×10−4M [-60mV] [734] – Mouse,
SKF96365 (Antagonist) Concentration range: 2.5×10−5M
[-60mV] [734] – Mouse, amiloride
Selective channel blockers AC1903 (Inhibition) (pIC50 4.8) [1145] – –
Functional Characteristics γ = 41-63 pS; conducts mono-and di-valent cations
non-selectively (PCa/PNa = 1.8 – 9.5); dual rectiﬁcation
(inward and outward) as a homomer, outwardly rectifying
when expressed with TRPC1 or TRPC4
γ = 28-37 pS; conducts mono and divalent cations with a
preference for divalents (PCa/PNa = 4.5–5.0); monovalent
cation current suppressed by extracellular Ca2+ and Mg2+,
dual rectiﬁcation (inward and outward), or inward
rectiﬁcation
γ = 25–75 pS; conducts mono and divalent cations with a
preference for divalents (PCa/ PCs = 5.9); modest outward
rectiﬁcation (monovalent cation current recorded in the
absence of extracellular divalents); monovalent cation
current suppressed by extracellular Ca2+ and Mg2+
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TRPM (melastatin) family
Members of the TRPM subfamily (reviewed by [292, 357, 773,
1141]) fall into the ﬁve subgroups outlined below.
TRPM1/M3 subgroup
In darkness, glutamate released by the photoreceptors and ON-
bipolar cells binds to the metabotropic glutamate receptor 6,
leading to activation of Go . This results in the closure of TRPM1.
When the photoreceptors are stimulated by light, glutamate re-
lease is reduced, and TRPM1 channels are more active, resulting
in cell membrane depolarization. Human TRPM1 mutations
are associated with congenital stationary night blindness
(CSNB), whose patients lack rod function. TRPM1 is also found
melanocytes. Isoforms of TRPM1 may present in melanocytes,
melanoma, brain, and retina. In melanoma cells, TRPM1 is preva-
lent in highly dynamic intracellular vesicular structures [416,
727]. TRPM3 (reviewed by [730]) exists as multiple splice variants
which differ signiﬁcantly in their biophysical properties. TRPM3
is expressed in somatosensory neurons and may be important
in development of heat hyperalgesia during inﬂammation (see
review [972]). TRPM3 is frequently coexpressed with TRPA1 and
TRPV1 in these neurons. TRPM3 is expressed in pancreatic beta
cells as well as brain, pituitary gland, eye, kidney, and adipose
tissue [729, 971]. TRPM3 may contribute to the detection of
noxious heat [1028].
TRPM2
TRPM2 is activated under conditions of oxidative stress (respira-
tory burst of phagocytic cells) and ischemic conditions. However,
the direct activators are ADPR(P) and calcium. As for many ion
channels, PIP2 must also be present (reviewed by [1102]). Nu-
merous splice variants of TRPM2 exist which differ in their ac-
tivation mechanisms [243]. The C-terminal domain contains a
TRP motif, a coiled-coil region, and an enzymatic NUDT9 ho-
mologous domain. TRPM2 appears not to be activated by NAD,
NAAD, or NAADP, but is directly activated by ADPRP (adenosine-
5’-O-disphosphoribose phosphate) [1003]. TRPM2 is involved in
warmth sensation [884], and contributes to neurological diseases
[79]. Recent study shows that 2’-deoxy-ADPR is an endogenous
TRPM2 superagonist [293].
TRPM4/5 subgroup
TRPM4 and TRPM5 have the distinction within all TRP chan-
nels of being impermeable to Ca2+ [1084]. A splice variant of
TRPM4 (i.e.TRPM4b) and TRPM5 are molecular candidates for en-
dogenous calcium-activated cation (CAN) channels [341]. TRPM4
is active in the late phase of repolarization of the cardiac ven-
tricular action potential. TRPM4 deletion or knockout enhances
beta adrenergic-mediated inotropy [637]. Mutations are associ-
ated with conduction defects [428, 637, 924]. TRPM4 has been
shown to be an important regulator of Ca2+ entry in to mast cells
[1011] and dendritic cell migration [53]. TRPM5 in taste receptor
cells of the tongue appears essential for the transduction of sweet,
amino acid and bitter stimuli [570] TRPM5 contributes to the slow
afterdepolarization of layer 5 neurons in mouse prefrontal cortex
[550]. Both TRPM4 and TRPM5 are required transduction of taste
stimuli [253].
TRPM6/7 subgroup
TRPM6 and 7 combine channel and enzymatic activities
(‘chanzymes’). These channels have the unusual property of per-
meation by divalent (Ca2+, Mg2+, Zn2+) and monovalent cations,
high single channel conductances, but overall extremely small
inward conductance when expressed to the plasma membrane.
They are inhibited by internal Mg2+ at 0.6 mM, around the free
level of Mg2+ in cells. Whether they contribute to Mg2+ home-
ostasis is a contentious issue. When either gene is deleted in mice,
the result is embryonic lethality. The C-terminal kinase region is
cleaved under unknown stimuli, and the kinase phosphorylates
nuclear histones. TRPM7 is responsible for oxidant- induced Zn2+
release from intracellular vesicles [4] and contributes to intestinal
mineral absorption essential for postnatal survival [666].
TRPM8
Is a channel activated by cooling and pharmacological agents
evoking a ‘cool’ sensation and participates in the thermosensa-
tion of cold temperatures [67, 180, 221] reviewed by [498, 585,
685, 1022].
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Nomenclature TRPM1 TRPM2
HGNC, UniProt TRPM1, Q7Z4N2 TRPM2, O94759
Chemical activators – Agents producing reactive oxygen (e.g. H2O2) and nitrogen (e.g. GEA 3162) species
Physical activators – Heat 35°C
Endogenous activators pregnenolone sulphate [531] intracellular cADPR (Agonist) (pEC50 5) [-80mV – -60mV] [70, 504, 986], intracellular ADP ribose (Agonist) (pEC50
3.9–4.4) [-80mV] [784], intracellular Ca2+ (perhaps via calmodulin), H2O2 (Agonist) Concentration range:
5×10−7M-5×10−5M [physiological voltage] [294, 355, 511, 914, 1063], membrane PIP2 [1002], arachidonic acid
(Potentiation) Concentration range: 1×10−5M-3×10−5M [physiological voltage] [355]
Activators – GEA 3162
Endogenous channel blockers Zn2+ (pIC50 6) Zn2+ (pIC50 6), extracellular H+
Channel blockers – 2-APB (Antagonist) (pIC50 6.1) [-60mV] [987], ACAA (Antagonist) (pIC50 5.8) [physiological voltage] [510],
clotrimazole (Antagonist) Concentration range: 3×10−6M-3×10−5M [-60mV – -15mV] [378], econazole
(Antagonist) Concentration range: 3×10−6M-3×10−5M [-60mV – -15mV] [378], ﬂufenamic acid (Antagonist)
Concentration range: 5×10−5M-1×10−3M [-60mV – -50mV] [377, 987], miconazole (Antagonist) Concentration
range: 1×10−5M [-60mV] [987]
Functional Characteristics Conducts mono- and di-valent cations
non-selectively, dual rectiﬁcation (inward and
outward)
γ = 52-60 pS at negative potentials, 76 pS at positive potentials; conducts mono- and di-valent cations
non-selectively (PCa/PNa = 0.6-0.7); non-rectifying; inactivation at negative potentials; activated by oxidative stress
probably via PARP-1, PARP inhibitors reduce activation by oxidative stress, activation inhibited by suppression of
APDR formation by glycohydrolase inhibitors.
Comments – Additional endogenous activators include 2’-deoxy-ADPR, 3’-deoxy-ADPR, 2’-phospho-ADPR, 2-F-ADPR and
ADP-ribose-2’-phosphate (ADPRP) [293, 1003]. 8-Br-cADPR acts as a gating inhibitor [504].
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Nomenclature TRPM3 TRPM4
HGNC, UniProt TRPM3, Q9HCF6 TRPM4, Q8TD43
Other channel blockers – Intracellular nucleotides including ATP, ADP, adenosine 5’-monophosphate and
AMP-PNP with an IC50 range of 1.3-1.9 μM
Physical activators heat (Q10 = 7.2 between 15 - 25°C), hypotonic cell swelling [333, 1028, 1029] Membrane depolarization (V  = -20 mV to + 60 mV dependent upon conditions) in the
presence of elevated [Ca2+]i, heat (Q10 = 8.5 @ +25 mV between 15 and 25°C)
Endogenous activators pregnenolone sulphate (pEC50 4.9) [1033], sphingosine (Agonist) (pEC50 4.9)
[physiological voltage] [334], sphinganine (Agonist) (pEC50 4.7) [334],
epipregnanolone sulphate [618]
intracellular Ca2+ (Agonist) (pEC50 3.9–6.3) [-100mV – 100mV] [712, 716, 717, 959]
Activators CIM2016 (pEC50 6.1) [367, 972], nifedipine BTP2 (Agonist) (pEC50 8.1) [-80mV] [959], decavanadate (Agonist) (pEC50 5.7)
[-100mV] [716]
Gating inhibitors 2-APB (Antagonist) (pIC50 4) [1097] ﬂufenamic acid (Antagonist) (pIC50 5.6) [100mV] [1005] – Mouse, clotrimazole
(Antagonist) Concentration range: 1×10−6M-1×10−5M [100mV] [720]
Endogenous channel blockers Mg2+ (Antagonist) (pIC50 2) [728] – Mouse, extracellular Na+ (TRPM3α2 only) –
Channel blockers isosakuranetin (pIC50 6.3) [934], primidone (pIC50 6.2) [519], maprotiline (pIC50 5.8)
[519], diclofenac (pIC50 5.2) [948], liquiritigenin (pIC50 5.2) [934], naringenin (pIC50
5.2) [934, 935], Gd3+ (Antagonist) (pIC50 4) [333, 545], La3+ (Antagonist) (pIC50 4)
[333, 545]
9-phenanthrol (pIC50 4.6–4.8) [327], spermine (Antagonist) (pIC50 4.2) [100mV] [718],
adenosine (pIC50 3.2)
Functional Characteristics TRPM31235: γ = 83 pS (Na+ current), 65 pS (Ca2+ current); conducts mono and
di-valent cations non-selectively (PCa/PNa = 1.6) TRPM3α1: selective for monovalent
cations (PCa/PCs0.1);
TRPM3α2: conducts mono- and di-valent cations non-selectively (PCa/PCs = 1-10);
In- and outwardly rectifying currents by co-application of pregnenolone sulphate and
clotrimazole or single application of CIM0216 [367, 1027].
γ = 23 pS (within the range 60 to +60 mV); permeable to monovalent cations;
impermeable to Ca2+; strong outward rectiﬁcation; slow activation at positive potentials,
rapid deactivation at negative potentials, deactivation blocked by decavanadate
Comments G protein βγ subunits can act as endogenous inhibitors of TRPM3 channel activity [45,
216, 819].
–
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Nomenclature TRPM5 TRPM6
HGNC, UniProt TRPM5, Q9NZQ8 TRPM6, Q9BX84
EC number – 2.7.11.1
Other chemical activators – constitutively active, activated by reduction of intracellular Mg2+
Physical activators membrane depolarization (V
 
= 0 to + 120 mV dependent upon conditions), heat (Q10
= 10.3 @ -75 mV between 15 and 25°C)
–
Endogenous activators intracellular Ca2+ (Agonist) (pEC50 4.5–6.2) [-80mV – 80mV] [389, 580, 1005] – Mouse extracellular H+ (Potentiation), intracellular Mg2+
Activators – 2-APB (Agonist) (pEC50 3.4–3.7) [-120mV – 100mV] [562]
Endogenous channel blockers – Mg2+ (inward current mediated by monovalent cations is blocked) (pIC50 5.5–6), Ca2+
(inward current mediated by monovalent cations is blocked) (pIC50 5.3–5.3)
Channel blockers ﬂufenamic acid (pIC50 4.6), intracellular spermine (pIC50 4.4), Extracellular H+ (pIC50
3.2)
ruthenium red (pIC50 7) [voltage dependent -120mV]
Functional Characteristics γ = 15-25 pS; conducts monovalent cations selectively (PCa/PNa = 0.05); strong outward
rectiﬁcation; slow activation at positive potentials, rapid inactivation at negative
potentials; activated and subsequently desensitized by [Ca2+]I
γ= 40–87 pS; permeable to mono- and di-valent cations with a preference for divalents
(Mg2+ > Ca2+; PCa/PNa = 6.9), conductance sequence Zn2+ > Ba2+ > Mg2+= Ca2+ =
Mn2+ > Sr2+ > Cd2+> Ni2+; strong outward rectiﬁcation abolished by removal of
extracellular divalents, inhibited by intracellular Mg2+ (IC50 = 0.5 mM) and ATP
Comments TRPM5 is not blocked by ATP –
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Nomenclature TRPM7 TRPM8
HGNC, UniProt TRPM7, Q96QT4 TRPM8, Q7Z2W7
EC number 2.7.11.1 –
Chemical activators – agonist activities are temperature dependent and potentiated by cooling
Physical activators – depolarization (V
 
+50 mV at 15°C), cooling (< 22-26°C)
Endogenous activators Extracellular H+ (Potentiation) –
Activators 2-APB Concentration range: >1×10−3M [688] – Mouse, naltriben [390] icilin (Agonist) (pEC50 6.7–6.9) [physiological voltage] [25, 74] – Mouse, (-)-menthol
(inhibited by intracellular Ca2+) (pEC50 4.6) [-120mV – 160mV] [1020]
Selective activators – WS-12 (Full agonist) (pEC50 4.9) [physiological voltage] [605, 896] – Rat
Channel blockers spermine (Inhibition) (pKi 5.6) [-110mV – 80mV] [508] – Rat, 2-APB (Inhibition) (pIC50
3.8) [-100mV – 100mV] [562] – Mouse, carvacrol (Inhibition) (pIC50 3.5) [-100mV –
100mV] [759] – Mouse, Mg2+ (Antagonist) (pIC50 2.5) [80mV] [688] – Mouse, La3+
(Antagonist) Concentration range: 2×10−3M [-100mV – 100mV] [852] – Mouse
BCTC (Antagonist) (pIC50 6.1) [physiological voltage] [74] – Mouse, 2-APB (Antagonist)
(pIC50 4.9–5.1) [100mV – -100mV] [404, 697] – Mouse, capsazepine (Antagonist) (pIC50
4.7) [physiological voltage] [74] – Mouse
Selective channel blockers – PF-05105679 (Antagonist) (pIC50 7) [voltage dependent] [28]
Functional Characteristics γ = 40-105 pS at negative and positive potentials respectively; conducts mono-and
di-valent cations with a preference for monovalents (PCa/PNa = 0.34); conductance
sequence Ni2+ > Zn2+ > Ba2+ = Mg2+ > Ca2+ = Mn2+ > Sr2+ > Cd2+; outward
rectiﬁcation, decreased by removal of extracellular divalent cations; inhibited by
intracellular Mg2+, Ba2+, Sr2+, Zn2+, Mn2+ and Mg.ATP (disputed); activated by and
intracellular alkalinization; sensitive to osmotic gradients
γ = 40-83 pS at positive potentials; conducts mono- and di-valent cations non-selectively
(PCa/PNa = 1.0–3.3); pronounced outward rectiﬁcation; demonstrates densensitization to
chemical agonists and adaptation to a cold stimulus in the presence of Ca2+; modulated
by lysophospholipids and PUFAs
Comments 2-APB acts as a channel blocker in the μM range. Recent study shows cAMP inhibits
TRPM7-mediated Ca2+ inﬂux [110]. Waixenicin-A speciﬁcally inhibits TRPM7 [1152].
Cannabidiol and 9-tetrahydrocannabinol are examples of cannabinoid activators. TRPM8
is insensitive to ruthenium red. Icilin requires intracellular Ca2+ for full agonist activity.
Comments: Ca2+ activates all splice variants of TRPM2, but
other activators listed are effective only at the full length iso-
form [243]. Inhibition of TRPM2 by clotrimazole, miconazole,
econazole, ﬂufenamic acid is largely irreversible. Co-application
of pregnenolone sulphate and clotrimazole caused TRPM3 cur-
rents to acquire an inwardly rectifying component at negative
voltages, resulting in a biphasic conductance-voltage relationship.
Evidence was presented that the inward current might reﬂect the
permeation of cations through the opening of a non-canonical
pore [1027]. TRPM3 activity is impaired in chronic fatigue syn-
drome/myalgic encephalomyelitis patients suggesting changes in
intracellular Ca2+ concentration, which may impact natural killer
cellular functions [120]. TRPM4 exists as multiple spice vari-
ants: data listed are for TRPM4b. The sensitivity of TRPM4b
and TRPM5 to activation by [Ca2+]i demonstrates a pronounced
and time-dependent reduction following excision of inside-out
membrane patches [1005]. The V
 
for activation of TRPM4 and
TRPM5 demonstrates a pronounced negative shift with increasing
temperature. Activation of TRPM8 by depolarization is strongly
temperature-dependent via a channel-closing rate that decreases
with decreasing temperature. The V
 
is shifted in the hyperpolar-
izing direction both by decreasing temperature and by exogenous
agonists, such as (-)-menthol [1020] whereas antagonists produce
depolarizing shifts in V
 
[684]. The V
 
for the native channel is far
more positive than that of heterologously expressed TRPM8 [684].
It should be noted that (-)-menthol and structurally related com-
pounds can elicit release of Ca2+ from the endoplasmic reticulum
independent of activation of TRPM8 [612]. Intracellular pH mod-
ulates activation of TRPM8 by cold and icilin, but not (-)-menthol
[25].
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TRPML (mucolipin) family
The TRPML family [188, 810, 816, 1096, 1129] consists of three
mammalian members (TRPML1-3). TRPML channels are prob-
ably restricted to intracellular vesicles and mutations in the
gene (MCOLN1) encoding TRPML1 (mucolipin-1) cause the neu-
rodegenerative disorder mucolipidosis type IV (MLIV) in man.
TRPML1 is a cation selective ion channel that is important for
sorting/transport of endosomes in the late endocytotic pathway
and speciﬁcally, ﬁssion from late endosome-lysosome hybrid vesi-
cles and lysosomal exocytosis [863]. TRPML2 and TRPML3 show
increased channel activity in low extracellular sodium and are ac-
tivated by similar small molecules [332]. A naturally occurring
gain of function mutation in TRPML3 (i.e. A419P) results in the
varitint waddler (Va) mouse phenotype (reviewed by [715, 816]).
Nomenclature TRPML1 TRPML2 TRPML3
HGNC, UniProt MCOLN1, Q9GZU1 MCOLN2, Q8IZK6 MCOLN3, Q8TDD5
Endogenous activators phosphatidyl (3,5) inositol bisphosphate (Also activates
other TRPMLs) (pEC50 7.3) [234]
– –
Activators ML SA1 (pEC50 7.3) [-140mV] [894], MK6-83 (pEC50 7)
[-200mV] [154], SF-22 (pEC50 6.3) [-200mV] [154],
SF-51 (pEC50 4.5) [894]
TRPML1Va: Constitutively active, current potentiated by
extracellular acidiﬁcation (equivalent to intralysosomal
acidiﬁcation)
ML SA1 Concentration range: 1×10−5M [-140mV]
[894], phosphatidyl (3,5) inositol bisphosphate
Concentration range: 1×10−6M [-140mV] [234]
TRPML2Va: Constitutively active, current potentiated by
extracellular acidiﬁcation (equivalent to intralysosomal
acidiﬁcation)
ML SA1 Concentration range: 1×10−5M [-140mV]
[894], phosphatidyl (3,5) inositol bisphosphate
Concentration range: 1×10−6M [-140mV] [234]
Selective activators Channel blockers – Gd3+ (Antagonist) (pIC50 4.7) [-80mV] [690] – Mouse
– ML2-SA1 (Agonist) (pEC50 5.9) [-100mV] [802]
Functional Characteristics TRPML1Va: γ = 40 pS and 76-86 pS at very negative
holding potentials with Fe2+ and monovalent cations as
charge carriers, respectively; conducts Na+∼= K+>Cs+
and divalent cations (Ba2+>Mn2+>Fe2+>Ca2+>
Mg2+> Ni2+>Co2+> Cd2+>Zn2+Cu2+); monovalent
cation ﬂux suppressed by divalent cations (e.g. Ca2+,
Fe2+); inwardly rectifying
Conducts Na+; monovalent cation ﬂux suppressed by
divalent cations; inwardly rectifying
TRPML3Va: γ = 49 pS at very negative holding
potentials with monovalent cations as charge carrier;
conducts Na+ > K+ > Cs+ with maintained current in
the presence of Na+, conducts Ca2+ and Mg2+, but not
Fe2+, impermeable to protons; inwardly rectifying Wild
type TRPML3: γ = 59 pS at negative holding potentials
with monovalent cations as charge carrier; conducts
Na+ > K+ > Cs+ and Ca2+ (PCa/PK ∼= 350), slowly
inactivates in the continued presence of Na+ within the
extracellular (extracytosolic) solution; outwardly
rectifying
Comments TRPML1 current is potentiated by acidic pH and
sphingosine [894].
– Current is activated by Na+-free extracellular
(extracytosolic) solution, and is inhibited by
extracellular acidiﬁcation (equivalent to intra-lysosomal
acidiﬁcation). Channel blockers include the ML-SI series
of compounds (e.g. ML-SI1; concentration range
5x10-5 M; -120mV) [649].
Comments: Data in the table are for TRPML proteins mu-
tated (i.e TRPML1Va, TRPML2Va and TRPML3Va) at loci equivalent
to TRPML3 A419P to allow plasma membrane expression when
expressed in HEK-293 cells and subsequent characterisation by
patch-clamp recording [233, 330, 484, 690, 1094]. Data for wild
type TRPML3 are also tabulated [484, 485, 690, 1094]. It should
be noted that alternative methodologies, particularly in the case
of TRPML1, have resulted in channels with differing biophysical
characteristics (reviewed by [810]). Initial functional characteris-
tics of TRPML channels are performed on their Va mutations of
TRPMLs at loci equivalent to TRPML3 A419P. Current pharma-
cological characterization of channel activators and blockers are
conducted on wild-type channel proteins using endolysosomal
patch-clamp [154, 234, 802, 894].
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TRPP (polycystin) family
The TRPP family (reviewed by [213, 215, 316, 387, 1077]) or PKD2
family is comprised of PKD2 (PC2), PKD2L1 (PC2L1), PKD2L2
(PC2L2), which have been renamed TRPP1, TRPP2 and TRPP3,
respectively [1084]. It should also be noted that the nomenclature
of PC2 was TRPP2 in old literature. However, PC2 has been uni-
formed to be called TRPP2 [356]. PKD2 family channels are clearly
distinct from the PKD1 family, whose function is unknown. PKD1
and PKD2 form a hetero-oligomeric complex with a 1:3 ratio.
[943]. Although still being sorted out, TRPP family members ap-
pear to be 6TM spanning nonselective cation channels.
Nomenclature TRPP1 TRPP2 TRPP3
HGNC, UniProt PKD2, Q13563 PKD2L1, Q9P0L9 PKD2L2, Q9NZM6
Activators – Calmidazolium (in primary cilia): 10 μM –
Channel blockers – phenamil (pIC50 6.9), benzamil (pIC50 6),
ethylisopropylamiloride (pIC50 5), amiloride (pIC50 3.8),
Gd3+ Concentration range: 1×10−4M [-50mV] [161], La3+
Concentration range: 1×10−4M [-50mV] [161], ﬂufenamate
–
Functional Characteristics TRPP1 (PKD2) is a cation channel found in primary cilia of
inner medullary collecting duct (IMCD) cells, but not at the
plasma membrane; conducts K+>Na+>Ca2+ (1:0.4:0.025).
PKD2 shows a large outward conductance (90-117 pS)
[584, 781]. Activators or channel blockers remain to be
investigated.
Currents have been measured directly from primary cilia
and also when expressed on plasma membranes. Primary
cilia appear to contain heteromeric TRPP2 + PKD1-L1,
underlying a gently outwardly rectifying nonselective
conductance (PCa/PNa 6: PKD1-L1 is a 12 TM protein of
unknown topology). Primary cilia heteromeric channels
have an inward single channel conductance of 80 pS and
an outward single channel conductance of 95 pS.
Presumed homomeric TRPP2 channels are gently outwardly
rectifying. Single channel conductance is 120 pS inward,
200 pS outward [205]. TRPP2 (PKD2L1) displays calcium
dependent activation. Calcium accumulation due to
prolonged channel activity may lead to outward-moving
Ca2+ ions to close the channel [206].
The functional characteristics of PKD2L2(PC2L2) has not
been established yet.
Comments: Data in the table are extracted from [195, 215] and
[898]. Broadly similar single channel conductance, mono- and
di-valent cation selectivity and sensitivity to blockers are observed
for TRPP2 co-expressed with TRPP1 [214]. Ca2+, Ba2+ and Sr2+ per-
meate TRPP3, but reduce inward currents carried by Na+. Mg2+
is largely impermeant and exerts a voltage dependent inhibition
that increases with hyperpolarization.
Searchable database: http://www.guidetopharmacology.org/index.jsp Transient Receptor Potential channels S200
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.14749/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Ion channels. British Journal of Pharmacology (2019) 176, S142–S228
TRPV (vanilloid) family
Members of the TRPV family (reviewed by [1012]) can broadly be
divided into the non-selective cation channels, TRPV1-4 and the
more calcium selective channels TRPV5 and TRPV6.
TRPV1-V4 subfamily
TRPV1 is involved in the development of thermal hyperalge-
sia following inﬂammation and may contribute to the detec-
tion of noxius heat (reviewed by [794, 925, 954]). Numerous
splice variants of TRPV1 have been described, some of which
modulate the activity of TRPV1, or act in a dominant nega-
tive manner when co-expressed with TRPV1 [883]. The phar-
macology of TRPV1 channels is discussed in detail in [343] and
[1026]. TRPV2 is probably not a thermosensor in man [756], but
has recently been implicated in innate immunity [576]. TRPV3
and TRPV4 are both thermosensitive. There are claims that
TRPV4 is also mechanosensitive, but this has not been estab-
lished to be within a physiological range in a native environment
[129, 567].
TRPV5/V6 subfamily
TRPV5 and TRPV6 are highly expressed in placenta, bone, and
kidney. Under physiological conditions, TRPV5 and TRPV6 are
calcium selective channels involved in the absorption and reab-
sorption of calcium across intestinal and kidney tubule epithelia
(reviewed by [202, 280, 687, 1075]).
Nomenclature TRPV1 TRPV2
HGNC, UniProt TRPV1, Q8NER1 TRPV2, Q9Y5S1
Other chemical activators NO-mediated cysteine S-nitrosylation –
Physical activators depolarization (V
 
0 mV at 35°C), noxious heat (> 43°C at pH 7.4) –
Endogenous activators extracellular H+ (at 37°C) (pEC50 5.4), 12S-HPETE (Agonist) (pEC50 5.1) [-60mV] [412] –
Rat, anandamide (pEC50 5) [11], LTB4 (Agonist) (pEC50 4.9) [-60mV] [412] – Rat, 5S-HETE
–
Activators resiniferatoxin (Agonist) (pEC50 8.4) [physiological voltage] [910], capsaicin (Agonist)
(pEC50 7.5) [-100mV – 160mV] [1020], piperine (Agonist) (pEC50 4.4–5) [-70mV] [645],
camphor, diphenylboronic anhydride, phenylacetylrinvanil [31]
2-APB (pEC50 5) [699, 817] – Rat, 9-tetrahydrocannabinol (pEC50 4.8) [817] – Rat,
cannabidiol (pEC50 4.5) [817], probenecid (pEC50 4.5) [50] – Rat, 2-APB (Agonist) (pEC50
3.8–3.9) [physiological voltage] [404, 455] – Mouse, diphenylboronic anhydride (Agonist)
Concentration range: 1×10−4M [-80mV] [174, 455] – Mouse
Selective activators olvanil (Agonist) (pEC50 7.7) [physiological voltage] [910], DkTx (pEC50 6.6)
[physiological voltage] [99] – Rat
–
Channel blockers 5’-iodoresiniferatoxin (pIC50 8.4), 6-iodo-nordihydrocapsaicin (pIC50 8), AMG 9810
(Inhibition) (pIC50 7.8) [physiological voltage] [312], BCTC (Antagonist) (pIC50 7.5)
[148], capsazepine (Antagonist) (pIC50 7.4) [-60mV] [642], ruthenium red (pIC50 6.7–7)
ruthenium red (pIC50 6.2), TRIM (Inhibition) Concentration range: 5×10−4M [455] –
Mouse
Selective channel blockers AMG517 (pIC50 9) [95], AMG628 (pIC50 8.4) [1046] – Rat, A425619 (pIC50 8.3) [261],
A778317 (pIC50 8.3) [85], SB366791 (pIC50 8.2) [345], JYL1421 (Antagonist) (pIC50 8)
[1055] – Rat, JNJ17203212 (Antagonist) (pIC50 7.8) [physiological voltage] [950],
SB452533 (Antagonist) (pKB 7.7), SB705498 (Antagonist) (pIC50 7.1) [344]
–
Labelled ligands [3H]A778317 (Channel blocker) (pKd 8.5) [85], [
125I]resiniferatoxin (Channel blocker,
Antagonist) (pIC50 8.4) [-50mV] [1034] – Rat, [3H]resiniferatoxin (Activator)
–
Functional Characteristics γ = 35 pS at – 60 mV; 77 pS at + 60 mV, conducts mono and di-valent cations with a
selectivity for divalents (PCa/PNa = 9.6); voltage- and time- dependent outward
rectiﬁcation; potentiated by ethanol; activated/potentiated/upregulated by PKC
stimulation; extracellular acidiﬁcation facilitates activation by PKC; desensitisation
inhibited by PKA; inhibited by Ca2+/ calmodulin; cooling reduces vanilloid-evoked
currents; may be tonically active at body temperature
Conducts mono- and di-valent cations (PCa/PNa = 0.9–2.9); dual (inward and outward)
rectiﬁcation; current increases upon repetitive activation by heat; translocates to cell
surface in response to IGF-1 to induce a constitutively active conductance, translocates to
the cell surface in response to membrane stretch
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Nomenclature TRPV3 TRPV4
HGNC, UniProt TRPV3, Q8NET8 TRPV4, Q9HBA0
Other chemical activators NO-mediated cysteine S-nitrosylation Epoxyeicosatrieonic acids and NO-mediated cysteine S-nitrosylation
Physical activators depolarization (V
 
+80 mV, reduced to more negative values following heat stimuli), heat
(23°C - 39°C, temperature threshold reduces with repeated heat challenge)
Constitutively active, heat (> 24°C - 32°C), mechanical stimuli
Activators incensole acetate (pEC50 4.8) [678] – Mouse, 2-APB (Full agonist) (pEC50 4.6) [-80mV –
80mV] [175] – Mouse, diphenylboronic anhydride (Full agonist) (pEC50 4.1–4.2) [voltage
dependent -80mV – 80mV] [174] – Mouse, thymol (Full agonist) (pEC50 3.3) [1093] –
Mouse, eugenol (Full agonist) (pEC50 2.5) [1093] – Mouse, camphor (Full agonist) (pEC50
2) [672] – Mouse, (-)-menthol (pEC50 1.7) [-80mV – 80mV] [609] – Mouse, carvacrol (Full
agonist) Concentration range: 5×10−4M [-80mV – 80mV] [1093] – Mouse
phorbol 12-myristate 13-acetate (Agonist) (pEC50 7.9) [physiological voltage] [1091],
arachidonic acid (pEC50 5) [1059] – Mouse
Selective activators 6-tert-butyl-m-cresol (pEC50 3.4) [1024] – Mouse GSK1016790A (pEC50 8.7) [physiological voltage] [984], 4α-PDH (pEC50 7.1)
[physiological voltage] [495] – Mouse, 4α-PDD (Agonist) (pEC50 6.5) [1091], RN1747
(pEC50 6.1) [physiological voltage] [1016], bisandrographolide (Agonist) (pEC50 6)
[-60mV] [915] – Mouse
Channel blockers ruthenium red (Inhibition) (pIC50 6) [775] – Mouse, diphenyltetrahydrofuran (Antagonist)
(pIC50 5–5.2) [-80mV – 80mV] [174] – Mouse, forsythoside B (Inhibition) (pIC50 5.2)
[1137], osthole (Inhibition) (pIC50 4.4) [945]
ruthenium red (Inhibition) (pIC50 6.7) [342] – Rat, Gd3+, La3+
Selective channel blockers – HC067047 (Inhibition) (pIC50 7.3) [-40mV] [275], RN-9893 (Antagonist) (pIC50 6.2)
[1065], RN1734 (Inhibition) (pIC50 5.6) [physiological voltage] [1016]
Functional Characteristics γ = 197 pS at = +40 to +80 mV, 48 pS at negative potentials; conducts mono- and
di-valent cations; outward rectiﬁcation; potentiated by arachidonic acid
γ = 60 pS at –60 mV, 90-100 pS at +60 mV; conducts mono- and di-valent cations with a
preference for divalents (PCa/PNa =6–10); dual (inward and outward) rectiﬁcation;
potentiated by intracellular Ca2+ via Ca2+/ calmodulin; inhibited by elevated intracellular
Ca2+via an unknown mechanism (IC50 = 0.4 μM)
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Nomenclature TRPV5 TRPV6
HGNC, UniProt TRPV5, Q9NQA5 TRPV6, Q9H1D0
Other channel blockers Pb2+ = Cu2+ = Gd3+ > Cd2+ > Zn2+ > La3+ > Co2+ > Fe2 –
Activators constitutively active (with strong buffering of intracellular Ca2+) 2-APB (Potentiation)
constitutively active (with strong buffering of intracellular Ca2+)
Channel blockers ruthenium red (pIC50 6.9), Mg2+ ruthenium red (Antagonist) (pIC50 5) [-80mV] [386] – Mouse, Cd2+, La3+, Mg2+
Functional Characteristics γ = 59–78 pS for monovalent ions at negative potentials, conducts mono- and di-valents
with high selectivity for divalents (PCa/PNa > 107); voltage- and time- dependent inward
rectiﬁcation; inhibited by intracellular Ca2+ promoting fast inactivation and slow
downregulation; feedback inhibition by Ca2+ reduced by calcium binding protein 80-K-H;
inhibited by extracellular and intracellular acidosis; upregulated by 1,25-dihydrovitamin D3
γ = 58–79 pS for monovalent ions at negative potentials, conducts mono- and di-valents
with high selectivity for divalents (PCa/PNa > 130); voltage- and time-dependent inward
rectiﬁcation; inhibited by intracellular Ca2+ promoting fast and slow inactivation; gated by
voltage-dependent channel blockade by intracellular Mg2+; slow inactivation due to
Ca2+-dependent calmodulin binding; phosphorylation by PKC inhibits Ca2+-calmodulin
binding and slow inactivation; upregulated by 1,25-dihydroxyvitamin D3
Comments: Activation of TRPV1 by depolarisation is strongly
temperature-dependent via a channel opening rate that increases
with increasing temperature. The V
 
is shifted in the hyperpolar-
izing direction both by increasing temperature and by exogenous
agonists [1020]. TRPV3 channel dysfunction caused by genetic
gain-of-function mutations is implicated in the pathogenesis of
skin inﬂammation, dermatitis, and chronic itch. In rodents, a
sponateous gain-of-function matation of the TRPV3 gene causes
the development of skin lesions with pruritus and dermatitis [34,
573]. In contrast to other thermoTRP channels, TRPV3 sensitizes
rather than desensitizes, upon repeated stimulation with either
heat or agonists [175, 579, 1095]. The sensitivity of TRPV4 to heat,
but not 4α-PDD is lost upon patch excision. TRPV4 is activated by
anandamide and arachidonic acid following P450 epoxygenase-
dependent metabolism to 5,6-epoxyeicosatrienoic acid (reviewed
by [719]). Activation of TRPV4 by cell swelling, but not heat,
or phorbol esters, is mediated via the formation of epoxye-
icosatrieonic acids. Phorbol esters bind directly to TRPV4. Dif-
ferent TRPV4 mutations load to a broad spectrum of dominant
skeletal dysplasias [512, 840] and spinal muscular atrophies and
hereditary motor and sensory neuropathies [41, 218]. Similar
mutations were also found in patients with Charcot-Marie-Tooth
disease type 2C [533]. TRPV5 preferentially conducts Ca2+ un-
der physiological conditions, but in the absence of extracellu-
lar Ca2+, conducts monovalent cations. Single channel conduc-
tances listed for TRPV5 and TRPV6 were determined in divalent
cation-free extracellular solution. Ca2+-induced inactivation oc-
curs at hyperpolarized potentials when Ca2+ is present extracellu-
larly. Single channel events cannot be resolved (probably due to
greatly reduced conductance) in the presence of extracellular diva-
lent cations. Measurements of PCa/PNa for TRPV5 and TRPV6 are
dependent upon ionic conditions due to anomalous mole frac-
tion behaviour. Blockade of TRPV5 and TRPV6 by extracellular
Mg2+ is voltage-dependent. Intracellular Mg2+ also exerts a volt-
age dependent block that is alleviated by hyperpolarization and
contributes to the time-dependent activation and deactivation of
TRPV6 mediated monovalent cation currents. TRPV5 and TRPV6
differ in their kinetics of Ca2+-dependent inactivation and recov-
ery from inactivation. TRPV5 and TRPV6 function as homo- and
hetero-tetramers.
Further reading on Transient Receptor Potential channels
Aghazadeh Tabrizi M et al. (2017) Medicinal Chemistry, Pharmacology, and Clinical Implications of
TRPV1 Receptor Antagonists. Med Res Rev 37: 936-983 [PMID:27976413]
Basso L et al. (2017) Transient Receptor Potential Channels in neuropathic pain. Curr Opin Pharmacol
32: 9-15 [PMID:27835802]
Ciardo MG et al. (2017) Lipids as central modulators of sensory TRP channels. Biochim. Biophys. Acta
1859: 1615-1628 [PMID:28432033]
Clapham DE et al. (2003) International Union of Pharmacology. XLIII. Compendium of voltage-
gated ion channels: transient receptor potential channels. Pharmacol. Rev. 55: 591-6
[PMID:14657417]
Diaz-Franulic I et al. (2016) Allosterism and Structure in Thermally Activated Transient Receptor
Potential Channels. Annu Rev Biophys 45: 371-98 [PMID:27297398]
Emir TLR. (2017) Neurobiology of TRP Channels Neurobiology of TRP Channels [PMID:29356487]
Grayson TH et al. (2017) Transient receptor potential canonical type 3 channels: Interactions, role
and relevance - A vascular focus. Pharmacol. Ther. 174: 79-96 [PMID:28223224]
Nilius B et al. (2014) Mammalian transient receptor potential (TRP) cation channels. Preface. Handb
Exp Pharmacol 223: v - vi [PMID:25296415]
Rubaiy HN. (2019) Treasure troves of pharmacological tools to study transient receptor potential
canonical 1/4/5 channels. Br. J. Pharmacol. 176: 832-846 [PMID:30656647]
Wu LJ et al. (2010) International Union of Basic and Clinical Pharmacology. LXXVI. Current progress
in the mammalian TRP ion channel family. Pharmacol. Rev. 62: 381-404 [PMID:20716668]
Zhu MX. (2011) Various TRP Channels (CRC Press/Taylor & Francis) [PMID:22593967]
Zierler S et al. (2017) TRPM channels as potential therapeutic targets against pro-inﬂammatory dis-
eases. Cell Calcium 67: 105-115 [PMID:28549569]
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Voltage-gated calcium channels
Ion channels → Voltage-gated ion channels → Voltage-gated calcium channels
Overview: Calcium (Ca2+) channels are voltage-gated ion chan-
nels present in the membrane of most excitable cells. The nomen-
clature for Ca2+channels was proposed by [267] and approved
by the NC-IUPHARSubcommittee on Ca2+ channels [139].
Ca2+ channels form hetero-oligomeric complexes. The α1 sub-
unit is pore-forming and provides the binding site(s) for prac-
tically all agonists and antagonists. The 10 cloned α1-subunits
can be grouped into three families: (1) the high-voltage activated
dihydropyridine-sensitive (L-type, CaV1.x) channels; (2) the high-
voltage activated dihydropyridine-insensitive (CaV2.x) channels
and (3) the low-voltage-activated (T-type, CaV3.x) channels. Each
α1 subunit has four homologous repeats (I–IV), each repeat having
six transmembrane domains and a pore-forming region between
transmembrane domains S5 and S6. Gating is thought to be asso-
ciated with the membrane-spanning S4 segment, which contains
highly conserved positive charges. Many of the α1-subunit genes
give rise to alternatively spliced products. At least for high-voltage
activated channels, it is likely that native channels comprise co-
assemblies of α1, β and α2–δ subunits. The γ subunits have not
been proven to associate with channels other than the α1s skele-
tal muscle Cav1.1 channel. The α2–δ1 and α2–δ2 subunits bind
gabapentin and pregabalin.
Nomenclature Cav1.1 Cav1.2 Cav1.3 Cav1.4
HGNC, UniProt CACNA1S, Q13698 CACNA1C, Q13936 CACNA1D, Q01668 CACNA1F, O60840
Activators FPL64176 (pEC50 ∼7.8),
(-)-(S)-BayK8644 (pEC50 ∼7.8)
(-)-(S)-BayK8644 (pEC50 ∼7.8),
FPL64176 Concentration range:
1×10−6M-5×10−6M [582] – Rat
FPL64176 (pEC50 ∼7.8),
(-)-(S)-BayK8644 (pEC50 ∼7.8)
(-)-(S)-BayK8644 (pEC50 ∼7.8)
Gating inhibitors nifedipine (Antagonist) (pIC50 6.3)
Concentration range:
1×10−7M-1×10−4M [voltage dependent
-90mV] [530] – Rat, nimodipine
(Antagonist) (pIC50 ∼6) [-70mV],
nitrendipine (Antagonist) (pIC50 6)
[-80mV] [69] – Rat
isradipine (arterial smooth muscle-like
activity) (pIC50 8.8) [743], isradipine
(dopamine neuron neuron-like activity)
(pIC50 8.5) [743], nifedipine (Antagonist)
(pIC50 7.7) [-80mV] [793, 814] – Rat,
nimodipine (Antagonist) (pIC50 6.8)
[-80mV] [1098] – Rat
nitrendipine (Inhibition) (pIC50 8.4)
[906], isradipine (dopamine neuron-like
activity; splice variant-dependent) (pIC50
7.8–8.2) [743], nifedipine (Antagonist)
(pIC50 7.7) [906], nimodipine
(Antagonist) (pIC50 5.7–6.6) [-80mV –
-40mV] [856, 1098] – Rat
nifedipine (Antagonist) (pIC50 6)
[-100mV] [646], nimodipine (Antagonist)
(pIC50 ∼6) [-70mV], nitrendipine
(Antagonist) (pIC50 ∼6) [-70mV]
Channel blockers diltiazem (Antagonist), verapamil
(Antagonist)
diltiazem (Antagonist), verapamil
(Antagonist)
verapamil (Antagonist) diltiazem (pIC50 4) [-80mV] [64] –
Mouse, verapamil Concentration range:
1×10−4M [-80mV] [64] – Mouse
Sub/family-selective channel blockers calciseptine (Antagonist) calciseptine (Antagonist) – –
Functional Characteristics L-type calcium current: High
voltage-activated, slow voltage
dependent inactivation
L-type calcium current: High
voltage-activated, slow
voltage-dependent inactivation, rapid
calcium-dependent inactivation
L-type calcium current:
moderate-voltage, slow
voltage-dependent inactivation, more
rapid calcium-dependent inactivation
L-type calcium current: Moderate
voltage-activated, slow
voltage-dependent inactivation
Comments – – Cav1.3 activates more negative
potentials than Cav1.2 and is about 5-10
fold less sensitive to dihydropyridine
antagonists.
Cav1.4 is less sensitive to dihydropyridine
antagonists than other Cav1 channels
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Nomenclature Cav2.1 Cav2.2 Cav2.3
HGNC, UniProt CACNA1A, O00555 CACNA1B, Q00975 CACNA1E, Q15878
Gating inhibitors – NP118809 (pIC50 7) [-80mV] [1127] – Rat –
Selective gating inhibitors ω-agatoxin IVA (P current component: Kd =2nM, Q
component Kd= >100nM) (pIC50 7–8.7) [-100mV –
-90mV] [103, 665] – Rat, ω-agatoxin IVB (pKd 8.5)
[-80mV] [10] – Rat
– SNX482 (Antagonist) (pIC50 7.5–8) [physiological
voltage] [700]
Channel blockers – – Ni2+ (Antagonist) (pIC50 4.6) [-90mV] [1073]
Sub/family-selective channel blockers ω-conotoxin MVIIC (pIC50 8.2–9.2) Concentration
range: 2×10−6M-5×10−6M [physiological voltage]
[559] – Rat
ω-conotoxin GVIA (Antagonist) (pIC50 10.4) [-80mV]
[559] – Rat, ω-conotoxin MVIIC (Antagonist) (pIC50
6.1–8.5) [-80mV] [380, 559, 641] – Rat
–
Functional Characteristics P/Q-type calcium current: Moderate voltage-activated,
moderate voltage-dependent inactivation
N-type calcium current: High voltage-activated,
moderate voltage-dependent inactivation
R-type calcium current: Moderate voltage-activated,
fast voltage-dependent inactivation
Nomenclature Cav3.1 Cav3.2 Cav3.3
HGNC, UniProt CACNA1G, O43497 CACNA1H, O95180 CACNA1I, Q9P0X4
Gating inhibitors kurtoxin (Antagonist) (pIC50 7.3–7.8) [-90mV] [171, 899] –
Rat
kurtoxin (Antagonist) (pIC50 7.3–7.6) [-90mV] [171, 899] –
Rat
–
Channel blockers Z944 (Pore blocker) (pIC50 7.3) [-80mV] [999], TTA-A2
(Pore blocker) (pIC50 7) [-75mV] [296], mibefradil
(Antagonist) (pIC50 6–6.6) [-110mV – -100mV] [630], Ni2+
(Antagonist) (pIC50 3.6–3.8) [voltage dependent -90mV]
[543] – Rat
TTA-A2 (Pore blocker) (pIC50 8) [-75mV] [296], mibefradil
(Antagonist) (pIC50 5.9–7.2) [-110mV – -80mV] [630],
Z944 (Pore blocker) (pIC50 6.8) [-75mV] [999], Ni2+
(Antagonist) (pIC50 4.9–5.2) [voltage dependent -90mV]
[543]
TTA-A2 (Pore blocker) (pIC50 7.5) [-75mV] [296], mibefradil
(Antagonist) (pIC50 5.8) [-110mV] [630], Ni2+ (Antagonist)
(pIC50 3.7–4.1) [voltage dependent -90mV] [543] – Rat
Functional Characteristics T-type calcium current: Low voltage-activated, fast
voltage-dependent inactivation
T-type calcium current: Low voltage-activated, fast
voltage-dependent inactivation
T-type calcium current: Low voltage-activated, moderate
voltage-dependent inactivation
Comments: In many cell types, P and Q current components
cannot be adequately separated and many researchers in the ﬁeld
have adopted the terminology ‘P/Q-type’ current when referring
to either component. Both of these physiologically deﬁned cur-
rent types are conducted by alternative forms of Cav2.1. Zi-
conotide (a synthetic peptide equivalent to ω-conotoxin MVIIA)
has been approved for the treatment of chronic pain [1072].
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Voltage-gated proton channel
Ion channels → Voltage-gated ion channels → Voltage-gated proton channel
Overview: The voltage-gated proton channel (provisionally de-
noted Hv1) is a putative 4TM proton-selective channel gated by
membrane depolarization and which is sensitive to the transmem-
brane pH gradient [131, 208, 209, 827, 868]. The structure of Hv1
is homologous to the voltage sensing domain (VSD) of the su-
perfamily of voltage-gated ion channels (i.e. segments S1 to S4)
and contains no discernable pore region [827, 868]. Proton ﬂux
through Hv1 is instead most likely mediated by a water wire com-
pleted in a crevice of the protein when the voltage-sensing S4 helix
moves in response to a change in transmembrane potential [826,
1079]. Hv1 expresses largely as a dimer mediated by intracellular
C-terminal coiled-coil interactions [564] but individual promoters
nonetheless support gated H+ ﬂux via separate conduction path-
ways [502, 547, 787, 989]. Within dimeric structures, the two pro-
tomers do not function independently, but display co-operative
interactions during gating resulting in increased voltage sensitiv-
ity, but slower activation, of the dimeric,versus monomeric, com-
plexes [322, 990].
Nomenclature Hv1
HGNC, UniProt HVCN1, Q96D96
Channel blockers Zn2+ (pIC50 ∼5.7–6.3), Cd2+ (pIC50 ∼5)
Functional Characteristics Activated by membrane depolarization mediating macroscopic currents with time-, voltage- and pH-dependence; outwardly rectifying; voltage dependent kinetics with relatively slow
current activation sensitive to extracellular pH and temperature, relatively fast deactivation; voltage threshold for current activation determined by pH gradient (pH = pHo -pHi)
across the membrane
Comments: The voltage threshold (Vthr) for activation of Hv1 is
not ﬁxed but is set by the pH gradient across the membrane such
that Vthr is positive to the Nernst potential for H+, which ensures
that only outwardly directed ﬂux of H+ occurs under physiolog-
ical conditions [131, 208, 209]. Phosphorylation of Hv1 within
the N-terminal domain by PKC enhances the gating of the chan-
nel [682]. Tabulated IC50 values for Zn2+ and Cd2+ are for het-
erologously expressed human and mouse Hv1 [827, 868]. Zn2+
is not a conventional pore blocker, but is coordinated by two,
or more, external protonation sites involving histamine residues
[827]. Zn2+ binding may occur at the dimer interface between
pairs of histamine residues from both monomers where it may
interfere with channel opening [683]. Mouse knockout stud-
ies demonstrate that Hv1 participates in charge compensation
in granulocytes during the respiratory burst of NADPH oxidase-
dependent reactive oxygen species production that assists in the
clearance of bacterial pathogens [828]. Additional physiological
functions of Hv1 are reviewed by [131].
Further reading on Voltage-gated proton channel
Castillo K et al. (2015) Voltage-gated proton (H(v)1) channels, a singular voltage sensing domain.
FEBS Lett. 589: 3471-8 [PMID:26296320]
DeCoursey TE. (2018) Gating currents indicate complex gating of voltage-gated proton channels.
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DeCoursey TE. (2018) Voltage and pH sensing by the voltage-gated proton channel, HV1. J R Soc
Interface 15: [PMID:29643227]
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Voltage-gated sodium channels
Ion channels → Voltage-gated ion channels → Voltage-gated sodium channels
Overview: Sodium channels are voltage-gated sodium-selective
ion channels present in the membrane of most excitable cells.
Sodium channels comprise of one pore-forming α subunit, which
may be associated with either one or two β subunits [425]. α-
Subunits consist of four homologous domains (I-IV), each con-
taining six transmembrane segments (S1-S6) and a pore-forming
loop. The positively charged fourth transmembrane segment (S4)
acts as a voltage sensor and is involved in channel gating. The
crystal structure of the bacterial NavAb channel has revealed a
number of novel structural features compared to earlier potassium
channel structures including a short selectivity ﬁlter with ion se-
lectivity determined by interactions with glutamate side chains
[767]. Interestingly, the pore region is penetrated by fatty acyl
chains that extend into the central cavity whichmay allow the en-
try of small, hydrophobic pore-blocking drugs [767]. Auxiliary β1,
β2, β3 and β4 subunits consist of a large extracellular N-terminal
domain, a single transmembrane segment and a shorter cytoplas-
mic domain.
The nomenclature for sodium channels was proposed
by Goldin et al., (2000) [319] and approved by the
NC-IUPHAR Subcommittee on sodium channels (Catter-
all et al., 2005, [137]).
Nomenclature Nav1.1 Nav1.2 Nav1.3 Nav1.4
HGNC, UniProt SCN1A, P35498 SCN2A, Q99250 SCN3A, Q9NY46 SCN4A, P35499
Sub/family-selective
activators
batrachotoxin, veratridine batrachotoxin (Agonist) (pKd 9.1)
[physiological voltage] [574] – Rat,
veratridine (Partial agonist) (pKd 5.2)
[physiological voltage] [138] – Rat
batrachotoxin, veratridine batrachotoxin (Full agonist) Concentration
range: 5×10−6M [-100mV] [1050] – Rat,
veratridine (Partial agonist) Concentration
range: 2×10−4M [-100mV] [1050] – Rat
Channel blockers tetrodotoxin (Pore blocker) (pKd 8)
[-100mV] [916] – Rat
– – –
Sub/family-selective
channel blockers
Hm1a [744] – Rat, saxitoxin (Pore blocker) saxitoxin (Pore blocker) (pIC50 8.8)
[-120mV] [108] – Rat, tetrodotoxin (Pore
blocker) (pIC50 8) [-120mV] [108] – Rat,
lacosamide (Antagonist) (pIC50 4.5)
[-80mV] [1] – Rat
tetrodotoxin (Pore blocker) (pIC50 8.4)
[163], saxitoxin (Pore blocker)
saxitoxin (Pore blocker) (pIC50 8.4)
[-100mV] [780] – Rat, tetrodotoxin (Pore
blocker) (pIC50 7.6) [-120mV] [143],
μ-conotoxin GIIIA (Pore blocker) (pIC50 5.9)
[-100mV] [143]
Functional Characteristics Activation V0.5 = -20 mV. Fast inactivation
(τ = 0.7 ms for peak sodium current).
Activation V0.5 = -24 mV. Fast inactivation
(τ = 0.8 ms for peak sodium current).
Activation V0.5 = -24 mV. Fast inactivation
(0.8 ms)
Activation V0.5 = -30 mV. Fast inactivation
(0.6 ms)
Searchable database: http://www.guidetopharmacology.org/index.jsp Voltage-gated sodium channels S208
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.14749/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Ion channels. British Journal of Pharmacology (2019) 176, S142–S228
Nomenclature Nav1.5 Nav1.6 Nav1.7 Nav1.8 Nav1.9
HGNC, UniProt SCN5A, Q14524 SCN8A, Q9UQD0 SCN9A, Q15858 SCN10A, Q9Y5Y9 SCN11A, Q9UI33
Sub/family-selective
activators
batrachotoxin (Full agonist) (pKd
7.6) [physiological voltage] [892] –
Rat, veratridine (Partial agonist)
(pEC50 6.3) [-30mV] [1043] – Rat
batrachotoxin, veratridine batrachotoxin, veratridine – –
Sub/family-selective
channel blockers
tetrodotoxin (Pore blocker) (pKd
5.8) [-80mV] [187, 1130] – Rat
tetrodotoxin (Pore blocker) (pIC50
9) [-130mV] [224] – Rat, saxitoxin
(Pore blocker)
tetrodotoxin (Pore blocker) (pIC50
7.6) [-100mV] [496], saxitoxin
(Pore blocker) (pIC50 6.2) [1038]
tetrodotoxin (Pore blocker) (pIC50
4.2) [-60mV] [15] – Rat
tetrodotoxin (Pore blocker) (pIC50
4.4) [-120mV] [191] – Rat
Selective channel
blockers
– – – PF-01247324 (Pore blocker) (pIC50
6.7) [voltage dependent] [768]
–
Functional Characteristics Activation V0.5 = -26 mV. Fast
inactivation (τ = 1 ms for peak
sodium current).
Activation V0.5 = -29 mV. Fast
inactivation (1 ms)
Activation V0.5 = -27 mV. Fast
inactivation (0.5 ms)
Activation V0.5 = -16 mV.
Inactivation (6 ms)
Activation V0.5 = -32 mV. Slow
inactivation (16 ms)
Comments: Sodium channels are also blocked by local anaes-
thetic agents, antiarrythmic drugs and antiepileptic drugs. In gen-
eral, these drugs are not highly selective among channel subtypes.
There are two clear functional ﬁngerprints for distinguishing dif-
ferent subtypes. These are sensitivity to tetrodotoxin (NaV1.5,
NaV1.8 and NaV1.9 are much less sensitive to block) and rate of
fast inactivation (NaV1.8 and particularly NaV1.9 inactivate more
slowly). All sodium channels also have a slow inactivation process
that is engaged during long depolarizations (>100 msec) or repet-
itive trains of stimuli. All sodium channel subtypes are blocked by
intracellular QX-314.
Further reading on Voltage-gated sodium channels
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Other ion channels
Ion channels → Other ion channels
A number of ion channels in the human genome do not ﬁt readily into the classiﬁcation of either ligand-gated or voltage-gated ion channels. These are identiﬁed below.
Aquaporins
Ion channels → Other ion channels → Aquaporins
Overview: Aquaporins and aquaglyceroporins are membrane
channels that allow the permeation of water and certain other
small solutes across the cell membrane, or in the case of AQP6,
AQP11 and AQP12A, intracellular membranes, such as vesicles
and the endoplasmic reticulum membrane [514]. Since the isola-
tion and cloning of the ﬁrst aquaporin (AQP1) [807], 12 additional
mammalianmembers of the family have been identiﬁed, although
little is known about the functional properties of one of these
(AQP12A; Q8IXF9) and it is thus not tabulated. The other 12 aqua-
porins can be broadly divided into three families: orthodox aqua-
porins (AQP0,-1,-2,-4,-5, -6 and -8) permeablemainly to water, but
for some additional solutes [201]; aquaglyceroporins (AQP3,-7 -9
and -10), additionally permeable to glycerol and for some isoforms
urea [493], and superaquaporins (AQP11 and 12) located within
cells [422]. Some aquaporins also conduct ammonia and/or H2O2
giving rise to the terms ’ammoniaporins’ (’aquaammoniaporins’)
and ’peroxiporins’, respectively. Aquaporins are impermeable to
protons and other inorganic and organic cations, with the possi-
ble exception of AQP1 [493]. One or more members of this family
of proteins have been found to be expressed in almost all tissues
of the body [reviewed in Yang (2017) [1104]]. AQPs are involved
in numerous processes that include systemic water homeostasis,
adipocyte metabolism, brain oedema, cell migration and ﬂuid se-
cretion by epithelia and loss of function mutations of some hu-
man AQPs, or their disruption by autoantibodies further under-
score their importance [reviewed by Verkman et al. (2014) [1013],
Kitchen et al. (2105) [493]].
Functional AQPs exist as homotetramers that are the water con-
ducting units wherein individual AQP subunits (each a protomer)
have six transmembrane helices and two half helices that con-
stitute a seventh ’pseudotransmembrane domain’ that surrounds
a narrow water conducting channel [514]. In addition to the
four pores contributed by the protomers, an additional hydropho-
bic pore exists within the center of the complex [514] that may
mediate the transport of gases (e.g. O2, CO2, NO) and cations
(the central pore is the proposed transport pathway for cations
through AQP1) by some AQPs [314, 460]. Although numerous
small molecule inhibitors of aquaporins, particularly APQ1, have
been reported primarily from Xenopus oocyte swelling assays, the
activity of most has subsequently been disputed upon retesting
using assays of water transport that are less prone to various ar-
tifacts [271] and they are therefore excluded from the tables [see
Tradtrantip et al. (2017) [993] for a review].
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Nomenclature AQP0 AQP1 AQP2
HGNC, UniProt MIP, P30301 AQP1, P29972 AQP2, P41181
Endogenous activator AQP0 is gated by calmodulin [493] cGMP (see comment) –
Permeability water (rat single channel permeability 0.25 x 10-14cm3s-1) (Rat) [1106] water (rat single channel permeability 6.0 x
10-14cm3s-1), ammonia, H2O2 [314, 1106]
water (rat single channel permeability 3.3 x
10-14cm3s-1) [606]
Inhibitors Hg2+ Ag+, Hg2+, pCMBS Hg2+
Comments AQP0 appears permeable to CO2 [314]. Human, but not mouse, AQP1 appears permeable to
CO2, probably through the central pore of the
tetrameric complex [314]. NO also appears permeable
[371]. Permeability to H202 has been demonstrated for
rat, but not human, AQP1 [87]. Numerous small
molecule inhibitors of AQP1 have been proposed, but
re-evaluation indicates that they have no signiﬁcant
effect upon water permeability at concentrations in
excess of their originally reported IC50 values [310]. A
ﬁfth pore located at the central axis of the tetrameric
complex has, controversially, been described as a cation
conductance activated by cGMP and phosphorylation
by protein kinases A and C. Evidence in support and
against this proposal is discussed in detail by Kitchen et
al. (2015) [493].
–
Nomenclature AQP3 AQP4 AQP5 AQP6
HGNC, UniProt AQP3, Q92482 AQP4, P55087 AQP5, P55064 AQP6, Q13520
Permeability water (rat single channel permeability 2.1 x
10-14cm3s-1), glycerol, ammonia, H2O2 [87,
314, 1106]
water (rat single channel permeability 24 x
10-14cm3s-1 [1106]
water (rat single channel permeability 5.0 x
10-14cm3s-1), H2O2 [460]
water (zero, or very low basal, permeability is
enhanced by low pH and in mouse and rat by
Hg2+), glycerol, ammonia, urea, anions [314,
393, 493, 823]
Activators – – – Hg2+
Inhibitors Auphen (pIC50 6.1) [631], Audien (pIC50 4.8)
[631], Hg2+
– Hg2+ –
Comments AQP3 is also inhibited by acid pH: permeability
to urea is controversial [493].
AQP4 is inhibited by PKC activation (although
this is probably due to
phosphorylation-dependent protein
localisation rather than inhibition of the
channel per se), but not by HgCl2. An isoform
of AQP4 (AQP4M23 vs. AQPM1) may conduct
CO2 [314]. AQP4 is predicted to be
permeable to NO [1056].
AQP5 may conduct CO2 [314]. AQP6 is an intracellular channel that localises
to acid secreting intercalated cells of the renal
collecting ducts. Notably, AQP6 is activated by
Hg2+ and by low pH and is unusually
permeable to anions (with the permeability
sequence NO3->I->>Br->Cl->>Fl-) as well as
water, both through the monomeric pore
[493, 823]. AQP6 may also conduct CO2
[314].
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Nomenclature AQP7 AQP8 AQP9 AQP10
HGNC, UniProt AQP7, O14520 AQP8, O94778 AQP9, O43315 AQP10, Q96PS8
Permeability water (high), glycerol, ammonia, urea [314,
420]
water (mouse single channel permeability 8.2
x 10-14cm3s-1), ammonia, H202 [87, 314,
493, 606]
water (low), glycerol, ammonia, urea, H202,
monocarboxylates [314, 392, 823, 1060]
water (low), glycerol, urea [421]
Inhibitors Auphen (Effective at 15 μM), Hg2+ Hg2+ Hg2+, phloretin Hg2+
Comments AQP7 also transports silicon [310]. Permeability to urea is controversial, but might
be explained by differences between mouse
and human caused by a pore-lining amino
acid residue that differs between species [493].
AQP9 may conduct CO2 [314] and also
transport silicon [310].
It is not known if AQP10 is permeable to
ammonia. Permeability to silicon has been
described [310].
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Chloride channels
Ion channels → Other ion channels → Chloride channels
Overview: Chloride channels are a functionally and structurally
diverse group of anion selective channels involved in processes
including the regulation of the excitability of neurones, skeletal,
cardiac and smooth muscle, cell volume regulation, transepithe-
lial salt transport, the acidiﬁcation of internal and extracellular
compartments, the cell cycle and apoptosis (reviewed in [251]).
Excluding the transmittergated GABAA and glycine receptors (see
separate tables), well characterised chloride channels can be clas-
siﬁed as certain members of the voltage-sensitive ClC subfamily,
calcium-activated channels, high (maxi) conductance channels,
the cystic ﬁbrosis transmembrane conductance regulator (CFTR)
and volume regulated channels [1014]. No ofﬁcial recommenda-
tion exists regarding the classiﬁcation of chloride channels. Func-
tional chloride channels that have been cloned from, or charac-
terised within, mammalian tissues are listed with the exception
of several classes of intracellular channels (e.g. CLIC) that are re-
viewed by in [259].
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ClC family
Ion channels → Other ion channels → Chloride channels → ClC family
Overview: The mammalian ClC family (reviewed in [8, 157, 251,
254, 442]) contains 9 members that fall, on the basis of sequence
homology, into three groups; ClC-1, ClC-2, hClC-Ka (rClC-K1)
and hClC-Kb (rClC-K2); ClC-3 to ClC-5, and ClC-6 and -7. ClC-1
and ClC-2 are plasma membrane chloride channels. ClC-Ka and
ClC-Kb are also plasma membrane channels (largely expressed in
the kidney and inner ear) when associated with barttin (BSND,
Q8WZ55), a 320 amino acid 2TM protein [272]. The localisation
of the remaining members of the ClC family is likely to be pre-
dominantly intracellular in vivo, although they may trafﬁc to the
plasma membrane in overexpression systems. Numerous recent
reports indicate that ClC-4, ClC-5, ClC-6 and ClC-7 (and by in-
ference ClC-3) function as Cl-/H+ antiporters (secondary active
transport), rather than classical Cl- channels [328, 551, 698, 790,
873]; reviewed in [8, 812]). It has recently been reported that the
activity of ClC-5 as a Cl-/H+ exchanger is important for renal en-
docytosis [723]. Alternative splicing increases the structural di-
versity within the ClC family. The crystal structure of two bacte-
rial ClC proteins has been described [255] and a eukaryotic ClC
transporter (CmCLC) has recently been described at 3.5 Å reso-
lution [284]. Each ClC subunit, with a complex topology of 18
intramembrane segments, contributes a single pore to a dimeric
‘double-barrelled’ ClC channel that contains two independently
gated pores, conﬁrming the predictions of previous functional and
structural investigations (reviewed in [157, 254, 442, 812]). As
found for ClC-4, ClC-5, ClC-6 and ClC-7, the prokaryotic ClC
homologue (ClC-ec1) and CmCLC function as H+/Cl antiporters,
rather than as ion channels [7, 284]. The generation of monomers
from dimeric ClC-ec1 has ﬁrmly established that each ClC subunit
is a functional unit for transport and that cross-subunit interaction
is not required for Cl-/H+ exchange in ClC transporters [837].
Nomenclature ClC-1 ClC-2
HGNC, UniProt CLCN1, P35523 CLCN2, P51788
Endogenous activators – arachidonic acid
Activators – lubiprostone, omeprazole
Channel blockers 9-anthroic acid, S-(-)CPB, S-(-)CPP, Cd2+, Zn2+, fenoﬁbric acid, niﬂumic acid GaTx2 (pKd 10.8) [voltage dependent -100mV], Cd
2+, NPPB, Zn2+,
diphenylamine-2-carboxylic acid
Functional Characteristics γ = 1–1.5 pS; voltage-activated (depolarization) (by fast gating of single protopores and a
slower common gate allowing both pores to open simultaneously); inwardly rectifying;
incomplete deactivation upon repolarization, ATP binding to cytoplasmic cystathionine
β-synthetase related (CBS) domains inhibits ClC-1 (by closure of the common gate),
depending on its redox status
γ = 2–3 pS; voltage-activated by membrane hyperpolarization by fast protopore and slow
cooperative gating; channels only open negative to ECl resulting in steady-state inward
rectiﬁcation; voltage dependence modulated by permeant anions; activated by cell
swelling, PKA, and weak extracellular acidosis; potentiated by SGK1; inhibited by
phosphorylation by p34(cdc2)/cyclin B; cell surface expression and activity increased by
association with Hsp90
Comments CIC-1 is constitutively active CIC-2 is also activated by amidation
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Nomenclature ClC-Ka ClC-Kb ClC-3 ClC-4
HGNC, UniProt CLCNKA, P51800 CLCNKB, P51801 CLCN3, P51790 CLCN4, P51793
Activators niﬂumic acid (pEC50 3–5) niﬂumic acid (pEC50 3–5) – –
Channel blockers 3-phenyl-CPP, DIDS, niﬂumic acid 3-phenyl-CPP, DIDS phloretin (pIC50 4.5) Zn2+ (pIC50 4.3) [745], Cd2+ (pIC50 4.2)
[745]
Functional Characteristics γ = 26 pS; linear current-voltage relationship
except at very negative potentials; no time
dependence; inhibited by extracellular
protons (pK = 7.1); potentiated by
extracellular Ca2+
Bidirectional rectiﬁcation; no time
dependence; inhibited by extracellular
protons; potentiated by extracellular Ca2+
Cl-/H+ antiporter [638]; pronounced
outward rectiﬁcation; slow activation, fast
deactivation; activity enhanced by CaM
kinase II; inhibited by intracellular
Ins(3,4,5,6)P4 and extracellular acidosis
Cl-/H+ antiporter (2Cl-:1H+) [19, 790, 873];
extreme outward rectiﬁcation;
voltage-dependent gating with midpoint of
activation at +73 mV [742]; rapid activation
and deactivation; inhibited by extracellular
acidosis; non-hydrolytic nucleotide binding
required for full activity
Comments CIC-Ka is constitutively active (when
co-expressed with barttin), and can be
blocked by benzofuran derivatives
CIC-Kb is constitutively active (when
co-expressed with barttin), and can be
blocked by benzofuran derivatives
insensitive to the channel blockers DIDS,
NPPB and tamoxifen (10 μM)
–
Nomenclature ClC-5 ClC-6 ClC-7
HGNC, UniProt CLCN5, P51795 CLCN6, P51797 CLCN7, P51798
Channel blockers – DIDS (pIC50 3) DIDS (pIC50 4.4) [882], NS5818 (pIC50 4.3) [882], NPPB
(pIC50 3.8) [882]
Functional Characteristics Cl-/H+ antiporter (2Cl-:1H+) [790, 873, 911, 1153];
extreme outward rectiﬁcation; voltage-dependent gating
with midpoint of activation of 116.0 mV; rapid activation
and deactivation; potentiated and inhibited by intracellular
and extracellular acidosis, respectively; ATP binding to
cytoplasmic cystathionine β-synthetase related (CBS)
domains activates ClC-5
Cl-/H+ antiporter (2Cl-:1H+) [698]; outward rectiﬁcation,
rapid activation and deactivation
Cl-/H+ antiporter (2Cl-:1H+) [328, 551, 882]; strong
outward rectiﬁcation; voltage-dependent gating with a
threshold more positive than + 20 mV; very slow activation
and deactivation
Comments Insensitive to the channel blockers DIDS (1 mM),
diphenylamine-2-carboxylic acid (1 mM), 9-anthroic acid
(2 mM), NPPB (0.5 mM) and niﬂumic acid (1 mM)
– active when co-expressed with Ostm1
Comments: ClC channels display the permeability sequence Cl-
> Br- > I- (at physiological pH). ClC-1 has signiﬁcant opening
probability at resting membrane potential, accounting for 75%
of the membrane conductance at rest in skeletal muscle, and is
important for stabilization of the membrane potential. S-(-)CPP,
9-anthroic acid and niﬂumic acid act intracellularly and exhibit a
strongly voltage-dependent block with strong inhibition at neg-
ative voltages and relief of block at depolarized potentials ([565]
and reviewed in [811]). Inhibition of ClC-2 by the peptide GaTx2,
from Leiurus quinquestriatus herbareus venom, is likely to occur
through inhibition of channel gating, rather than direct open
channel blockade [980]. Although ClC-2 can be activated by cell
swelling, it does not correspond to the VRAC channel (see be-
low). Alternative potential physiological functions for ClC-2 are
reviewed in [798]. Functional expression of human ClC-Ka and
ClC-Kb requires the presence of barttin [272, 877] reviewed in
[276]. The properties of ClC-Ka/barttin and ClC-Kb/barttin tab-
ulated are those observed in mammalian expression systems: in
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oocytes the channels display time- and voltage-dependent gating.
The rodent homologue (ClC-K1) of ClC-Ka demonstrates limited
expression as a homomer, but its function is enhanced by barttin
which increases both channel opening probablility in the phys-
iological range of potentials [272, 289, 877] reviewed in [276]).
ClC-Ka is approximately 5 to 6-fold more sensitive to block by
3-phenyl-CPP and DIDS than ClC-Kb, while newly synthesized
benzofuran derivatives showed the same blocking afﬁnity (<10
μM) on both CLC-K isoforms [566]. The biophysical and pharma-
cological properties of ClC-3, and the relationship of the protein
to the endogenous volume-regulated anion channel(s) VRAC [20,
340] are controversial and further complicated by the possibility
that ClC-3 may function as both a Cl-/H+ exchanger and an ion
channel [20, 790, 1052]. The functional properties tabulated are
those most consistent with the close structural relationship be-
tween ClC-3, ClC-4 and ClC-5. Activation of heterologously ex-
pressed ClC-3 by cell swelling in response to hypotonic solutions
is disputed, as are many other aspects of its regulation. Depen-
dent upon the predominant extracellular anion (e.g. SCN- versus
Cl-), CIC-4 can operate in two transport modes: a slippage mode
in which behaves as an ion channel and an exchanger mode in
which unitary transport rate is 10-fold lower [19]. Similar ﬁnd-
ings have been made for ClC-5 [1128]. ClC-7 associates with a β
subunit, Ostm1, which increases the stability of the former [535]
and is essential for its function [551].
CFTR
Ion channels → Other ion channels → Chloride channels → CFTR
Overview: CFTR, a 12TM, ABC transporter-type protein, is a
cAMP-regulated epithelial cell membrane Cl- channel involved in
normal ﬂuid transport across various epithelia. Of the 1700 muta-
tions identiﬁed in CFTR, the most common is the deletion mutant
F508 (a class 2 mutation) which results in impaired trafﬁcking
of CFTR and reduces its incorporation into the plasma membrane
causing cystic ﬁbrosis (reviewed in [192]). Channels carrying the
F508 mutation that do trafﬁc to the plasma membrane demon-
strate gating defects. Thus, pharmacological restoration of the
function of the F508 mutant would require a compound that
embodies ’corrector’ (i.e. facilitates folding and trafﬁcking to the
cell surface) and ’potentiator’ (i.e. promotes opening of channels
at the cell surface) activities [192]. In addition to acting as an an-
ion channel per se, CFTR may act as a regulator of several other
conductances including inhibition of the epithelial Na channel
(ENaC), calcium activated chloride channels (CaCC) and volume
regulated anion channel (VRAC), activation of the outwardly rec-
tifying chloride channel (ORCC), and enhancement of the sulpho-
nylurea sensitivity of the renal outer medullary potassium channel
(ROMK2), (reviewed in [710]). CFTR also regulates TRPV4, which
provides the Ca2+ signal for regulatory volume decrease in airway
epithelia [33]. The activities of CFTR and the chloride-bicarbonate
exchangers SLC26A3 (DRA) and SLC26A6 (PAT1) are mutually en-
hanced by a physical association between the regulatory (R) do-
main of CFTR and the STAS domain of the SCL26 transporters, an
effect facilitated by PKA-mediated phosphorylation of the R do-
main of CFTR [499].
Nomenclature CFTR
HGNC, UniProt CFTR, P13569
Activators felodipine (Potentiation) (pKi 8.4) [772], CBIQ (Potentiation), NS004 (Potentiation), UCCF-029 (Potentiation), UCCF-339 (Potentiation), UCCF-853 (Potentiation), apigenin
(Potentiation), capsaicin (Potentiation), genistein (Potentiation), ivacaftor (Potentiation), nimodipine (Potentiation), phenylglycine-01 (Potentiation), sulfonamide-01 (Potentiation)
Selective inhibitors crofelemer (pIC50 5.2) [994]
Channel blockers glibenclamide (pKi 4.7) [895], intracellular CFTRinh-172 (intracellular application prolongs mean closed time), GaTx1, extracellular GlyH-101
Functional Characteristics γ = 6-10 pS; permeability sequence = Br- ≥ Cl- > I- > F-, (PI/PCl = 0.1–0.85); slight outward rectiﬁcation; phosphorylation necessary for activation by ATP binding at binding
nucleotide binding domains (NBD)1 and 2; positively regulated by PKC and PKGII (tissue speciﬁc); regulated by several interacting proteins including syntaxin 1A, Munc18 and PDZ
domain proteins such as NHERF (EBP50) and CAP70
Comments UCCF-339, UCCF-029, apigenin and genistein are examples of ﬂavones. UCCF-853 and NS004 are examples of benzimidazolones. CBIQ is an example of a benzoquinoline. Felodipine
and nimodipine are examples of 1,4-dihydropyridines. Phenylglycine-01 is an example of a phenylglycine. Sulfonamide-01 is an example of a sulfonamide. Malonic acid hydrazide
conjugates are also CFTR channel blockers (see Verkman and Galietta, 2009 [1014])
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Comments: In addition to the agents listed in the table, the novel
small molecule, ataluren, induces translational read through of
nonsense mutations in CFTR (reviewed in [908]). Corrector com-
pounds that aid the folding of DF508CFTR to increase the amount
of protein expressed and potentially delivered to the cell surface
include VX-532 (which is also a potentiator), VRT-325, KM11060,
Corr-3a and Corr-4a see [1014] for details and structures of Corr-
3a and Corr-4a). Inhibition of CFTR by intracellular applica-
tion of the peptide GaTx1, from Leiurus quinquestriatus herbareus
venom, occurs preferentially for the closed state of the channel
[302]. CFTR contains two cytoplasmic nucleotide binding do-
mains (NBDs) that bind ATP. A single open-closing cycle is hy-
pothesised to involve, in sequence: binding of ATP at the N-
terminal NBD1, ATP binding to the C-terminal NBD2 leading to
the formation of an intramolecular NBD1-NBD2 dimer associated
with the open state, and subsequent ATP hydrolysis at NBD2 fa-
cilitating dissociation of the dimer and channel closing, and the
initiation of a new gating cycle [21, 679]. Phosphorylation by PKA
at sites within a cytoplasmic regulatory (R) domain facilitates the
interaction of the two NBD domains. PKC (and PKGII within in-
testinal epithelial cells via guanylinstimulated cyclic GMP forma-
tion) positively regulate CFTR activity.
Calcium activated chloride channel
Ion channels → Other ion channels → Chloride channels → Calcium activated chloride channel
Overview: Chloride channels activated by intracellular calcium
(CaCC) are widely expressed in excitable and non-excitable cells
where they perform diverse functions [359]. The molecular nature
of CaCC has been uncertain with both CLCA, TWEETY andBEST
genes having been considered as likely candidates [251, 360, 589].
It is now accepted that CLCA expression products are unlikely
to form channels per se and probably function as cell adhesion
proteins, or are secreted [762]. Similarly, TWEETY gene products
do not recapictulate the properties of endogenous CaCC. The be-
strophins encoded by genes BEST1-4 have a topology more consis-
tent with ion channels [360] and form chloride channels that are
activated by physiological concentrations of Ca2+, but whether
such activation is direct is not known [360]. However, currents
generated by bestrophin over-expression do not resemble native
CaCC currents. The evidence for and against bestrophin proteins
forming CaCC is critically reviewed by Duran et al. [251]. Re-
cently, a new gene family, TMEM16 (anoctamin) consisting of 10
members (TMEM16A-K; anoctamin 1-10) has been identiﬁed and
there is ﬁrm evidence that some of these members form chloride
channels [250, 525]. TMEM16A (anoctamin 1; Ano 1) produces
Ca2+-activated Cl- currents with kinetics similar to native CaCC
currents recorded from different cell types [133, 839, 879, 1110].
Knockdown of TMEM16A greatly reduces currents mediated by
calcium-activated chloride channels in submandibular gland cells
[1110] and smooth muscle cells from pulmonary artery [625]. In
TMEM16A(-/-) mice secretion of Ca2+-dependent Cl- secretion by
several epithelia is reduced [746, 839]. Alternative splicing regu-
lates the voltage- and Ca2+- dependence of TMEM16A and such
processing may be tissue-speciﬁc manner and thus contribute to
functional diversity [286]. There are also reports that TMEM16B
(anoctamin 2; Ano 2) supports CaCC activity (e.g.[792]) and in
TMEM16B(-/-) mice Ca-activated Cl- currents in the main olfac-
tory epithelium (MOE) and in the vomeronasal organ are virtually
absent [88].
Nomenclature CaCC
HGNC, UniProt ANO1, Q5XXA6
Endogenous activators intracellular Ca2+
Selective inhibitors crofelemer (pIC50 5.2) [994]
Endogenous channel blockers Ins(3,4,5,6)P4
Channel blockers 9-anthroic acid, DCDPC, DIDS, NPPB, SITS, ﬂufenamic acid, ﬂuoxetine, mibefradil, niﬂumic acid, tannic acid
Functional Characteristics γ = 0.5–5 pS; permeability sequence, SCN- > NO3-> I- > Br- > Cl- > F-; relative permeability of SCN-:Cl- 8. I-:Cl- 3, aspartate:Cl- 0.15, outward rectiﬁcation (decreased by
increasing [Ca2+]i); sensitivity to activation by [Ca2+]i decreased at hyperpolarized potentials; slow activation at positive potentials (accelerated by increasing [Ca2+]i); rapid
deactivation at negative potentials, deactivation kinetics modulated by anions binding to an external site; modulated by redox status
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Comments: Blockade of ICl(Ca) by niﬂumic acid, DIDS and
9-anthroic acid is voltage-dependent whereas block by NPPB is
voltage-independent [359]. Extracellular niﬂumic acid; DCDPC
and 9-anthroic acid (but not DIDS) exert a complex effect upon
ICl(Ca) in vascular smooth muscle, enhancing and inhibiting in-
wardly and outwardly directed currents in a manner dependent
upon [Ca2+]i (see [539] for summary). Considerable crossover in
pharmacology with large conductance Ca2+-activated K+ chan-
nels also exists (see [329] for overview). Two novel compounds,
CaCCinh-A01 and CaCCinh-B01 have recently been identiﬁed as
blockers of calcium-activated chloride channels in T84 human in-
testinal epithelial cells [203] for structures). Signiﬁcantly, other
novel compounds totally block currents mediated by TMEM116A,
but have only a modest effect upon total current mediated by
CaCC native to T84 cells or human bronchial epithelial cells, sug-
gesting that TMEM16A is not the predominant CaCC in such cells
[693]. CaMKII modulates CaCC in a tissue dependent manner
(reviewed by [359, 539]). CaMKII inhibitors block activation of
ICl(Ca) in T84 cells but have no effect in parotid acinar cells. In
tracheal and arterial smooth muscle cells, but not portal vein my-
ocytes, inhibition of CaMKII reduces inactivation of ICl(Ca). Intra-
cellular Ins(3,4,5,6)P4 may act as an endogenous negative regula-
tor of CaCC channels activated by Ca2+, or CaMKII. Smooth mus-
cle CaCC are also regulated positively by Ca2+-dependent phos-
phatase, calcineurin (see [539] for summary).
Maxi chloride channel
Ion channels → Other ion channels → Chloride channels → Maxi chloride channel
Overview: Maxi Cl- channels are high conductance, anion selec-
tive, channels initially characterised in skeletal muscle and sub-
sequently found in many cell types including neurones, glia, car-
diacmuscle, lymphocytes, secreting and absorbing epithelia, mac-
ula densa cells of the kidney and human placenta syncytiotro-
phoblasts [855]. The physiological signiﬁcance of the maxi Cl-
channel is uncertain, but roles in cell volume regulation and apop-
tosis have been claimed. Evidence suggests a role for maxi Cl-
channels as a conductive pathway in the swelling-induced release
of ATP from mouse mammary C127i cells that may be impor-
tant for autocrine and paracrine signalling by purines [252, 854].
A similar channel mediates ATP release from macula densa cells
within the thick ascending of the loop of Henle in response to
changes in luminal NaCl concentration [78]. A family of human
high conductance Cl- channels (TTYH1-3) that resemble Maxi
Cl- channels has been cloned [949], but alternatively, Maxi Cl-
channels have also been suggested to correspond to the voltage-
dependent anion channel, VDAC, expressed at the plasma mem-
brane [46, 733].
Nomenclature Maxi Cl-
Activators cytosolic GTPγS, extracellular chlorpromazine, extracellular tamoxifen, extracellular toremifene, extracellular triﬂupromazine
Endogenous channel blockers intracellular arachidonic acid
Channel blockers DIDS (pIC50 4.4) [882], extracellular Zn2+ (pIC50 4.3) [745], NPPB (pIC50 3.8) [882], extracellular Gd3+, SITS, diphenylamine-2-carboxylic acid
Functional Characteristics γ = 280-430 pS (main state);
permeability sequence, I > Br > Cl > F > gluconate (PCIPCl = 1.5);
ATP is a voltage dependent permeant blocker of single channel activity (PATP/PCl = 0.08-0.1); channel activity increased by patch-excision; channel opening probability (at
steady-state) maximal within approximately ± 20 mV of 0 mV, opening probability decreased at more negative and (commonly) positive potentials yielding a bell-shaped curve;
channel conductance and opening probability regulated by annexin 6
Comments Maxi Cl- is also activated by G protein-coupled receptors and cell swelling. Tamoxifen and toremifene are examples of triphenylethylene anti-oestrogens
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Comments: Differing ionic conditions may contribute to vari-
able estimates of γ reported in the literature. Inhibition by
arachidonic acid (and cis-unsaturated fatty acids) is voltage-
independent, occurs at an intracellular site, and involves both
channel shut down (Kd = 4-5 μM) and a reduction of γ (Kd = 13-
14 μM). Blockade of channel activity by SITS, DIDS, Gd3+ and
arachidonic acid is paralleled by decreased swelling-induced re-
lease of ATP [252, 854]. Channel activation by anti-oestrogens
in whole cell recordings requires the presence of intracellular nu-
cleotides and is prevented by pre-treatment with 17β-estradiol,
bucladesine, or intracellular dialysis with GDPβS [222]. Ac-
tivation by tamoxifen is suppressed by low concentrations of
okadaic acid, suggesting that a dephosphorylation event by pro-
tein phosphatase PP2A occurs in the activation pathway [222]. In
contrast, 17β-estradiol and tamoxifen appear to directly inhibit
the maxi Cl- channel of human placenta reconstituted into giant
liposomes and recorded in excised patches [836].
Volume regulated chloride channels
Ion channels → Other ion channels → Chloride channels → Volume regulated chloride channels
Overview: Volume activated chloride channels (also termed
VSOAC, volume-sensitive organic osmolyte/anion channel; VRC,
volume regulated channel and VSOR, volume expansion-sensing
outwardly rectifying anion channel) participate in regulatory vol-
ume decrease (RVD) in response to cell swelling. VRACmay also be
important for several other processes including the regulation of
membrane excitability, transcellular Cl- transport, angiogenesis,
cell proliferation, necrosis, apoptosis, glutamate release from as-
trocytes, insulin (INS, P01308) release from pancreatic β cells and
resistance to the anti-cancer drug, cisplatin (reviewed by [80, 680,
710, 735]). VRAC may not be a single entity, but may instead
represent a number of different channels that are expressed to a
variable extent in different tissues and are differentially activated
by cell swelling. In addition to ClC-3 expression products (see
above) several former VRAC candidates including MDR1 (ABCB1
P-glycoprotein), Icln, Band 3 anion exchanger and phospholem-
man are also no longer considered likely to fulﬁl this function (see
reviews [710, 867]).
Nomenclature VRAC
Activators GTPγS
Endogenous channel blockers intracellular Mg2+, arachidonic acid
Channel blockers 1,9-dideoxyforskolin, 9-anthroic acid, DCPIB, DIDS, IAA-94, NPPB, NS3728, carbenoxolone, clomiphene, diBA-(5)-C4, gossypol, meﬂoquine, mibefradil, nafoxidine,
nordihydroguiaretic acid, quinidine, quinine, tamoxifen
Functional Characteristics γ = 10-20 pS (negative potentials), 50-90 pS (positive potentials); permeability sequence SCN > I > NO3- >Br- > Cl- > F- > gluconate; outward rectiﬁcation due to voltage
dependence of γ; inactivates at positive potentials in many, but not all, cell types; time dependent inactivation at positive potentials; intracellular ionic strength modulates
sensitivity to cell swelling and rate of channel activation; rate of swelling-induced activation is modulated by intracellular ATP concentration; ATP dependence is independent of
hydrolysis and modulated by rate of cell swelling; inhibited by increased intracellular free Mg2+ concentration; swelling induced activation of several intracellular signalling
cascades may be permissive of, but not essential to, the activation of VRAC including: the Rho-Rho kinase-MLCK; Ras-Raf-MEK-ERK; PIK3-NOX-H2O2 and Src-PLCγ-Ca2+ pathways;
regulation by PKCα required for optimal activity; cholesterol depletion enhances activity; activated by direct stretch of β1-integrin
Comments VRAC is also activated by cell swelling and low intracellular ionic strength. VRAC is also blocked by chromones, extracellular nucleotides and nucleoside analogues
Comments: In addition to conducting monovalent anions, in many cell types the activation of VRAC by a hypotonic stimulus can allow the efﬂux of organic osmolytes such as amino acids and polyols
that may contribute to RVD.
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Comments on Chloride channels: Other chloride
channels
In addition to some intracellular chloride channels that are not
considered here, plasma membrane channels other than those
listed have been functionally described. Many cells and tis-
sues contain outwardly rectifying chloride channels (ORCC) that
may correspond to VRAC active under isotonic conditions. A
cyclic AMP-activated Cl- channel that does not correspond to
CFTR has been described in intestinal Paneth cells [1000]. A Cl
channel activated by cyclic GMP with a dependence on raised
intracellular Ca2+ has been recorded in various vascular smooth
muscle cells types, which has a pharmacology and biophysical
characteristics very different from the ‘conventional’ CaCC [635,
796]. It has been proposed that bestrophin-3 (BEST3, Q8N1M1)
is an essential component of the cyclic GMP-activated channel
[636]. A proton-activated, outwardly rectifying anion channel has
also been described [532].
Further reading on Chloride channels
Adkins GB et al. (2015) Potential role of cardiac chloride channels and transporters as novel thera-
peutic targets. Pharmacol. Ther. 145: 67-75 [PMID:25160469]
Huang F et al. (2012) International Union of Basic and Clinical Pharmacology. LXXXV: calcium-
activated chloride channels. Pharmacol. Rev. 64: 1-15 [PMID:22090471]
KamaleddinMA. (2018)Molecular, biophysical, and pharmacological properties of calcium-activated
chloride channels. J. Cell. Physiol. 233: 787-798 [PMID:28121009]
Kunzelmann K. (2015) TMEM16, LRRC8A, bestrophin: chloride channels controlled by Ca(2+) and
cell volume. Trends Biochem. Sci. 40: 535-43 [PMID:26254230]
Pedersen SF et al. (2016) Biophysics and Physiology of the Volume-Regulated Anion Channel
(VRAC)/Volume-Sensitive Outwardly Rectifying Anion Channel (VSOR). Pﬂugers Arch. 468: 371-
83 [PMID:26739710]
Peretti M et al. (2015) Chloride channels in cancer: Focus on chloride intracellular channel 1 and 4
(CLIC1 AND CLIC4) proteins in tumor development and as novel therapeutic targets. Biochim.
Biophys. Acta 1848: 2523-31 [PMID:25546839]
Sabirov RZ et al. (2016) The properties, functions, and pathophysiology of maxi-anion channels.
Pﬂugers Arch. 468: 405-20 [PMID:26733413]
Zegarra-Moran O et al. (2017) CFTR pharmacology. Cell. Mol. Life Sci. 74: 117-128 [PMID:27704174]
Connexins and Pannexins
Ion channels → Other ion channels → Connexins and Pannexins
Overview: Gap junctions are essential for many physiological
processes including cardiac and smooth muscle contraction, reg-
ulation of neuronal excitability and epithelial electrolyte transport
[114, 185, 274]. Gap junction channels allow the passive diffusion
of molecules of up to 1,000 Daltons which can include nutrients,
metabolites and second messengers (such as IP3) as well as cations
and anions. 21 connexin genes and 3 pannexin genes which
are structurally related to the invertebrate innexin genes) code
for gap junction proteins in humans. Each connexin gap junc-
tion comprises 2 hemichannels or ’connexons’ which are them-
selves formed from 6 connexin molecules. The various connexins
have been observed to combine into both homomeric and het-
eromeric combinations, each of which may exhibit different func-
tional properties. It is also suggested that individual hemichannels
formed by a number of different connexins might be functional
in at least some cells [372]. Connexins have a common topol-
ogy, with four α-helical transmembrane domains, two extracellu-
lar loops, a cytoplasmic loop, and N- and C-termini located on the
cytoplasmic membrane face. In mice, the most abundant connex-
ins in electrical synapses in the brain seem to be Cx36, Cx45 and
Cx57 [955]. Mutations in connexin genes are associated with the
occurrence of a number of pathologies, such as peripheral neu-
ropathies, cardiovascular diseases and hereditary deafness. The
pannexin genes Px1 and Px2 are widely expressed in the mam-
malian brain [1023]. Like the connexins, at least some of the pan-
nexins can form hemichannels [114, 778].
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Nomenclature Cx23 Cx25 Cx26 Cx30 Cx30.2 Cx30.3 Cx31
HGNC, UniProt GJE1, A6NN92 GJB7, Q6PEY0 GJB2, P29033 GJB6, O95452 GJC3, Q8NFK1 GJB4, Q9NTQ9 GJB3, O75712
Endogenous inhibitors extracellular Ca2+ (blocked by raising external Ca2+)
Inhibitors carbenoxolone, ﬂufenamic acid, octanol
Nomenclature Cx31.1 Cx31.9 Cx32 Cx36 Cx37 Cx40 Cx40.1
HGNC, UniProt GJB5, O95377 GJD3, Q8N144 GJB1, P08034 GJD2, Q9UKL4 GJA4, P35212 GJA5, P36382 GJD4, Q96KN9
Endogenous inhibitors extracellular Ca2+ (blocked by raising external Ca2+)
Inhibitors carbenoxolone, ﬂufenamic acid, octanol
Nomenclature Cx43 Cx45 Cx46 Cx47 Cx50 Cx59 Cx62
HGNC, UniProt GJA1, P17302 GJC1, P36383 GJA3, Q9Y6H8 GJC2, Q5T442 GJA8, P48165 GJA9, P57773 GJA10, Q969M2
Endogenous inhibitors extracellular Ca2+ (blocked by raising external Ca2+)
Inhibitors carbenoxolone, ﬂufenamic acid, octanol
Nomenclature Px1 Px2 Px3
HGNC, UniProt PANX1, Q96RD7 PANX2, Q96RD6 PANX3, Q96QZ0
Inhibitors carbenoxolone, ﬂufenamic acid (little block by ﬂufenamic acid) carbenoxolone, ﬂufenamic acid (little block by ﬂufenamic acid) carbenoxolone, ﬂufenamic acid (little block by ﬂufenamic acid)
Comments Unaffected by raising external Ca2+ Unaffected by raising external Ca2+ Unaffected by raising external Ca2+
Comments: Connexins are most commonly named according
to their molecular weights, so, for example, Cx23 is the connexin
protein of 23 kDa. This can cause confusion when comparing be-
tween species – for example, the mouse connexin Cx57 is orthol-
ogous to the human connexin Cx62. No natural toxin or speciﬁc
inhibitor of junctional channels has been identiﬁed yet however
two compounds often used experimentally to block connexins are
carbenoxolone and ﬂufenamic acid [861]. At least some pannexin
hemichannels are more sensitive to carbenoxolone than connex-
ins but much less sensitive to ﬂufenamic acid [113]. It has been
suggested that 2-aminoethoxydiphenyl borate (2-APB) may be a
more effective blocker of some connexin channel subtypes (Cx26,
Cx30, Cx36, Cx40, Cx45, Cx50) compared to others (Cx32, Cx43,
Cx46, [47]).
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Further reading on Connexins and Pannexins
Decrock E et al. (2015) Connexin and pannexin signaling pathways, an architectural blueprint for
CNS physiology and pathology? Cell. Mol. Life Sci. 72: 2823-51 [PMID:26118660]
Esseltine JL et al. (2016) Next-Generation Connexin and Pannexin Cell Biology. Trends Cell Biol. 26:
944-955 [PMID:27339936]
Freund-Michel V et al. (2016) Expression and role of connexin-based gap junctions in pulmonary
inﬂammatory diseases. Pharmacol. Ther. 164: 105-19 [PMID:27126473]
Harris AL. (2018) Electrical coupling and its channels. J. Gen. Physiol. 150: 1606-1639
[PMID:30389716]
Sáez JC et al. (2015) Regulation of pannexin and connexin channels and their functional role in
skeletal muscles. Cell. Mol. Life Sci. 72: 2929-35 [PMID:26084874]
Willebrords J et al. (2017) Inhibitors of connexin and pannexin channels as potential therapeutics.
Pharmacol. Ther. 180: 144-160 [PMID:28720428]
Piezo channels
Ion channels → Other ion channels → Piezo channels
Overview: Piezo proteins are the pore-forming subunits of
trimeric mechanosensitive ion channels that open in response to
mechanical stimuli such as shear stress and membrane stretch, al-
lowing positively charged ions, including calcium, to ﬂow into the
cell. Piezo orthologs have thus far been identiﬁed in numerous
eukaryotes. Most vertebrates have two channel isoforms, Piezo1
and Piezo2. Across species, Piezos are very large proteins (2521
and 2752 amino acids for human Piezo1 and human Piezo2, re-
spectively) with numerous (>14) predicted transmembrane (TM)
domains per subunit and, strikingly, no homology to other known
proteins [1081]. Piezo channels play a critical role in sensory neu-
ron transduction [681, 1131]
Nomenclature Piezo1 Piezo2
HGNC, UniProt PIEZO1, Q92508 PIEZO2, Q9H5I5
Selective activators Yoda1 (pEC50 4.6) [952], Jedi2 (pEC50 3.8) [1054] – Mouse, Jedi1 [1054] – Mouse –
Inhibitors Dooku1 (pIC50 5.8) [273] –
Functional Characteristics Mechano-activated Mechano-activated
Comments: Yoda1 is a Piezo1 channel activator [273, 1049].
Further reading on Piezo channels
Chesler AT et al. (2018) Portraits of a pressure sensor. Elife 7: [PMID:29376828]
Ehmke H. (2018) The mechanotransduction of blood pressure. Science 362: 398-399
[PMID:30361358]
Gottlieb PA et al. (2012) Piezo1: properties of a cation selectivemechanical channel. Channels (Austin)
6: 214-9 [PMID:22790400]
Parpaite T et al. (2017) Piezo channels. Curr. Biol. 27: R250-R252 [PMID:28376327]
Volkers L et al. (2015) Piezo channels: from structure to function. Pﬂugers Arch. 467: 95-9
[PMID:25037583]
Wu J et al. (2017) Touch, Tension, and Transduction - The Function and Regulation of Piezo Ion
Channels. Trends Biochem. Sci. 42: 57-71 [PMID:27743844]
ZengWZ et al. (2018) PIEZOsmediate neuronal sensing of blood pressure and the baroreceptor reﬂex.
Science 362: 464-467 [PMID:30361375]
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Sodium leak channel, non-selective
Ion channels → Other ion channels → Sodium leak channel, non-selective
Overview: The sodium leak channel, non selective
(NC-IUPHAR tentatively recommends the nomencla-
ture NaVi2.1, W.A. Catterall, personal communication)
is structurally a member of the family of voltage-gated sodium
channel family (Nav1.1-Nav1.9) [542, 1121]. In contrast to the
latter, NaVi2.1, is voltage-insensitive (denoted in the subscript
’vi’ in the tentative nomenclature) and possesses distinctive ion
selectivity and pharmacological properties. NaVi2.1, which is
insensitive to tetrodotoxin (10 μM), has been proposed to me-
diate the tetrodotoxin-resistant and voltage-insensitive Na+ leak
current (IL-Na) observed in many types of neurone [595]. How-
ever, whether NaVi2.1 is constitutively active has been challenged
[951]. NaVi2.1 is widely distributed within the central nervous
system and is also expressed in the heart and pancreas speciﬁcally,
in rodents, within the islets of Langerhans [542, 595]. Recently,
NaVi2.1 has been proposed to be a core effector for the action of
inhibitory G proteins [789].
Nomenclature Navi2.1
HGNC, UniProt NALCN, Q8IZF0
Activators Constitutively active (Lu et al., 2007), or activated downstream of Src family tyrosine kinases (SFKs) (Lu et al.,2009; Swayne et al., 2009); positively modulated by decreased
extracellular Ca2+ concentration (Lu et al., 2010) [595, 596, 597, 951]
Channel blockers Gd3+ (pIC50 5.6), Cd2+ (pIC50 3.8), Co2+ (pIC50 3.6), verapamil (pIC50 3.4)
Functional Characteristics γ = 27 pS (by ﬂuctuation analysis), PNa/PCs = 1.3, PK/PCs = 1.2, PCa/PCs = 0.5, linear current voltage-relationship, voltage-independent and non-inactivating
Comments: In native and recombinant expression systems
NaVi2.1 can be activated by stimulation of NK1 (in hippocam-
pal neurones), neurotensin (in ventral tegmental area neurones)
andM3muscarinic acetylcholine receptors (in MIN6 pancreatic β-
cells) and in a manner that is independent of signalling through
G proteins [596, 951]. Pharmacological and molecular biological
evidence indicates such modulation to occur though a pathway
that involves the activation of Src family tyrosine kinases. It is
suggested that NaVi2.1 exists as a macromolecular complex with
M3 receptors [951] and peptide receptors [596], in the latter in-
stance in association with the protein UNC-80, which recruits Src
to the channel complex [596, 1045]. By contrast, stimulation of
Navi2.1 by decreased extracellular Ca2+ concentration is G pro-
tein dependent and involves a Ca2+-sensing G protein-coupled
receptor and UNC80 which links Navi2.1 to the protein UNC79
in the same complex [597]. Navi2.1 null mutant mice have se-
vere disturbances in respiratory rhythm and die within 24 hours
of birth [595]. Navi2.1 heterozygous knockout mice display in-
creased serum sodium concentrations in comparison to wildtype
littermates and a role for the channel in osmoregulation has been
postulated [905].
Further reading on Sodium leak channel, non-selective
Cochet-Bissuel M et al. (2014) The sodium leak channel, NALCN, in health and disease. Front Cell
Neurosci 8: 132 [PMID:24904279]
Lu TZ et al. (2012) NALCN: a regulator of pacemaker activity. Mol. Neurobiol. 45: 415-23
[PMID:22476981]
Philippart F et al. (2018) G_i/o protein-coupled receptors in dopamine neurons inhibit the sodium
leak channel NALCN. Elife 7: [PMID:30556810]
Waxman SG et al. (2014) Regulating excitability of peripheral afferents: emerging ion channel tar-
gets. Nat. Neurosci. 17: 153-63 [PMID:24473263]
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